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Abstract
Motor neurone disease (MND) or amyotrophic lateral sclerosis (ALS) is a
devastating disorder of the anterior horn cells of the spinal cord and the motor cranial
nuclei that leads to progressive muscle weakness and atrophy. Involvement of both
upper and lower motor neurons is characteristic. Major recent advances have shed
light on its etiology, the key mechanisms in both familial and sporadic ALS,
however, remain unknown. Although the SOD1 (G93A) mutant transgenic mouse
model is widely used as a tool to study the pathogenesis and investigate therapeutic
strategy, cure for ALS has not been discovered. More mouse models ofALS are
needed. Mice with the autosomal recessive gene wasted (wst) develop a set of
neurological features that include progressive muscle wasting, weight loss,
progressive paralysis, and degeneration ofmotor neurones in spinal cord and
brainstem. The wasted mutation is caused by a 15.8-kilobase deletion that completely
abolishes the detectable expression of eukaryotic elongation factor 1A2 (eEFlA2), a
tissue-specific protein that expresses only in nervous system, heart and skeletal
muscle. In this PhD thesis, I describe the characterization of neuromuscular
abnormalities of wasted mice and study expression of nerve-regulated genes using
real-time RT-PCR. Muscle of wasted mice showed evidence of denervation atrophy,
and the patterns of gene expression were characteristic for the type of denervation. 1
have constructed an epitope-tagged eEFl A2 plasmid and studied colocalisation of
eEFlA2 and spinal motor neurone (SMN) protein in HeLa cells, using quantitative
immunocolocalisation analysis. I have shown that a proportion of cytoplasmic
eEFl A2 colocalises with SMN. To study the role or eEFlA2,1 have constructed a
muscle-specific transgene and generated transgenic homozygous wasted mice that
specifically express human eEFl A2 in skeletal muscle, but not in neurones.
Transgenic wasted mice showed the same phenotype as spontaneous mutant wasted
mice. Muscle pathology and the patterns of gene expression were compatible with
denervation. These findings suggest that the loss of eEFl A2 in motor neurone, but
not muscle, leads to muscle atrophy in wasted mice.
XX
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1.1.1 Motor Neurone Disease
Motor neurone disease (MND) is also known as Lou Gehrig's disease or amyotrophic
lateral sclerosis (ALS). The progressive degeneration of upper and lower motor
neurones is the pathological hallmark of this disease and clinical signs reflect this. When
cortical (upper) motor neurones are involved, the weakness is associated with spasticity
and stiffness ofmovement. When spinal (lower) motor neurones are first involved, the
weakness arises from denervation of the affected muscles and is associated with muscle
twitching (fasciculations) and then muscle atrophy. Regardless of the site of onset, the
striking and devastating aspect of the illness is that it migrates ultimately to involve
virtually all of the motor neurones. Upper motor neurone signs may disappear as the
lower motor neurone weakness progresses. Sensory and cognitive functions are not
affected and certain motor neurone groups, including those in the oculomotor (Hughes,
1982) and Onuf s nuclei (Mannen et al., 1977), are also spared. Progressive motor
neurone degeneration leads to paralysis and death, usually from respiratory failure, after
around three years. Up to 50% ofmotor neurones may have degenerated before clinical
signs appear (Hansen and Ballantyne, 1978). Roland suggested using the plural form,
"motor neurone diseases", to describe all of the diseases of the motor system and the
anterior horn cells, including spinal muscular atrophy (SMA) (Rowland, 1982). Spinal
muscular atrophy is clinically and pathologically distinct from ALS itself.
1.1.2 Spinal Muscular Atrophy
Current classification of the form of SMA that has been mapped to chromosome 5q 13 is
based on clinical criteria, although the genotype-phenotype correlation is close to being
established (Brahe, 2000). Severe SMA (SMA type I, Werdnig-Hoffmann disease, acute
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SMA) is characterized by onset before 6 months of age, failure to achieve sitting without
support, and life expectancy of 2 years or less. SMA type II (chronic SMA) is usually
symptomatic between ages 6 months and 18 months, but may start earlier. SMA type III
(juvenile SMA, Kugelberg-Welander disease) becomes symptomatic after 18 months.
Life expectancy is into the sixth decade of life. Some forms ofMND are linked to
chromosome 5 and, thus, have been labelled SMA type IV (Moulard et al., 1998). Poor
muscle tone, muscle weakness, and lack ofmotor development are major clinical
manifestations of SMA type I. Ocular muscles are spared. The heart is normal.
Fasciculations are also present. A postural tremor of fingers is seen inevitably in SMA
type II, but only occasionally in SMA type I. SMA type III shows proximal muscle
weakness; the legs are more severely affected than the arms. As with SMA type I and
type II, the absence of tendon reflexes in most cases completes the clinical picture. SMA
type IV refers to "adult" onset of muscle weakness. The physical examination is similar
to that described for SMA type III.
1.1.3 Epidemiology
ALS has a prevalence rate of about 4 per 100,000 and an annual incidence rate of about
1 to 1.5 per 100,000. The incidence increases with age with a peak occurrence between
55 to 75 years of age, and occurs predominantly in men with a male-to-female ratio of
about 2:1. The average survival period after onset of symptoms is about 3 to 5 years.
The incidence ofALS is higher in the Western Pacific than in other areas of the world.
There are 3 major foci: the Chamorro people on the Islands ofGuam, Rota, and Tinian;
Japanese villagers on the Kii Peninsula of Honshu Island in Japan; the people living in
West New Guinea in Indonesia. Genetic factors did not play a role in the Western
Pacific ALS, and now the environmental factors, including excitotoxin from the cycad
seed and mineral imbalances in the soil and water, are being studied as possible causes
(Yanagihara et al., 1984; Spencer et al., 1987a; Spencer et al., 1987a). Based on the
genetic information available, ALS has been grossly divided into 2 categories: sporadic
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ALS (SALS) and familial ALS (FALS). Up to 10% of all ALS cases are familial
(Mulder et al., 1986).
For SMA, rigorous epidemiological studies reveal that the gene frequency is higher than
originally thought. In Italy the incidence was 7.8 per 100,000 live births, giving a carrier
frequency of 1 in 57. The acute or severe form occurred in 4.1 per 100,000 live births
(Mostacciuolo et al., 1992). A 1992 study from Germany showed that the incidence was
10 per 100,000 with a carrier rate of 1 in 50 (Thieme et al., 1993). Data from Iceland is
consistent with the above studies (Ludvigsson et al., 1999).
1.1.4 Pathology
The pathological hallmark of ALS is degeneration of large pyramidal neurones in the
motor cortex and associated corticospinal tracts (Wong et al., 1998). Lower motor
neurones originating in the brainstem nuclei and spinal cord anterior horn are also
affected. In most cases, motor neurones appear to undergo a process of involution or
shrinkage, losing volume in both cytoplasm and nucleus. Muscle biopsy reveals
denervation atrophy (Martin et al., 2000). "Amyotrophy" refers to neurogenic atrophy of
affected muscle groups; "lateral sclerosis" refers to the hardness to palpation of the
lateral columns of the spinal cord, where gliosis follows degeneration of the lateral
corticospinal tracts. Weakness and muscle atrophy are a consequence of large a motor
neurones in the brainstem and spinal cord. Among the earliest pathological changes in
the dying motor neurones is the appearance of fine wisps of ubiquitin-positive threads or
skeins (Leigh et al., 1988). Other intraneuronal inclusions are also seen in degenerating
neurones and glia. These are Bunina bodies, Lewy-like bodies, congomerate hyaline
inclusions, and advanced glycated end products (AGE) (Chou et al., 1998; Kikuchi et
al., 2000). Phosphorylated and nonphosphorylated neurofilaments are components of
congomerate hyaline inclusions. AGEs contain ubiquitin, phosphorylated neurofilament,
and superoxide dismutase I (SOD I). Mitochondrial abnormalities have been found in
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ALS patients (Borthwick et al., 1999; Beal, 2000). A case ofMND that was associated
with mutations in mitochondrial DNA has been reported (Comi et al., 1998).
Fragmentation of Golgi apparatus is also found in some patients with ALS (Gonatas et
al., 1998).
SMA selectively affects the a motor neurones in the spinal cord (Davies et al., 1991).
The brain cortex is unaffected. Autopsy reveals a decreased number ofmotor neurones
and gliosis in the anterior horn of the spinal cord as well as decreased numbers of lower
cranial motor neurones, and changes in muscle biopsy are also of acute and chronic
denervation (Hausmanowa-Petrusewicz et al., 1980). In addition, muscle biopsy reveals
group atrophy of type 1 and type 2 muscle fibres as opposed to the normal checkerboard
pattern, and shows features of muscle immaturity, suggesting an arrest in development
(Engel, 1970; Fidzianska, 1971). Rare angulated and large type 1 fibres are scattered
throughout. In the early stages of the disease, the biopsy may show universally small
fibres, with type 1 fibres being smaller than type 2, making the histological diagnosis
difficult (Iannaccone et al., 1987; Dubowitz, 1991).
1.2 Aetiology
1.2.1 Aetiology of Amyotrophic Lateral Sclerosis
The causes ofALS have been elusive. These include the involvement of environmental
factors, viral infection, autoimmune phenomena, cytoskeletal abnormalities, loss of
trophic factors, oxidative stress and excitotoxicity. Genetic factors also contribute to its
causes.
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1.2.1.1 Genetic Factors
Familial clustering ofALS has been recognized for many years. In some of these
families, there is clear evidence of autosomal dominant inheritance and rarely of
autosomal recessive inheritance. Identification ofmutations in the gene encoding Cu/Zn
superoxide dismutase 1 (SOD1) on chromosome 21 in 1993 is a breakthrough (Rosen et
al., 1993). SOD1, accounting for approximately 1% of total brain protein, is a copper
and zinc dependent, cytoplasmic enzyme. The structural gene is located on chromosome
21q22.1 (Siddique et al., 1991).Linkage studies performed in families with ALS led to a
peak multipoint lod score of 6.1 for a subset of 23 families linked to chromosome 21
(Figlewicz et al., 1994b). More than 100 different mutations have been identified in the
SOD gene (Parton et al., 2002), which may account for around 20% of all FALS
(Siddique et al., 1996). Most of the mutations are missense point mutation. A4V-SOD1
is the most common SOD1 mutation. Almost all of SOD 1 mutations are dominant,
except for D90A-SOD1, which can be either recessive or dominant (Andersen et al.,
1997; Al-Chalabi et al., 1998). The remaining 80% are caused by mutations in other
genes. Five per cent of SALS also have SOD1 mutations. Different heterozygous
mutations in SOD1 gene cause distinct clinical manifestations and histopathology. For
example, in patients with A4V-SOD1 mutation, the corticospinal tracts are spared
(Cudkowicz et al., 1998; Rowland, 1998).
1.2.1.1.1 Molecular Genetics of Autosomal Dominant ALS
Autosomal dominant forms of ALS include ALS1, ALS3, and ALS4. SODl mutation in
the region 21q22, causing ALS1 (Siddique et al., 1991), only accounts for
approximately 20% of all FALS and about 3% of SALS (Jackson et al., 1997; Shaw et
al., 1998). However, dominant mutations are unlikely to cause enzyme deficiencies due
to the compensatory allele, and a correlation between disease severity and the level of
enzyme activity has not been established (Esteban et al., 1994; Sjalander et al., 1995).
Knock-out mice, homozygous for SODl deletions, are unaffected by motor neurone
disease (Reaume et al., 1996), while mice overexpressing human SODl mutations
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develop motor neurone disease despite having higher SOD1 enzyme activity than their
nontransgenic littermates (Gurney et al., 1994). These evidences suggest that SOD1
mutations might produce an unknown toxic gain of function rather than an enzymatic
deficiency in the pathogenesis ofALS. Adult-onset autosomal dominant FALS neither
linked to chromosome 21 nor associated with SOD1 mutations is designated as ALS3
(Siddique et al., 1991), and its locus is identified on chromosome 18q (Fland et al.,
2002). Juvenile-onset ALS with dominant inheritance and no bulbar involvement, ALS4,
has been mapped to chromosome 9q34 (Chance el al., 1998). Patients with ALS4 are
associated with slowly progressive distal muscle weakness and atrophy and their life
expectancy can be very long (Rabin et al., 1999).
Dominant ALS with frontotemporal dementia (ALS/FTD) has been mapped to
chromosome 9q21-22 (Hosier et al., 2000). Another ALS/FTD, which includes
parkinsonism, is caused by mutations in the tau gene on chromosome 17q21 (Lynch et
al., 1994). X-linked dominant ALS is mapped to chromosome Xpl 1-Xql2 (Cole and
Siddique, 1999).
1.2.1.1.2 Molecular Genetics of Autosomal Recessive ALS
There are three forms of autosomal recessive, juvenile-onset ALS. Type l (ALS5) is the
most prevalent form and has been linked to chromosome 15ql5.1 -q21.1 (Hentati et al.,
1998). Families with ALS5 have onset between 8 and 18 years, with both upper and
lower motor neurone signs, fasciculations and atrophy of tongue, and occasionally, mild
mental retardation. Type 3 recessive ALS (ALS2) is linked to chromosome 2q33-q34
(Hentati et al., 1994; Hadano et al., 2001b). The gene has been identified and its 184 kD
protein product is call alsin, encoded by gene designated ALS2CR6 (Fladano et al.,
2001b; Yang et al., 2001). Patients with ALS2 have onset between 3 and 23 years, and
are characterized by spastic gait, distal muscle weakness and atrophy. Due to structural
similarity with other proteins, alsin is speculated to act as a regulator/activator of
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particular proteins that modulate microtubule assembly, membrane organization and
trafficking in cells, including neurones (Hadano et al., 2001a). ALS2CR6 is found in
neuronal cells throughout the brain and spinal cord, particularly in neurones in the
hippocampus and dentate gyrus, cerebellum, Purkinje cells, neurones in the cerebral
cortex and spinal grey matter including anterior horn cells. Two independent deletion
mutations in ALS2 result in frameshifts that generate premature stop codons (Hadano et
al., 2001b). In this form ofALS, two copies ofmutant gene must be present, and
therefore these mutations are likely to result in loss of function. The protein product of
this gene is found in all cell types, including motor neurones, however its normal
function is currently unknown. Families that are not linked to chromosome 15q or 2q are
classified as type 2 (Hentati et al., 1998).
1.2.1.1.3 Other candidate genes in ALS
Other candidate genes have been tested for a role in ALS pathogenesis. The other
isoforms of SOD, SOD2 and SOD3, are not linked to ALS (de Belleroche et al., 1995;
Siddique and Deng, 1996). The neurofilament heavy subunit tail domain has been shown
to harbor a small set of in-frame deletions and insertions in SALS patients, and one
FALS patient also had a 14-amino-acid deletion (Al-Chalabi et al., 1999). But because
only 1% ofALS patients have these mutations, mutations in neurofilament heavy chain
subunit are considered to be a risk factor rather than a major cause of disease (Figlewicz
et al., 1994a; Al-Chalabi et al., 1999). Overexpression of peripherin, a component of
intermediate filament protein associated with degenerating motor neurones in SALS, in
mice provokes degeneration ofmotor axons (Beaulieu et al., 1999; Beaulieu and Julien,
2003; Robertson et al., 2003). Apolipoprotein E (APOE) genotypes have been studied as
a risk factor, with a suggestion ofAPOE4 being more common in bulbar onset and with
early onset of disease (Al-Chalabi et al., 1996). An out-of-frame mutations of the
mitochondrial DNA-encoded subunit I of cytochrome c oxidase has been reported in a
patient with motor neurone-like degeneration (Comi et al., 1998). A homozygous
neuronal apoptosis inhibitory polypeptide (NAIP) mutation on chromosome 5q 13 has
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been reported in a sporadic case ofALS (Jackson et al., 1996). Mutations in the
apurinic/apyrimidine endonuclease (APEX nuclease) gene are also reported in ALS
patients (Olkowski, 1998). The APEX nuclease is a DNA repair enzyme. A significant
linkage disequilibrium for one common polymorphic locus in the APEX nuclease gene
between ALS and control subjects has been shown (Elayward et al., 1999). Mutant glial
glutamate transporter (EAAT2) mRNA was reported in brain, spinal cord, and
cerebrospinal fluid of up to 60% of patients with SALS, and was suggested as a result of
abnormal RNA processing (Lin et al., 1998). However, reports of similar splice variants
in normal subjects make this difficult to interpret (Nagai et al., 1998; Meyer et al.,1999).
The survival motor neurone (SMN) locus has been implicated in the modification of
mutant SOD1 disease in a transgenic mouse, a modification that delays disease onset
significantly (Kunst et al., 2000). Sixteen per cent ofALS patients have an abnormal
number of SMN1 gene (1 or 3 copies), compared with 4% in controls, suggesting an
abnormal SMN 1 gene locus may be a susceptibility factor for ALS (Corcia et al., 2002).
Vascular endothelial growth factor (VEGF) has been reported to be a modifier of
SODlG93A mice, and protects motor neurones against ischemic death (Lambrechts et al.,
2003). VEGF is an important angiogenesis factor expressed in several tissues and is
rapidly upregulated during hypoxia (Carmeliet, 2000). A discrete deletion in the VEGF
5'-UTR predisposed a subset of the knockout mice to adult-onset progressive motor
neurone degeneration, with some neuropathologic and clinical signs reminiscent of
human motor neurone degeneration (Oosthuyse et al., 2001). A case-control meta¬
analysis of four European populations demonstrated an association of three
polymorphisms in the 5'-UTR, known to affect VEGF expression, with SALS
(Lambrechts et al., 2003). However, a recent study, comprising a large number of
family-based and case-control samples, demonstrated a lack of association of the VEGF
polymorphisms with SALS (Chen et al., 2006).
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1.2.2 Aetiology of Spinal Muscular Atrophy
All cases of SMA linked to chromosome 5 are genetic. Many of the variants are also
genetic but linked to other chromosome. The gene locus of SMA type I. II, and III was
mapped to chromosome 5q in 1990, using linkage studies (Brzustowicz et al., 1990). A
first gene of SMA was isolated in 1995 and was given the name SMN gene (Lefebvre et
al., 1995). The second gene known as NAIP gene was found to be deleted in 68% of
SMA type I, but in only 2% in cases of SMA type II and III (Roy et al., 1995). The third
gene, BTF2p44 which encodes a subunit of the basal transcription factor TFIIH (Burglen
et al., 1997), has been shown to be missing in 15% of SMA patients, compared to only
1% of controls (Carter et al., 1997). There are two copies of the SMN gene on each
chromosome 5q, designated centromeric (SMNC or SMN2) and telomeric (SMN1 or
SMN 1) depending on their placement. The disease-causing mutations are found in the
telemetric copy. Only 5 nucleotides distinguish SMN 1 from SMN2 genes without any
effect on the amino acid sequence. One of these nucleotides is located in exon 7 and is
responsible for the alternative splicing of exon 7 which is specific to the SMN2
transcripts (Lorson et al., 1999). More than 95% of patients with SMA have a
homozygous deletion of SMN 1 (Monani et al., 1999). SMN2 produces mostly transcript
lacking the C-terminal 16 residues in exon 7 (SMNA7) (Lefebvre et al., 1995). This is
translated into an unstable protein, which is degraded rapidly. Thus, SMA patients
produce reduced levels of SMN. SMA type II and III patients produce more protein than
type I patients (Coovert et ah, 1997; Lefebvre et al., 1997). The SMN2 copy number
would be predicted to be important in determining phenotype. More copies are found in
the milder SMA patients than in the severe cases (Campbell et al., 1997; McAndrew et
al., 1997). However, siblings harboring identical SMN2 copy number but markedly
different clinical manifestations have been reported (Hahnen et al., 1995; Wang et al.,
1996; DiDonato et al., 1997). This indicates the existing of modifier loci lying outside
the SMN locus. The NAIP and SERF-1 have been suggested to act as phenotypic
modifiers (Roy et al., 1995; Scharf et al., 1998). Adult-onset forms of proximal SMA
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are also associated with SMN1 deletions on chromosome 5ql 1.2-13.3 (Clermont et al.,
1995).
1.3 Pathogenesis and Pathophysiology
1.3.1 Biological Properties of Motor Neurones
In order to consider possible causes ofMND and roles of elongation factor 1A2
(eEFl A2) in the pathogenesis ofMND, it is useful to briefly review some of the salient
anatomical and biological properties ofmotor neurones.
Critical to early motor neurone formation is the protein Sonic hedgehog that activates
transcription factors to induce formation ofmotor neurones (Tanabe and Jessell. 1996).
Additional proteins, such as Isl-1, are critical for initial spinal motor neurone formation
and identity (Pfaff et al., 1996). During developmental period, axons elongate from
newly specified motor neurones to seek and innervate target muscles. Axonal elongation
and guidance are driven by a combination of extrinsic, local chemical cues and
endogenously expressed molecules. Then, synapse formation with muscles occurs. At
about the time that synaptic structures are formed, nearly half of all spinal motor
neurones undergo a dramatic process of natural, programmed cell death. This step in
spinal cord development may precisely match numbers ofmotor neurones to the
available target muscle cells (Kandel and Schwartz, 2000).
1.3.2 Selective Vulnerability
Several biochemical features distinguish the lower motor neurone from other neural
cells. This must account for the reasons why only motor neurones are affected in ALS or
SMA, and why there is variation in the site of disease onset and in the relative degree of
upper versus lower motor neurones. The spinal and bulbar motor neurones release
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acetylcholine (Ach) as the neurotransmitter at the neuromuscular junction (NMJ). This is
synthesized by choline acetyltransferase, an intracellular enzyme that is a biological
marker for these cells in the spinal cord. The lower motor neurones are also
distinguished by cell surface molecules, such as the low-affinity neuronal growth factor
(NGF) receptor (p75) (McKay et al., 1996). The large ALS-susceptible neurones in the
anterior horn of the spinal cord bear androgen receptors (Matsuura et al., 1993). By
contrast, smaller motor neurones that innervate extraocular muscles and are largely
spared in ALS do not express surface androgen receptors (Rocha et al., 2000; Tachibana
et al., 2000; Wickham et al.,2000). Motor neurones are unusual in not containing the
Ca2+-buffering proteins parvalbumin and calbindin D-28K, with the exception of those
in the oculomotor tracts and Onuf s nucleus (Ince et al., 1993). Both proteins can protect
neurones from AMPA/kainate receptor-mediated (but not from NMDA receptor-
mediated) excitotoxicity (Waldvogel et al., 1991).
1.3.3 Hypotheses of the Pathogenesis of ALS
SALS and FALS are clinically and pathologically similar, suggesting a common
pathogenesis. An understanding of the mechanism ofmotor neurone injury and cell loss
in ALS is still limited. However, several hypotheses have been proposed. These are
immune or inflammatory mechanisms, free-radical-mediated oxidative stress,
excitotoxicity, disorganization of intermediate filaments, and impaired mitochondrial
function.
1.3.3.1 Immune or Inflammatory Mechanisms
Evidence for immune mechanisms include a higher incidence of immune disorders in
patients (Haverkamp et al., 1995), the presence of the CD4 and CD8 in the degenerating
anterior horn of the spinal cord (Engelhardt et al., 1993), the presence of
paraproteinemias and lymphomas (Younger et al., 1991), and the presence of IgG in
motor neurones (Engelhardt and Appel, 1990). Immune or inflammatory reactions may
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trigger increased intracellular calcium and motor neurone degeneration (Engelhardt et
al., 1997; Siklos et al., 1998). In addition, antibodies directed against GM1 gangliosides
and against voltage-dependent Ca2+ channels have been identified in sera from ALS
patients (Smith et al., 1996). However, these antibodies have not been demonstrated to
be toxic to motor neurones in culture. Moreover, treatment with immunosuppressant
drugs has not been shown to modify the course of the disease in ALS patients.
1.3.3.2 Free-radical-mediated Oxidative Stress
1.3.3.2.1 SOD1-induced neuroneal injury
Mutant SOD1 may catalyze aberrant biochemical reactions, resulting in the production
of potentially damaging reactive oxygen species, such as the superoxide anion (02*"),
the hydroxyl radical (OH*), hydrogen peroxide (H2O2), and peroxynitrite (ONOO").
SOD1 catalyzes the conversion of 02*"to H2O2 and oxygen. Copper atom at active site
mediates catalysis. S0D1 also involves in the generation ofOH*. ONOO" is generated
non-enzymatically by the reaction between 02*~ and nitric oxide (NO). NO is generated
by Ca2+-dependent nitric oxide synthase (NOS).
However, the loss-of-function hypothesis was disproved because the overexpression of
mutant SOD1 [G93A] in mice caused MND despite the presence of elevated SODl
activity (Gurney et al., 1994). In addition, the total elimination of SODl did not cause
MND in SODl knocked-out mice (Reaume et al., 1996). These evidence suggest that
SODl mutations must cause MND by a toxic gain of function.
1.3.3.2.2 Impaired ability to bind to copper
Cu3+, the cupric ion, is cytotoxic when it is not bound to protein. Cells have
mechanisms that chaperone it until it can be incorporated into enzyme. A copper
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chaperone protein for SOD1 (CCS) incorporates copper ions into both wild-type and
mutant mice SOD1 (Corson et al., 1998; Subramaniam et al., 2002). Copper chelation
was shown to improve spinal motor neurone survival in G93A mutant SOD1 transgenic
mice by more than 200% and to promote neurite outgrowth compared with that seen in
untreated animals (Azzouz et al., 2000). These studies raise a hypothesis that a reduced
ability ofmutant SOD1 to bind the ion may be a possible mechanism of neurotoxicity in
ALS. However, although the absence of CCS led to a significant reduction of amount of
copper-loaded mutant SOD1, it did not modify an onset and progression ofMND in
SOD1-mutant mice (Subramaniam et al., 2002).
1.3.3.2.3 Impaired ability of SOD1 to bind zinc
Impairing the ability of the SOD1 to bind zinc may cause oxidative damage (Estevez et
al., 1999). Reduced affinity ofmutant SOD1 for zinc enhances conversion ofONOO"
into nitronium ions, compared with wild-type SOD1 (Crow et al., 1997). The
neurofilament light subunit has been implicated as a potential target of aberrant
nitrosylation or as a high affinity-binding partner for zinc ions that may deplete the
SOD1 enzyme. Elevated levels of free nitrotyrosine have been detected in the spinal
cords in both SALS and FALS patients (Beal et al., 1997), as well as in SOD 1-knockout
mice (Ferrante et al., 1997). Nitrotyrosine may interfere with normal protein
phosphorylation and phosphorylation mediated signaling.
1.3.3.3 Glutamate Excitotoxicity
Glutamate is a prime candidate as a cause ofmotor neurone excitotoxicity because it is a
principle excitatory neurotransmitter in the motor system. In addition, the concentration
of glutamate is about 20,000-fold higher intracellularly than extracellularly. Tightly
regulated-dependent system ensures that extracellular glutamate concentrations remain
very low to prevent cell injury. A precise idea of the proposed glutamate-mediated
defect in ALS has come from the work of Rothstein and co-workers (Rothstein et al.,
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1992). They first showed that glutamic acid uptake was impaired in post-mortem spinal
cord and motor cortex ofALS patients (Rothstein et al., 1992), and the suggested that
this deficit could be explained by the selective loss of one of the subtypes of the
glutamic acid transporter protein, EAAT2, that is expressed uniquely in glial cells
(Rothstein et al., 1995). Reduced levels of EAAT2 have been described in both SALS
postmortem specimens (Bristol and Rothstein, 1996) and in transgenic mice with G85R
SOD1 mutation (Bruijn et al., 1997). The level of EAAT2 mRNA is not modified,
suggesting the anomaly is post-translational (Bristol and Rothstein, 1996). The specific
loss of EAAT2 could not be attributed simply to cell injury, because no significant
astroglial loss was observed (Rothstein et al., 1995). Multiple aberrant EAAT2 mRNA
species arising from exon skipping and intron retention have been detected in SALS
brains specimens and in the CSF of living patients (Lin et al., 1998). However, these
aberrant mutations are relatively infrequent (Lin et al., 1998; Meyer et al., 1998).
Moreover, other reports indicated that splice variants were not associated with ALS
(Aoki et al., 1998; Meyer et al., 1999; Flowers et al.,2001).
The AMPA (a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) subtype of
glutamate receptor is responsible for most fast excitatory transmission in the central
nervous system (CNS). Most ofAMPA receptors in the CNS incorporate the GluR2
subunit (Terro et al., 1998). The GluR2 subunit I is impermeable to calcium, while others
AMPA subunits and NMDA (N-methyl-D-aspartate) receptor are calcium-permeable.
The activity of the GluR2 subunit depends on post-transcriptional editing of GluR
mRNA (Sommer et al., 1991). The selective vulnerability ofmotor neurones to AMPA
could be explained either by the fact that the expression of GluR2 in motor neurones is
normally lower than in other neurones (Williams et al., 1997) or by an impairment in the
editing of GluR2 mRNA in patients with ALS (Takuma et al., 1999).
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1.3.3.4 Disorganization of Intermediate Filaments
Neurofilaments are cytoskeletal proteins made up of three associated subunits: light
(NF-L), medium (NF-M), and heavy (NF-H). They play a particular important role in
maintaining axonal integrity in motor neurones and in axonal transport. In both human
ALS patients and mutant SOD1 transgenic mice, neurofilament-rich, large-diameter
axons have been shown to be the targets for degeneration (Kawamura et al., 1981;
Bruijn et al., 1997). An intact neurofilament network is not required for SOD1 mediated
disease (Eyer et al., 1998). G37R SOD1 mice crossed with transgenic mice
overexpressing the human NF-H subunit led to a 65% increase in the mean lifespan of
these mice (Couillard-Despres et al., 1998). Crossing with NF-L null mice also extended
the lifespan ofG85R mice by approximately 15% (Williamson et al., 1998). Therefore,
the overexpression ofNF-H or lack ofNF-L, which tends to result in perikaryal
neurofilament accumulations, appears to be well tolerated by neurones and indeed is
even neuroprotective. However, having reduced the total neurofilament content in
mutant SOD1 mice by 40% has not been shown to find any change in the disease onset
or progression of the mutant SOD1-mediated MND (Nguyen et al., 2000). Also, there is
no change in the survival of the mutant SOD1 mice by increasing the neurofilament
density in an axon. This could be due to usage of two different mutant SOD1 transgenic
mice.
Another intermediate filament, which has been found in almost 90% ofmotor neurone
inclusion in SALS (Corbo and Hays, 1992) and SOD1 mutant mice (Tu et al., 1996), is
peripherin. Peripherin is a type III intermediate filament with molecular weight of 57 kD
and normally expressed in autonomic nerves and peripheral sensory neurones, with only
low amount in spinal motor neurones (Beaulieu et al., 1999a). Levels of peripherin
increase in response to cellular injury or inflammation (Troy et al., 1990).
Overexpression of peripherin in a transgenic mouse model which is deficient for NF-L
caused late onset and selective motor neurone degeneration (Beaulieu et al., 1999b).
Studies of interactions between peripherin and neurofilament in SW13 cell line, which
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lack endogenous intermediate filament proteins, have shown that peripherin may self
assembly to establish an intermediate filament network or heterodimerise with each of
the neurofilament subunits, resulting in a disorganized network and protein aggregation
(Beaulieu et al., 1999b). Recently, studies have shown that peripherin-mediated death of
motor neurones can be rescued by the overexpression ofNF-H (Beaulieu and Julien,
2003).
1.3.3.5 Impaired Mitochondrial Function
Mitochondrial function is known to decline with increasing age, which is the most
robust risk factor for neurodegenerative diseases. Mitochondrial degeneration has been
reported in ALS motor neurones (Wong et a/.,1995)and is an early pathological feature
in mutant SOD1 transgenic mice (Dal Canto and Gurney, 1994; Gurney et al., 1994),
preceding the onset ofmotor weakness (Kong and Xu, 1998). Abnormalities of
mitochondrial electron transfer chain, in addition to reduced or damaged mitochondrial
DNA, have been detected in muscle and liver biopsies from patients with SALS
(Wiedemann et al., 1998; Vielhaber et al., 1999; Vielhaber et al., 2000; Vielhaber et
al.,2003). Impaired mitochondrial function may lead to a cellular energy deficit. There is
a decrease in cytochrome-oxidase activity of individuals with SALS (Borthwick et al.,
1999). A study of ALS cybrids showed a significant decrease in complex-! activity and
increases in activities of free-radical-scavenging enzymes (Swerdlow et al., 1998).
Metabolically compromised neurones may be unable to maintain membrane potential,
resulting in opening of voltage dependent NMDA receptors and calcium influx.
Therefore, a much lower concentration of extracellular glutamate may initiate the
cascade of events leading to cell death.
1.3.3.6 Other Hypotheses
Motor neurones of SOD 1-mediated ALS most likely die as a result of apoptosis (Martin,
1999). In mice expressing G39A SOD1 mutation, the expression of anti-apoptotic Bcl-2
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delayed the onset ofMND and prolonged life (Kostic et al., 1997). However, some
studies have shown that motor neurone death in ALS is not apoptotic (He and Strong,
2000). Cyclin-dependent kinases (Cdks) are proline-directed Ser-Thr kinase
phosphorylating cell cycle and cytoskeletal proteins. The p35/Cdk5 complex is essential
for neurite outgrowth, cell adhesion, cortical development, neuronal adaptive changes,
and motor functions(Dhavan and Tsai, 2001; Smith et al., 2001). Mislocalization and
deregulation of Cdk5 activity by association with p25, a toxic capain-truncated form of
p35, also participate in the pathogenesis of ALS (Nguyen et al., 2001). Recently, a study
reports the detection of abnormal cell cycling signaling associated with Cdk5
deregulation in mice expressing a mutant G37R SOD1 linked to human ALS and its
potential involvement in motor neurone death (Nguyen et al., 2003).
1.3.4 Pathogenesis of Spinal Muscular Atrophy
SMN protein is found in both cytoplasm and nucleus of all tissues, with the greatest
expression in the brain, spinal cord and muscle, and the lowest expression in the
lymphocytes and fibroblasts (Coovert et al., 1997; Lefebvre et al., 1997). SMN forms a
complex with a series of proteins: Gemin 2 (Liu et al., 1997), Gemin 3 (a DEAD box
putative RNA helicase) (Charroux et al., 1999; Campbell et al., 2000), Gemin 5 (Gubitz
et al., 2002), the spliceosomal small nuclear ribonucleoprotein (RNP) Sm and Lsm
protein (Fischer et al., 1997), the small nucleolar RNP proteins including fibrillarin and
GAR1 (Jones et al., 2001; Pellizzoni et al., 2001a), heterogeneous nuclear RNP-Q and
coilin (Hebert et al., 2001). Another two proteins which are components of the SMN
complex with are Gemin 4 and Gemin 6, two novel proteins of unknown function
(Charroux et al., 2000; Pellizzoni et al., 2002). SMN can also interact directly or
indirectly with the FUSE-binding protein (Williams et al., 2000), transcription factor E2
(Strasswimmer et al., 1999), profilins (PFN-1 and 2) (Giesemann et al., 1999), a zinc-
finger protein called ZPR1 (Gangwani et al., 2001), RNA helicase A, RNA polymerase
II (Pellizzoni et al., 2001b), and RNA (Bertrandy et al., 1999). The complex has been
shown to function in snRNP biogenesis, cycling between the cytoplasm and nucleus. In
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the nucleus, it is involved in pre-mRNA splicing. PFN-2 is neurone specific and
functions in the depolymerization of actin filaments, suggesting a possible role for the
SMN-PFN-2 complex in neural transport (Giesemann et al., 1999).SMN has also been
reported to interact with the anti-apoptotic protein Bcl-2 (Iwahashi et al., 1997),
suggesting an interesting perspective for a role of the SMN protein in regulation of
cellular survival and with NAIP-mediated anti-apoptotic activity (Liston et al., 1996;
Roy et al., 1997). However, some studies do not show this interaction (Coovert et al.,
2000). The function of SMN protein is not fully understood and further studies will help
in elucidate the tissue specificity of the disease. The creation of an animal model using
conditional mutagenesis of the SMN gene should contribute to an understanding of the
pathogenesis of SMA.
1.4 Eukaryotic Translation Elongation Factor 1A2
1.4.1 An Overview of Translational Elongation
Eukaryotic protein synthesis is a highly complex process and uses large quantities of
cellular energy. The process comprises three steps: initiation, elongation, and
termination, followed by folding and, in many cases by post-translational modifications,
which give the protein a functional tertiary structure. After initiation, the formation of
the 80S initiation complex is followed by the repetitive cyclic event of pept ide chain
elongation, which is a series of reactions catalyzed by elongation factors (in eukaryotes
denoted as eEFs). Aminoacylated tRNA (aa-tRNA) is placed in the A (acceptor) site of
the ribosome prior to peptide bond formation with an amino acid or peptide attached to
the tRNA in the ribosomal P site. In eukaryotes, the factors involved in aa-tRNA
recruitment are eEFIA and eEFIB (EE-Tu and EF-Ts in prokaryotes respectively),
while translocation requires eEF2. In humans, eEFIB is composed of three subunits:
eEFl Ba, eEFlBp and eEFl By, and these subunits form a complex with eEFIA into a
'heavy' complex (eEFlH) (Janssen et al., 1994). In mammalian cells, eEFIA exists in









Figure 1-1 Translation elongation. Reproduced from Abbott and Proud (2004).
two different isoforms: the ubiquitous eEFl A1 and the tissue-specific eEFl A2 (Knudsen
et al., 1993). eEFlA binds GTP in the active form and then forms a complex with aa-
tRNA, which is carried to the A site. The ribosome triggers the hydrolysis of GTP, and
inactive eEFlA:GDP leaves the ribosome. The inactive GDP form is recycled to the
GTP conformation by guanine nucleotide exchange factor (GEF) eEFIB (Edmonds et
al., 1998). eEFlBa and eEFlBp, but not eEFl By, have nucleotide exchange activity,
particularly at their C-terminal regions. The ribosome acts as a GTPase-activating
protein for eEFlA. The regulation ofeEFlA activity by GTPase-activating proteins and
GEFs is critically important in efficient and accurate protein synthesis. However,
translational elongation activity is inversely related to translational fidelity (Carr-Schmid
et al., 1999). Abnormal high levels of elongation activity may result in premature
termination, or missense errors.
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1.4.2 eEF1A2 as an isoform of eEF1A
The mouse Eefla and human EEF1A belong to a multigene family, which are often
expressed in a developmental- or tissue-specific manner. In mammalian genome, many
Eefla-Wkz sequences exist and most of these are suspected to be pseudogenes, which all
originate from Eeflal (Uetsuki et al., 1989; Madsen et al., 1990; Ann et al., 1991; Lund
et al., 1996). The cDNAs of two actively transcribed isoforms of EEF1A in human, and
Eefla in rat and mouse have been cloned, with extensive homology to each other but
with a different 3'-UTR region (Brands et al., 1986; Lu and Werner. 1989; Ann et al.,
1991; Shirasawa et al., 1992; Knudsen et al., 1993; Lee et al., 1994). The two isoforms
are 92.4% identical at the amino acid level (Knudsen et al., 1993),and display equal
activities in an in vitro translation assay (Kahns et al., 1998). However, eEFlAl is
expressed ubiquitously (Lee et al., 1993b; Lee, et al., 1995), whereas eEFl A2 is
expressed tissue-specifically in terminally differentiated cells in brain, heart and skeletal
muscle (Lee et al., 1992; Knudsen et al., 1993; Lee et al., 1993b). Upregulation of
Eefla2 in brain, heart and muscle is shown to coincide with down-regulation of Eeflal
(Lee et al., 1992; Lee et al., 1993b; Lee et al., 1995), indicating that eEFlA2 takes over
the function of eEFl Al in protein synthesis in a tissue-specific manner. Human EEFlAI
has been mapped to chromosome 6ql4 by combined fluorescence in situ hybridization
(FISH) and PCR analysis of a somatic cell hybrid panel, and EEF1A2 has been mapped
to chromosome 20ql3.3 by FISH (Lund et al., 1996). Both human EEFlA1 and EEF1A2
have been cloned and sequenced, and the structure of each gene has been analyzed
(Uetsuki et al., 1989; Bischoff et al., 2000).
1.4.3 A Switch of Expression
Eeflal and Eefla2 are independent genes under different developmental control (Lee et
al., 1993b). In brain, heart and skeletal muscle, Eeflal mRNA levels are significantly
higher in developing embryos compared to those observed in adult tissues and stay
relatively constant throughout embryonic life. However, Eeflal expression is regulated
in a different manner in these different tissues. Its expression is downregulated but at a
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different time during development. The most dramatic decrease is in muscle and heart,
where levels ofEeflal diminish by 95% within the first month of postnatal life and
coincide with the termination of the myogenic process (Lee et al., 1993b). Eeflal
mRNA is detected late during embryonic period in brain and muscle, and steadily
increased to reach a plateau early during postnatal life. During in vivo neurogenesis and
myogenesis, Eefla2 mRNA accumulation correlates with the formation of postmitotic
neurones and myocytes. Both Eeflal and Eefla2 mRNA levels are remain steady after 1
month postnatal, indicating that their expression are independent of the aging process
(Lee et ah, 1992). The switch of expression most likely occurs once Eefla2 mRNA has
accumulated to levels capable of compensating for the reduction in the amount of
Eeflal (Lee et al., 1995). In the brain, Rnase protection analysis of total RNA isolated
from primary cultures of neonatal rat neurones, astrocyte and microglia demonstrates
that Eefla2 expression is strictly limited to terminally differentiated neurones (Lee et al.,
1995). Using in situ hybridization, Eefla2 mRNA has been shown to localize in certain
neurones, such as motor neuronees of the brain stem and Purkinje neurones in the
cerebellum (Lee et al., 1993a). In the brain of adult mice, eEFl A2 protein is also
demonstrated to localize in neurones, whereas eEFlAl is found in non-neuronal cells
(Khalyfa et al., 2001). Like its mRNA, eEFl A2 protein is present only in brain, heart
and skeletal muscle. In neurones, eEFl A1 is the major isoform prior to postnatal day 7.
but it is later replaced by eEFlA2, which is the only isoform present by postnatal day
14. The appearance of eEFl A2 protein during postdevelopmental period and the decline
in eEFl Al expression in brain, heart and muscle suggest that eEFl A1 is the embryonic
form of peptide elongation factor, whereas eEFl A2 is the adult form (Khalyfa et al.,
2001).
The switch of expression between eEFl Al and eEFlA2 has also been shown in toxin-
induced skeletal muscle injury in rats (Khalyfa et al., 1999). eEFlAl is rapidly
upregulated immediately after the Marcaine treatment, and corresponds with a decrease
of eEFl A2 protein presence. However, this switch is reverted when regeneration-
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associated proliferation ceases. An increased level of Eeflal mRNA expression has
been also observed in types 1 and 2 human diabetics as well as in nonobese diabetic
mice (Reynet and Kahn, 2001). Recently, it is shown that the expression of eEFl A2
protein is activated upon myogenic differentiation (Ruest et al., 2002). Differentiating
myoblast cultures express eEFlA2 protein at a late stage ofmyotube differentiation.
Upon serum deprivation-induced apoptosis, eEFl A2 protein disappears and is replaced
by eEFl Al in dying myotubes (Ruest et al., 2002).
1.4.4 Functions of eEF1A2
Although eEFlAl and eEFl A2 proteins share similar features such as molecular weight
of about 50 kD, pi 9.76, transcript length 1.8-1.9 kb, and 92.4% primary amino acid
sequence identity, the function of eEFl A2 is still elusive. Work in Xenopus and
Drosophila has shown that the amino acid differences have not led to an important
modification in function (Frydenberg et al., 1991; Morales et al., 1991). However, in
order to understand the functions of eEFlA2, it is worth briefly reviewing the functions
of eEFl Al. eEFlAl, which constitutes 1-3% of the total cytoplasmic content of the
eukaryotic cell (Slobin, 1980), is a component of the valyl-tRNA synthase complex (Bee
et al., 1989), is associated with the mRNA ribonuclease protein complex, and is a
participant in protein degradation (Merrick, 1992), including ubiquitin-dependent
degradation ofNa-acetylated proteins (Gonen et al., 1994). It has also been identified as
an actin-binding protein (Yang et al., 1990), functions in the reorganization of the cell
cytoskeleton, and is a component of the spindle-organizing centre in mammalian cell
(Marchesi and Ngo, 1993). An interaction between eEFlAl and calmodulin (Kaur and
Ruben, 1994) and between eEFlAl and microtubule (Shiina et al., 1994) have been
described. Most cytoplasmic mRNA is anchored to either microtubules or actin
filaments in eukaryotic cells, suggesting that the ability of eEFl Al to alter the assembly
and geometry of these polymers may be a crucial property of eEFlAl in regulating
peptide elongation (Condeelis, 1995). Moreover, eEFl A1 is known to be involved in
embryogenesis (Krieg et al., 1989), delayed cell senescence (Shepherd et al., 1989), cell
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proliferation (Sanders et al., 1996) and oncogenic transformation (Tatsuka et al., 1992).
eEFl A1 is shown to be an overexpressed actin-binding protein in metastatic rat
mammary adenocarcinoma (Edmonds et al., 1996). eEFlAl has been also shown to bind
viral RNA and RNA polymerase (Blackwell and Brinton, 1997; Das et al., 1998).
Because of the tissue-specific characteristics of eEFl A2, one cannot absolutely infer that
it functions in the same as eEFlAl. And why two isoforms of eEFl A exist is still
unclear. eEFlA2 acts as an important factor in protein synthesis as demonstrated by its
activity in poly(U)-directed polyphenylalanine synthesis assay (Kahns et al., 1998).
eEFlA2:GDP complex may exchanges GDP foe GTP to repeat the cycle of peptide
elongation during protein synthesis (Negrutskii and El'skaya, 1998). A comparison of
the GTPase activity has been shown that eEFlAl and eEFl A2 have indistinguishable
activity in an in vitro translation system. However, the GDP dissociation rate constant is
about 7 times higher for eEFlAl than for eEFlA2, and eEFlA2 binds GDP more
strongly than GTP whereas the opposite is true for eEFl Al (Kahns et al., 1998).
eEFl A2 is a specific binding partner to the M4 muscarinic acetylcholine receptor
(mAChR), and M4 mAChR acts as guanine exchange factor for eEFl A2 (McClatchy et
al., 2002). Differences in post-translational modification pattern might determine their
differences in nucleotide preference. Two methylation sites in eEFlAl (Lys55 and
Lysl65) are also modified in eEFlA2, but these two site are dimethylated in eEFl A1
whereas are trimethylated in eEFlA2 (Kahns et al., 1998). These trimethylated sites in
eEFl A2 may play a particular role in the synthesis of particular proteins in muscle.
Studies show that GTP inhibits binding of eEFl Al to G-protein, whereas GDP does not
have this effect (Dharmawardhane et al., 1991). This may affect the ability to bind actin
of eEFlA2 or at least in different manner from eEFl Al. Asparagine at position 197 in
eEFlAl is shown to influence nucleotide binding (Kahns et al., 1998). In eEFl A2, this
position is histidine. It seems likely that change of residue 197 could explain the
different nucleotide dissociation rate of the two isoforms. Protein synthesis consumes a
high proportion of cellular energy, and vast majority of this is used in peptide
elongation. It would be advantageous for particular cells to reduce the rate of protein
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synthesis in order to allow energy to be diverted to other processes, such as maintaining
membrane potential in neurones or supporting contraction in heart and skeletal muscle.
It could be possible that eEFl A2 uses less energy than eEFl A1 for the elongation
process. Studies using the yeast two-hybrid system have demonstrated that eEFl A2, in
contrast with eEFlAl, shows no or only a very weak affinity for the GEFs (Mansilla et
al., 2002). However, the N-terminal region of eEFlBa, which is not present in the
crystallographic structure, and subtle structural diversity caused by the amino acid
difference, may be involved in the interaction between eEFl A2 and GEFs, (Andersen et
al., 2000; Mansilla et al., 2002).
eEFlA2 is likely to be an important human oncogene (Lee, 2003). EEF1A2 gene is
amplified and its mRNA overexpressed in -30% of primary human ovarian cancer
(Anand et al., 2002). Expression of wild-type eEFl A2 transforms rodent fibroblasts and
increases their tumorigenicity in nude mice (Anand et al., 2002). Amplification of
EEF1A2 and increased eEFl A2 mRNA and protein overexpression has also been
reported in lungs and breast tumors (Wang et al., 2004; Tomlinson et al., 2005; Kulkarni
et al., 2006). In lung cancer, high expression of eEFl A2 correlates with increased Ki-67
expression and is associated with poor prognosis (Wang et al., 2004). Furthermore,
eEFlA2 may also have a role in metastatic development and it is overexpressed in
metastatic rat mammary adenocarcinoma cell lines relative to non-metastatic controls
(Pencil et al., 1993; Edmonds et al., 1996). Although these observations implicate
eEFlA2 in oncogenesis, little is known about the molecular mechanisms by which
eEFlA2 could enhance tumour development.
It has also been shown that the continuous expression of eEFl A2 resulting from
adenoviral gene transfer protects differentiated myotubes from apoptosis, in which
eEFlAl replaces eEFlA2, by delaying their death, suggesting a protective function for
eEFl A2 in skeletal muscle (Ruest et al., 2002). This noncanonical function of the two
proteins could probably explain the developmental switch of the two isoforms.
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eEFlA has been determined by mass spectroscopy to be a possible binding partner for
Akt2 and ectopic eEFl A2 expression has been shown to increase Akt (also known as
protein kinase B, PKB) abundance (Lau et al., 2006). Recently, eEFl A2 has been
demonstrated to be a novel activator ofAkt (Amiri et al., 2006). Akt activation by
eEFl A2 is dependent on PI3K. Furthermore, eEFlA2 induces filopodia production in
rodent and human cell lines and enhances cell division and migration in an Akt- and PI3-
K-dependent manner (Amiri et al., 2006). This indicates an important role for eEFl A2
in controlling phophatidylinositol signalling, actin remodelling, and cell motility.
1.4.5 Subcellular Localization and Protein-Protein Interaction
1.4.5.1 Interaction of eEF1A and ZPR1
eEFl A is preferentially located in the cytoplasm of cells (Edmonds et al., 1996; Minella
et al., 1996). eEFl A is reported to associated with the cytoskeleton through binding to
actin, and furthermore to have a pronounced presence in the nucleus (Codings et al.,
1994; Janssen et al., 1994; Barbarese et al., 1995; Billaut-Mulot et al., 1996; Sanders et
al., 1996). Upon mitogenic stimulation, a fraction of the cytoplasmic eEFl A is shown to
translocate into nucleus in complex with the zinc finger protein ZPR1 (Gangwani et al.,
1998). ZPR1 is located in the cytoplasm of quiescent mammalian cells, and
redistribution of ZPR1 from the cytoplasm to the nucleus can be occurred in
proliferating cells by treatment with mitogens, including epidermal growth factor (EGF)
(Galcheva-Gargova et al., 1996), suggesting that ZPR1 may function as a mitogenic
signaling molecule. ZPR1 also binds to a group of tyrosine kinase receptor such as the
EFG and platelet-derived growth factor receptors, but this binding is blocked after
mitogenic stimulation (Galcheva-Gargova et al., 1996). ZPR1 is about 98% cytoplasmic
in serum-starved cells and is about 96% nuclear in EGF-treated cells, whereas eEFl A is
not detected in the nucleus of serum-starved cells and 5% of the total eEFl A is detected
in the nucleus after stimulation with EGF, indicating that both ZPR1 and eEFl A are
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located in the nucleus ofmitogen-treated cells (Gangwani et al., 1998). The distribution
of ZPR1 in the nucleus has been demonstrated to correspond to an accumulation within
nucleoli (Galcheva-Gargova et al., 1996), and this distribution is characterized by
colocalization of ZPR1 with fibrillarin and RNA polymerase I (Galcheva-Gargova et al.,
1998). eEFIA can bind RNA and interact with RNA polymerase (Blackwell and
Brinton, 1997; Das et al., 1998). It is possible that the nucleolar complex of ZPR1 and
eEFl A may functionally interact with RNA. Disruption of the binding of ZPR1 to
eEFIA by mutational analysis results in an accumulation of cells in the G2/M phase of
cell cycle and defective growth (Gangwani et al., 1998).
Using monoclonal antibodies raised against ZPR1, ZPR1 was shown to localize in
nuclear structures called gems and Cajal bodies (Gangwani et al., 2001).
Immunoprecipiation experiment with monoclonal antibody to ZPR1 from extracts of
[^Sjmethionine-labeled A431 cells and western blot analysis revealed a prominent 40
kDa band of SMN (Gangwani et al., 2001). In addition, immunoprecipitations using
anti-SMN monoclonal antibodies from [ "Sjmethionine-labeled HeLa cell cytoplasmic
extract often pull down two unidentified bands of 60 and 50 kDa, which are similar to
molecular weight of ZPR1 and eEFIA respectively (Charroux et al., 2000). These
evidences raise a question if ZPR1 and eEFIA could be part of the SMN complex.
1.4.5.2 Interaction of ZPR1 and SMN
Like ZPR1, SMN protein is present in the cytoplasm and in small subnuclear bodies,
including gems (gemini of coiled bodies) and Cajal (coiled) bodies (Liu and Dreyfuss,
1996; Matera and Frey, 1998; Carvalho et al., 1999). Immunolocalisation studies using
anti-SMN monoclonal antibodies show several intense dots in HeLa cell nuclei, and
these structures are Cajal bodies (Liu and Dreyfuss, 1996). Gems differ from Cajal
bodies, in part, because of the absence of p80 coilin. In contrary, ZPR1 is not shown to
colocalize with p80 coilin (Gangwani et al., 1998). These SMN-containing subnuclear
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bodies are not detected in some cell types, including cardiac muscle (Young et al.,2000).
It has been reported that cytoplasmic SMN is involved in the biogenesis spliceosomal
small nuclear proteins (snRNP) (Fischer et al., 1997; Liu et al., 1997) and that nuclear
SMN may be involved in pre-mRNA splicing (Pellizzoni et al., 1998). SMN has also
been implicated in axonal transport in the spinal cord (Pagliardini et al., 2000).
Redistribution of SMN and ZPR1 from the cytoplasm to the nucleus is disrupted in cells
from patients with SMA type I that have SMN1 mutation (Gangwani et al., 2001).
Decreased ZPR1 expression prevents SMN localization to nuclear bodies, suggesting
that ZPR1 is required for SMN redistribution (Gangwani et al., 2001). IfeEFlAl or
eEFl A2 colocalises with ZPR1 or SMN, it would be interesting to study the role of
eEFIA on ZPR1 or SMN localization.
1.5 Denervation and Muscles
1.5.1 An Overview
Denervation, injury, immobilization, bed rest, steroid therapy, sepsis, cancer, and aging
are causes ofmuscle atrophy (Jagoe and Goldberg, 2001). The maintenance of muscle
mass is controlled by a balance between protein synthesis and protein degradation.
Denervation, immobilization, and unweighting in rats result in similar rate of loss in
muscle mass, consistent with the idea that there are common mechanisms leading to
atrophy (Bodine et al., 2001). Skeletal muscles in vertebrate derive from the paraxial
mesoderm. In response to numerous inductions, muscle precursor cells (myoblasts) start
expressing several transcriptional activators, which control the expression of muscle
structural genes. A family of four proteins with such a regulation function has been
identified, consisting ofMyoD, myogenin (Edmondson and Olson, 1989; Wright et al.,
1989), myf5 (Braun et al.,\ 989)and myogenic regulatory factor (MRF) 4 (Rhodes and
Konieczny, 1989), collectively referred to as the MyoD family (Buckingham, 1992).
Myogenin and MyoD have been shown to be nuclear proteins (Tapscott el al., 1988;
Chapter 1 - Introduction 27
Brennan and Olson, 1990). This family belongs to a group of proteins containing a basic
DNA-binding motif and a basic helix-loop-helix (bHLH) dimerization domain,
including protooncogene c-myc (Stone et al., 1987), the protein Twist involved in
mesoderm formation (Thisse et al. ,1988), and the achaete-scute involved in
neurogenesis (Villares and Cabrera, 1987). MyoD, myogenin, myf5 and MRF4 are
expressed exclusively in skeletal muscle; there is no detectable expression in cardiac or
smooth muscle. In addition to activating the expression ofmuscle-specific genes
associated with terminal differentiation, members of the MyoD family can activate one
another's expression and positively autoregulating their own expression in transfected
cells (Thayer et al., 1989; Edmondson et al., 1992). Members of the MyoD family
contain transcription activation domains in their amino and carboxyl termini that are
important for efficient activation ofmuscle-specific transcription. The myogenic bHLH
region functions in only certain cellular context. It plays a dual role in the control of
muscle-specific transcription by mediating DNA binding and by conferring specificity to
transcriptional activation (Davis et al., 1990; Anthony-Cahill et al., 1992). Fine mapping
of the basic regions ofMyoD and myogenin has revealed that two adjacent amino acid,
alanine and threonine, which compose a so-called myogenic recognition motif, in the
center of their DNA-binding domains confer muscle specificity to the basic region
(Davis et al., 1990; Brennan et al., 1991).
All bHLH proteins recognize the nucleotide consensus sequence CANNTG, known as
E-box, which is found in the control regions ofmost skeletal muscle-specific genes
where it mediates muscle-specific transcription and trans-activation by myogenic HLH
proteins (Lassar et al., 1989; Emerson, 1990; Olson, 1990; Weintraub et al.. 1991).
These E-boxes are surrounded by binding sites for other transcription factors that
collaborate with the myogenic regulators to induce muscle transcription. The muscle
creatine kinase gene, for example, is regulated by an enhancer that contains binding sites
for myogenic HLH proteins, the muscle enhancer factor-2 (MEF-2), and the mesoderm-
restricted homeodomain protein MHox (Cserjesi et al., 1992). However, there are
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muscle genes that are regulated by myogenic HLH proteins but which lack E-boxes.
Activation of these types of genes is mediated by "intermediate" myogenic factors,
which are themselves regulated by the MyoD family. Among these factors is MEF-2, a
member of the MADS box family of transcription factors (Pollock and Treisman, 1991;
Yu et al., 1992). MEF-2 binds an A+T rich element found in the promoters and
enhancers of numerous muscle-specific genes. MEF-2 transcripts are ubiquitous but
accumulate preferentially in skeletal muscle, heart and brain, and detected only in
skeletal and cardiac muscle nuclei, not in myoblast and nonmuscle cells (Yu et al.,
1992). It has been reported to participate in the activation of genes specifically expressed
in skeletal muscle, heart and neuronal tissues (Black and Olson, 1998; Krainc et al.,
1998). Therefore, MEF-2 may be a plausible candidate as a factor that activates the
expression of eEFlA2.
MyoD and myf5 are expressed in proliferating myoblasts prior to initiation of
differentiation, whereas myogenin does not become expressed at high levels until
differentiation has been triggered by withdrawal of growth factors (Sassoon et al., 1989).
Myogenin is expressed during differentiation of all skeletal muscle cells, suggesting that
the myogenin gene responses to a common myogenic regulatory pathway or is essential
for skeletal muscle differentiation (Sassoon et al., 1989). MyoD is important for
inducing myoblast fusion. Transactivation experiments indicate that MRF4 differs from
myogenin and MyoD in its ability to activate certain muscle specific genes (Yutzey et
al., 1990). MRF4 fails to activate transcription of the muscle creatine kinase, troponin-1,
and myosin light chain-1/3 enhancers, whereas MyoD, myf5 and myogenin bind with
equivalent affinities to the E-boxes of these genes.
1.5.2 Expression of Genes in Denervated Muscles
Responses ofmuscle to denervation can indicate that innervation modulates processes in
the myofibre (Merlie et al., 1984; Witzemann et al., 1989). Innervation down-regulates a
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subset of skeletal muscle synaptic proteins, such as nicotinic acetylcholine receptors
(nAChRs) (Schuetze and Role, 1987), voltage-gated sodium channels, and adhesion
molecules (Covault et al., 1986), but does not modify the expression of other enzymes or
structural proteins, such as creatine kinase, myosin light chain, and skeletal a-actin.
nAChR genes, as well as other genes encoding for synaptic proteins, are initially
expressed during myoblast differentiation but are later down-regulated by innervation.
Myogenin and MyoD mRNA levels are down-regulated by innervation (Eftimie et al.,
1991). Denervation of adult muscle leads to a large accumulation of both transcripts.
The changes in myogenin and MyoD mRNA levels during innervation, and after
denervation, precede the changes of nAChR mRNA (Eftimie et al., 1991).
The muscular chloride channel C1C-1 mRNA levels are shown to be down-regulated in
denervated muscles (Sedehizade et al., 1997). C1C-1 is essential for a normal excitability
ofmature muscle fibres (Klocke et al., 1994), and not found in myotubes (Steinmeyer et
al., 1991). Its mRNA levels are upregulated during the first few weeks after birth. The
functional destruction of the C1C-1 channel lead to the disease myotonia (Koch el al.,
1992).Whereas C1C-1 mRNA levels are lowered in mouse model of SMA, the a-subunit
of nAchR (nAChRa), MyoD and myogenin mRNA levels are strongly elevated in
muscle affected (Sedehizade et al., 1997). Myogenin and MyoD are known to control
the expression of the nAChRa gene by binding to and activating the enhancer region of
the nAChRa gene (Piette el al., 1990; Eftimie et al., 1991). This might be the reason
why there is the positive correlation between the expression of nAChRa, myogenin and
MyoD mRNA.
1.5.3 Other Muscle-Specific Genes
There also are other muscle-specific genes that are developmentally regulated, and
display isoform switching. Some of these are genes encoding contractile proteins, and
others are genes encoding enzymes involved in energy metabolism. Myosin heavy chain.
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a major component of contractile apparatus, has several developmentally regulated
isoforms. An embryonic isoform is replaced with neonatal isoforms during development,
and these are later replaced by fibre-type specific adult isoforms (Schiaffino et al., 1989;
LaFramboise et al., 1991). The functional significance of these complex changes might
lie in the different physiological needs of fetal, neonatal and adult muscles (Reiser et al.,
1988). Troponin T is another contractile protein that undergoes complex changes in
isoform type during development (Wang et al., 2001). Creatine kinase (Martinuzzi el al.,
1986; Schweighoffer et al., 1986), aldolase A (Schweighoffer et al., 1986), lactic
dehydrogenase (Martinuzzi et al., 1988), glycogen phosphorylase (Martinuzzi et al.,
1986; Schweighoffer et al., 1986; Martinuzzi et al., 1988), phosphoglycerate mutase
(Martinuzzi et al., 1988), and cytochrome c oxidase (COX) Via (Taanman et al., 1992)
are examples of muscle enzymes that switch from their fetal, or ubiquitous, non-muscle
isoforms to the correspondent muscle isoforms as development progresses.
1.5.4 Mitochondrial Translation and Tissue-Specific Mitochondrial
Proteins
In addition to COX Via, an alternative spliced variant of the voltage-dependent anion
channel (VDAC, also called porin) isoform 3 is also specifically expressed to brain,
heart and skeletal muscle in the mouse (Blachly-Dyson et al., 1993; Sampson et al.,
1998). VDACs are functionally conserved proteins found in the outer mitochondrial
membrane of all eukaryotes, and are the binding site for a few muscle enzymes,
including creatine kinase. VDACs also conduct ATP. Oxidative phosphorylation
(OXPFIOS) disorders are generally multisystemic diseases that affect predominantly
highly aerobic post-mitotic tissues, such as neurone and muscle (Smeitink et al., 2001).
Generation ofATP by OXPHOS ofADP requires the four complexes of the respiratory
chains (complexes I-IV) and ATP synthase (complex V), all ofwhich are located in the
inner mitochondrial membrane. These five complexes consist of subunits that are
encoded by both nuclear and mitochondrial genomes. The nuclear genomes encode most
of the mitochondrial proteins, and control many mitochondrial functions, including
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mitochondrial gene expression. In addition to coding for 13 structural proteins,
mitochondrial DNA (mtDNA) also codes for rRNA genes and tRNA genes, which are
required for mitochondrial translation (Grossman and Shoubridge, 1996). In human,
complex IV is the only respiratory chain complex that contains muscle-specific,
developmentally regulated subunits (Bonne et al., 1993). Nuclear gene defects that
impair mitochondrial translation have not been reported in patients with mitochondrial
disorders. Except for the rRNAs and tRNAs encoded in mtDNA, all of the elements
required for mitochondrial translation are encoded by nuclear genes. It is not known how
either initiation of translation or selection of the initiation codon takes place in
mammalian mitochondria.
1.5.5 Neuromuscular Junction and SMN
Using SMA animal models, it has been established that muscle atrophy precedes loss of
motor neurones (Frugier et al., 2000; Monani et al., 2000), and the observed muscle
phenotype was neurogenic in origin (Frugier et al., 2000). It has been shown that SMN
accumulates in growth-cone-like structure in neuronal cells during neuronal
differentiation (Fan and Simard, 2002). The amount and subcellular localization of SMN
vary during early mouse skeletal muscle development, and the cytoplasmic SMN peaks
at postnatal day 6 just prior to the maturation of the NMJ (Fan and Simard, 2002),
consistent with other reported indicating downregulation of SMN expression during
myogenesis in vitro (Burlet et al., 1998) and in comparisons of fetal and adult skeletal
muscles (Williams et al., 1999). During the first two weeks of postnatal life, diffuse
staining and numerous small dot-like SMN particles were detected, as well as intense
SMN staining in NMJ; however, after maturation, the intensity of cytoplasmic staining
and number of dot-like SMN particles decreased significantly while remaining
concentrated in the NMJ (Fan and Simard, 2002). These evidences suggest that the
cytoplasmic SMN may possess a neuronal- and muscle-specific function. mRNAs and
the structures needed for protein translation have been found in both neuronal dendrites
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and axons (Job and Eberwine, 2001), suggesting that eEFl A may be functionally
involved with SMN.
1.6 The wasted Mutant Mice and Eef1a2 Gene
Mice with the autosomal recessive gene wasted (wst), the spontaneous mutation arising
in the inbred mouse HRS/J variant at the Jackson laboratory in 1972, have been reported
to develop neurological and immunological abnormalities (Shultz et al., 1982). Wasted
mice, bearing homozygous wst/wst, can be recognized at 20 days of age by tremor and
uncoordinated body movements and then develop weight loss and progressive hindlimb
paralysis, and die by the age of 28 days. Neuropathological examination reveals
prominent vacuolar degeneration of anterior horn cells of the spinal cord and motor
nuclei of the brainstem with the prominent accumulation of phosphorylated
neurofilament heavy subunit (Lutsep and Rodriguez, 1989). Immunological involvement
accompanied at the same time includes decreased numbers of circulating B and T
lymphocytes, and progressive atrophy of spleen and thymus, which is the result of
significant decline in cell numbers in these organs (Shultz et al., 1982; Goldowitz et al.,
1985). Lymphoid cells from wasted mice aged more than 26 days have a defective
response to radiation-induced DNA damage whereas fibroblasts have a normal DNA
repair (Nordeen et al., 1984; Inoue et al., 1986; Tezuka et al., 1986). These observed
defects in DNA repair in wasted mice cells are not identical to those reported in cells
from patients with ataxia-telangiectasia, the human autosomal recessive disorder
characterized by immunodeficiency, ataxia, chromosomal instability, and
hypersensitivity of lymphocytes to ionizing radiation, which is caused by defects in the
ATM gene. Abnormally low levels of adenosine deaminase have been found in
erythrocytes from the wasted mouse, suggesting that wasted mice are immunodeficient
(Abbott et al., 1986). In addition, compared with normal mice, wasted mice also show
an increase in lymphocyte apoptosis (Potter et al., 1998).
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It has been shown that the wasted mutation is caused by a deletion spanning 15.8
kilobases that removes the promoter region and first exon, which is non-coding, in the 5'
region ofmouse Eefla2 gene on distal chromosome 2 (Chambers et al., 1998). No
evidence has been found of any other gene in this region. The deletion in this region
completely abolishes the detectable expression of this gene in brain, heart and skeletal
muscle. Expression of Eeflal is normal but, like non-mutant mice, gradually declines in
these tissues until is not detectable by postnatal day 25. Therefore, these tissues in
wasted mice do not express both Eeflal and Eefla2, probably leading to a deficiency of
protein synthesis in wasted mice, and development of neurological symptoms. However,
roles of eEFlA2 in peptide elongation remain to be proved, although a high level of
homology between these two proteins may suggest their similar functions. In the brain,
eEFlA2 has been shown to colocalize with the M4 subtype of the muscarinic AchR
(mAChR), and the intracellular third loop ofM4 behaves as a GEF for eEFl A2
(McClatchy et al., 2002), suggesting that eEFl A2 may play a role in the signaling ofM4
mAchR in the brain, and the absence of eEFl A2 may cause motor symptoms of upper
neurone degeneration via abnormal functioning ofmAchR.
1.7 Project Aims
The overall aim of this project was to address the relative roles of eEFl A2 in muscle and
neurone of wasted mice, which represent one of the few animal models for studying the
pathogenesis ofmotor neurone diseases. There were three related aspects to this project.
Firstly, to describe the characterization of neuromuscular abnormalities ofwasted mice.
Secondly, to study distribution and colocalisation of eEFlA2 and SMA. The last aim,
which was the major, crucial, experiment was to construct a muscle-specific transgene
and generate transgenic homozygous wasted mice that specifically express human
eEFl A2 in skeletal muscle, but not in neurones, in order to evaluate the phenotype that
results from loss of eEF!A2 in neurones but not muscle.
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Chapter 2 Materials and Methods
2.1 Materials
2.1.1 Solutions and buffers
Unless otherwise indicated, solutions and buffers were prepared using either distilled or
double distilled water, and were stored at room temperature. Cell culture media were
supplied by Invitrogen.
2.1.2 Chemicals and reagents
Unless otherwise indicated, all laboratory chemicals for general use were obtained from
either Sigma-Aldrich Ltd or Fisher Scientific Ltd.
2.1.3 Enzymes
Taq polymerase was supplied at a concentration of 5 U/pl by Invitrogen. High-fidelity
Tag polymerase was purchased from Invitrogen. Restriction enzymes and DNA ligase
were obtained either from New England Biolabs Applied Science or Roche. RNAase-A
and DNase-I were supplied by Ambion.
2.1.4 Cell lines
Epicurican Coli JM109 competent cells were obtained from Stratagene.
2.1.5 Vectors
pcDNAT3.1(+)C-myc-His plasmid was purchased from Invitrogen. pHSA2000CAT
plasmid was kindly provided by Edna Hardeman.
2.1.6 Antibiotics
All antibiotics were purchased from Sigma-Aldrich Ltd.
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2.1.7 Markers
The 1 kb ladder DNA marker was obtained from Gibco BRL Life Technologies. The
protein markers were obtained from Roche.
2.1.8 Mice
Non-transgenic and wasted mice were housed at the Biomedical Research Facility.
Transgenic mice were housed at the Transgenic unit at the Western General Hospital.
All mice were maintained in accordance with procedures outlined in the Home Office
Animals (Scientific procedures) Act 1986. They were maintained on a 12-hourlight/ 12-
hour dark cycle with access to food and water ad libitum. The diet was a standard chow
diet.
2.1.9 General reagents, solution and buffer preparations
2.1.9.1 General solutions and buffers
Acrylamide 30% stock (19:1)
25% Acrylamide, 1.5% N, N'-
methylenebisacrylamide
Acrylagelmide gel sample loading 2x stock
buffer 98% deionized formamide, 10 mM EDTA pl l 8.0,
0.025% xylene cyanol FF, 0.025% bromophenol
blue
Agarose gel sample loading buffer 20 g Ficoll, 20 ml of 500 mM EDTA, in 100 ml
dH20, Orange-G
10% Ammonium persulphate 10% weight: volume APS: dfLO
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Stored aliquots at 4 °C
Betaine 5.5 M in dH20
Stored aliquots at -20 °C
Bjerrum and Schafer-Neilson
transfer buffer
5.82 g Tris, 2.93 g Glycine, 0.375 g SDS, 200 ml
Methanol, dH20 to 1 L
DNA extraction buffer 10 mM Tris HC1 pH 7.0, 1 mM EDTA, 1%
Sodium dodecyl sulphate (SDS), 0.3 M Sodium
acetate pH 7.0
Deoxyribonucleoside triphospahtes 10 nM/pl of each dATP, dCTP. dGTP and dTTP in
dH20, stored aliquots at -20 °C
Ethidium bromide 10 mg/ml in dH20
Stored in darkness at room temperature
Laemnli running buffer 1 Ox stock
30.8 g Tris, 144.2 g Glycine, 10 g SDS, dH20 to
L
Microinjection buffer 10 mM Tris, 0.1 mM EDTA, pH 7.4
Autoclave and filter sterilize
Normal Ringer Solution 120 mM NaCl, 5 mM KC1, 2 CaCl2, 1 mM MgCl2,
0.4 NaH2P04, 23.8 NaHC03, 5.6 Glucose
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0.2 M Phosphate buffer, pH 7.6 13 ml of 0.2 M Sodium monobasic phosphate




25:24:1, Fluka (Sigma-Aldrich Ltd)
lOx PCR buffer lOx stock
750 mM Tris HC1 pH 9.0, 200 mM Ammonium
sulphate, 0.1% weight: volume Tween
10% Sodium dodecyl sulphate 10% weight: volume SDS: dFLO, pH 7.2
Heat to dissolve
Tail tip DNA extraction buffer 10 mM Tris pH 7.0, 1 mM EDTA, 1% SDS. 0.3 M
sodium acetate pH 7.0
lOx TAE 1 Ox stock
0.4 M Tris HCL PH 8.0, 0.2 M Sodium acetate. 10
mM EDTA, 9 ml/L glacial acetic acid
20x TBE 20x stock
1.8 M Tris, 1.8 M Boric acid, 40 mM EDTA, pH
8.0
TE (Tris-EDTA) 10 mM Tris HC1 pH 7.6, 1 mM EDTA pH 8.0
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2.1.9.2 Growth media for bacterial cultures
Luria-Bertani (LB)-agar 15 g/L Bacto-agar, 10 g/L Bacto-tryptone, 5 g/L
Bacto-yeast extract, 5 g/L NaCl, pi I 7.0
Luria-Bertani (LB)-broth 10 g/L Bacto-tryptone, 5 g/L Bacto-yeast extract. 5





stock 50 mg/ml in dH20
(50-100 pg/L in media)
stock 34 mg/ml in dL^O
(20 pg/L in media)
stock 10 mg/ml in dfLO
(10 pg/L in media)
2.1.9.4 Enzymes
Proteinase K stock 50 mg/ml in dfLO
2.1.10 General equipment
Unless otherwise indicated, centrifugation was performed on an eppendorf 5415
microfuge. The vortex used was a Jencons MSI minishaker. Absorbance at 260 and 280
nm were read on a Pharmacia Biotech Ultrospec 3000 spectrophotometer. Mice were
weight on a Soehnie, and their muscles were weighted on Sartorius BP150.
Chapter 2 - Materials and Methods 39
2.2 Methods
2.2.1 Standard DNA protocols
2.2.1.1 Extraction of genomic DNA from ear notches
Mice were ear notched at weaning (21 days old) for the purpose of identification and
genotyping. Early ear notching was performed at 18-20 days old in the case that early
phenotypes were to studied. There were two methods used.
2.2.1.1.1 Sodium hydroxide method
This is a quick method used for genotyping non-genetically modified mice. Mice were
ear notched and the ear pieces were stored at -20 °C to avoid degradation of genomic
DNA. DNA extraction was performed by boiling the ear notches in 0.6 ml of fresh 50
mM NaOH at 95 °C for 10 minutes. The tubes were vortexed and 50 pi of 1 M Tris-HCl
pH 8.0 was added. The tubes were centrifuged at maximum speed for 6 minutes. The
0.3-ml supernatant was transferred to a new tube, and stored at -20 °C. 1 pi was used in
the PCR.
2.2.1.1.2 Phenol: chloroform: isoamyl alcohol extraction
Phis method was used for genotyping transgenic mice and other mice that were housed
in the Transgenic unit because it gave a cleaner result. Ear notches were incubated at 55
°C on a rocking tray overnight in 200 ml of digestion buffer containging 5 pi of
Proteinase K (10 mg/ml). An equal volume of phenol: chloroform: isoamyl alcohol (25:
24: 1) was added to the DNA solution to be purified in a 1.5-ml microcentrifuge tube,
and mixed gently for 5 minutes on a rocking platform. The tube was then
microcentrifuged at for 10 minutes at 13,000 rpm at room temperature. The aqueous
(top) phase containing DNA was removed using a 1000-pl pipetor and transferred to a
new tube. The phenol: chloroform: isoamyl alcohol extraction steps were repeated until
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a white precipitate was not present at the aqueous/organic interface. The DNA was then
precipitated from the final aqueous phase by ethanol precipitation.
2.2.1.2 Small scale plasmid DNA preparation (miniprep, Sigma)
A single colony was inoculated into 5 ml of LB-broth containing 100 pg/ml ampici 11 in
in a 50-ml tube, and was incubated with vigorous shaking at 225 rpm at 37 °C overnight.
The cells were pelleted by centrifugation at 3000 rpm for 5 min. The cells were
resuspended in 200 pi of the Resuspension solution containing RNase A. The
resuspended cells were lyzed by adding 200 pi of the Lysis buffer. The cell debris was
precipitated by adding 350 pi of the Neutralization/Binding buffer, and was centrifuged
at more than 12,000 x g for 10 minutes. The clear lysate containing the plasmid DNA
was bound to the column and centrifuged at more than 12,000 x g for 1 minute. Then,
100 pi of TE buffer was used to elute the plasmid DNA.
2.2.1.3 Large scale plasmid DNA preparation (maxiprep, Sigma)
A single colony was inoculated into LB-broth containing an appropriate antibiotic, and
incubated with vigorous shaking at 225 rpm at 37 °C overnight. 150 ml of the overnight
culture was pelleted by centrifugation at 5000 x g for 10 minutes. The cell pellets were
resuspended in 12 ml of Resuspension/RNase A solution. 12 ml of Lysis solution was
added and gently mixed by inversion. The lysis reaction was incubated at room
temperature for 3-5 minutes. 12 ml of chilled Neutralization solution was added to the
mixture and mixed immediately by gentle inversion. The chromosomal DNA, cell
debris, proteins, lipids were allowed to precipitate for 5 minutes. The resulting lysate
supernatant was filtered by attaching vacuum source to VacCap and vacuum was
applied. 9 ml of Binding solution was then added to the filtered lysate. The filtered
mixture was transferred to the prepared Binding column with vacuum on. The lysate was
allowed to pass through. The column was then washed twice using Washing solution 1
and Washing solution 2 containing ethanol. The pellet was allowed to dye for 10
minutes. 3 ml of of dH20 was used to elute the plasmid DNA.
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2.2.1.4 Ethanol precipitation
The volume of the DNA sample was measured. The salt concentration was adjusted by
adding 1/10 volume of sodium acetate, ph 5.2, (final concentration 0.3 M). Aftermixing
well, 2 volume of ice-cold 100% ethanol (calculated after salt addition) were added and
mixed well again. The DNA was then allowed to precipitate for 20-30 minutes on ice.
The DNA was pelleted by centrifugation at 13,000 rpm for 15 minutes and the
supernatant was decanted. The DNA was washed twice with 70% ethanol and allowed to
air dry. The DNA was then resuspended in an appropriate volume (30-50 ul) of TE
buffer.
2.2.1.5 Spectrophotometric quantification of DNA
DNA concentration and purity of a sample was calculated from the optical density (OD),
which was determined by UV Spectrophotometry, e.g. DNA concentration (pg/ml) =
(OD260 - OD320) x 50 (DNA extinction coefficient) x dilution factor (i.e. 1000/20).
2.2.1.6 Restriction enzyme digestion
Restriction enzyme digestion was performed by incubating double-strand DNA
molecules with an appropriate amount of restriction enzyme. In its respective buffer as
recommended by the supplier, and at the optimal temperature for that specific enzyme.
Typical digestions included a unit of enzyme per microgram of starting DNA, and one
enzyme unit usually (depending on the supplier) is defined as the amount of enzyme
needed to completely digest one microgram of double-stranded DNA in one hour at the
appropriate temperature. The volume of the reaction depended on the amount and size of
the DNA being digested. Larger DNAs were digested in larger total volumes (between
50-100 pi), as were greater amounts of DNA. These reactions usually are incubated for
1 -3 hours, to insure complete digestion, at the optimal temperature for enzyme activity.
If the DNA was to be used in a subsequent manipulation such as dephosphorylation or
ligation, the enzyme was inactivated by heating at the recommended temperature for 10
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minutes. An aliquot of the digestion should be assayed by agarose gel electrophoresis
versus non-digested DNA and a size marker, if necessary. An aliquot of the digestion
was assayed by agarose gel electrophoresis versus non-digested DNA and a size marker,
if necessary prior to use in further procedures.
2.2.1.7 The polymerase chain reaction (PCR)
2.2.1.7.1 Primer design
The sequence of the gene of interest was searched on the NCBI and ENSMBL
databases. The location of introns, coding region and any other points of interest such as
polymorphism were studied. Oligonucleotide primers were designed using the Primer3.
The criteria used to select primers included (1) primers with similar melting
temperatures with 40-60% GC content, (2) size of PCR product between 150-500 bp, (3)
primers 18-22 nucleotides, (4) GC at 3' end of primer, (5) no primer should contain more
than 4 contiguous base pairs of homology to itself or counterpart and (6) the PCR
product should have a predicted melting temperature (Tm) of 76-82 °C. Primers were
placed on different exons so RNA-specific PCR is different in size from DNA
contamination. Primers were purchased from either Invitrogen or Sigma, which were
supplied as lyophilised products at a scale of synthesis of 50 nM.
2.2.1.7.2 PCR conditions
The amplification of DNA fragment using the PCR was performed in an MJ Gradient
Cycler, by adding the reagents to either a 0.2 ml thin walled tube or a 48 well microtitre
plate. Unless otherwise indicated, PCR was carried out in lxPCR buffer, with 200 Um
of dNTPs, 100 ug of each primer, 0.2 U of Taq polymerase, and template DNA, in a
volume of 25 pi. The pipettes, tips, tubes, and reagents were sterile and kept separately
from those used in other experiments. PCR reaction was set up in a designated room,
where PCR products were prohibited. After an initial denaturation step of 95 °C for 3
minutes, the actual cycling steps consisted of 25-30 cycles of a denaturation step of 95
°C for 30 seconds, the appropriate annealing temperature (usually 55 °C) for 30 seconds,
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and the extension step of 72 °C for 30 second, followed by the late extension step of 72
°C for 10 minutes. After PCR, aliquots of the mixture were loaded onto an agarose gel
and electrophoresed to detect amplified products.
2.2.1.8 Agarose gel electrophoresis
Agarose gel electrophoresis was employed to check the progression of a restriction
enzyme digestion, to quickly determine the yield and purity of a PCR reaction, and to
size fractionate DNA molecules, which then could be eluted from the gel. Prior to gel
casting, dried agarose is dissolved in buffer (0.5xTBE or lxTAE buffer) by heating and
the warm gel solution then was poured into a mold, which was fitted with a well-
forming comb. The percentage of agarose in the gel varied. Although 0.8% agarose gels
typically were used, in cases where the accurate size fractionation ofDNA molecules
smaller than l kb was required, a 1-2% agarose gel was prepared, depending on the
expected size(s) of the fragment(s). Ethidium bromide was included in the gel matrix to
enable fluorescent visualization of the DNA fragments under UV light. Agarose gels
were submerged in electrophoresis buffer in a horizontal electrophoresis apparatus. The
DNA samples were mixed with loading buffer and loaded into the sample wells.
Electrophoresis usually was at 150 - 200 mA for 0.5-1 hour at room temperature,
depending on the desired separation. When low-melting agarose was used for
preparative agarose gels, electrophoresis was at 100-120 mA for 0.5-1 hour, again
depending on the desired separation. Size markers were co-electrophoresed with DNA
samples, when appropriate for fragment size determination. After electrophoresis, the
gel was placed on a UV light box and an image of the fluorescent ethidium bromide-
stained DNA separation pattern was taken using a digital imager.
2.2.1.9 Elution of DNA fragments from agarose gel
DNA fragments were eluted from low-melting temperature agarose Ix TAE gels using
QIAquick gel extration kit (Qiagen). The band of interest was excised with a sterile
razor blade, placed in a microcentrifuge tube, frozen at -70 °C, and then melted.
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2.2.1.10 Purification of a PCR product for cloning
After an aliquot of the PCR mixture was analyzed on an agarose gel, the remainder of
the reaction was purified by QIAquick PCR purification kit (Qiagen), which was used
for purification of PCR products of 100 bp - 10 kb. After purification, amplified DNA
fragments were used to ligate into a cloning vector.
2.2.1.11 Treatment of plasmid DNA for cloning
Vector and construct DNA were digested with restriction endonucleases, and purified
from agarose gels (see 2.2.1.9). Removing 5' phosphates from the plasmid vector was
not performed to prevent self-ligation of the vector because all of the vectors used and
cut with two different restriction enzymes did not carried identical sticky ends.
2.2.1.12 Ligation of DNA
The enzyme used t ligate DNA fragments was T4 DNA ligase. Each reaction was
performed in a 20 ul reaction containing lx T4 DNA ligase buffer supplemented with
ATP, 1 U of T4 DNA ligase, insert and vector DNA, and distilled water. A 3-fold molar
excess of insert DNA: vector DNA was used for most cloning experiments. Ligations
were performed at 16 °C or 4 °C overnight to facilitate sticky end ligation.
2.2.1.13 Transformation of competent Escherichia coli
For subcloning transformations, the host cells used were E.coli strain JM109 (Epicurean
Coli) purchased from Stratagene, and stored at -80 °C. This E.coli strain is endonuclease
(iendA) deficient, greatly improving the quality of miniprep DNA, and is recombinant
(recA) deficient, improving insert stability. The cells were thawed on ice for 10 minutes.
A 100 pi aliquot was used for one transformation, which was performed in a 14-ml
Falcon tube. 3 pi of 20 pi ligation reaction were added, mixed with the cells, and
incubated on ice for 30 minutes. The cells were then heat-pulsed at 42 °C for 45 seconds,
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and returned to ice for another 2 minutes. 900 pi of pre-warmed LB media (with no
antibiotics) were added and mixed with the cells. The samples were then incubated at 37
°C on rotor-shaker at 225-250 rpm for 45 minutes to recover the cells. After incubation,
aliquots of 100 ul were plated on LB-agar plates (pre-warmed at room temperature) with
an appropriate selective antibiotic, and incubated overnight at 37 °C.
2.2.1.14 Colony screening
Autoclaved toothpicks were used to pick single colonies for PCR. A colony was first
suspended in a small amount of dL^O (typically 5 pi), and subsequently streated on a
fresh LB-agar plate. The suspended colony was incubated at 95 °C for 3 minutes, and I
ul was subsequently used for PCR.
2.2.1.15 Sequencing of DNA
Automated dye-terminator cycle-sequencing, which is a chain termination method, was
used to sequence plasmid DNA and PCR products. Plasmid DNA was ready for direct
sequencing once it had been extracted and appropriately diluted. PCR products,
however, first had to be cleaned (see 2.2.1.10). The primer was a primer used in PCR,
and each primer was used in a separate reaction. The DNA was sequenced in both
directions. The sequencing reactions were set up in 0.5 ml PCR tubes and contained
BigDye (which contains Taq DNA polymerase, standard dNTPs, and labeled ddNTPs;
ABgene), one primer, DNA template, and dcioniscd water to a total volume of 10 ul. The
sequencing process was carried out in an MJ Gradient Cycler, and comprised one cycle of
96 °C for I minute, followed by 24 cycles of 96 °C for 30 seconds, 50 °C for 15 seconds,
and 64 °C for 4 minutes. After the completion of the thermocycler steps, the labeled
sequencing products were run on polyacrylamide gels and sequenced on the ABI 3100
Automated Capillary DNA Sequencer (Applied Biosystem) at the MRC facility unit,
Western General Hospital. The sequences were then analysed using the Bioedit software.
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2.2.2 Reverse transcription - PCR (RT-PCR)
2.2.2.1 Isolation of total RNA from mouse tissues
The tissues of interest were removed from mice using sterile, RNase-free instruments.
The tissues were then flash frozen by immersion in liquid nitrogen and stored in
cryovials in liquid nitrogen prior to RNA extraction. The RNA samples were processed
simultaneously to reduce the variability among the different RNA samples. Total RNA
was isolated using TRIzolIM reagent. The 50-mg frozen tissue was homogenized in l.O
ml of TRIzol. 200 pi of chloroform for each 1.0 ml of TRIzol used were added. The
samples were vigorously shaked for 15 seconds and incubated for 3 minutes at room
temperature. The homogenate was then at 12,000 rprn for 15 minutes at 4 °C. The
colourless, upper aqueous phase containing the RNA was removed and transferred to a
clean microcentrifuge tube and 500 pi of isopropanolol per 1 ml of the T RIzol used were
added and mixed well. The RNA was allowed to precipitate at room temperature for 15
minutes, and then centrifuged at 12,000 rpm for 15 minutes at 4 °C. The supernatant was
discarded and the RNA pellets were washed twice using 1 ml of 75% ethanol. The
samples were vortexed after addition of each ethanol wash and centrifuged at 7,500 rpm
for 3 minutes at 4 °C. The last drop of ethanol was removed and the RNA pellets were
allowed to dry for approximately 10 minutes at room temperature. After drying, the
RNA pellets were resuspended in 1 pi ofDEPC-treated ddH20 per 1 mg of tissue
sample, vortex mixed, placed on ice for 10 minutes, heated at 65 °C for 10 minutes and
placed on ice before storage. The total RNA was stored at -70 °C.
2.2.2.2 Isolation of total RNA from HeLa cells
The PARIS1M kit (Ambion) was used to extract RNA from HeLa cells. The procedure
was done at room temperature as recommended by the manufacturer. The RNA was
eluted in 50 pi of Elution Solution, and stored at -70 °C. Prior to using the RNA in RT-
PCR, trace ofDNA contamination was removed by treating the RNA with DNase.
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2.2.2.3 Treatment of RNA for RT-PCR
The RNA was treated with recombinant DNase I (Ambion) to remove trace to moderate
amounts of contaminating DNA prior to using it in RT-PCR. 0.1 volume of lOx DNase I
buffer and 1 pi of DNase I were added to the RNA in 50 pi reaction. The sample was
then incubated at 37 °C for 20-30 minutes. 1 volume of DNase Inactivation Reagent was
added and the sample was incubated for 2 minutes at room temperature with occasional
mixing. The sample was centrifuged at 13,000 rpm for 1.5 minutes at 4 °C. The
supernatant containing treated RNA was transferred to a new tube.
2.2.2.4 Quantification of total RNA
RNA concentration and purity of a sample was determined by UV Spectrophotometry,
e.g. RNA concentration (pg/ml) = (OD260 - OD320) x 40 (RNA extinction coefficient) x
dilution factor (i.e. 500/10).
2.2.2.5 cDNA synthesis
First-strand complementary DNA was reversed transcribed from total RNA using
RETROSCRIPT kit (Ambion) according to the manufacturer's instructtions. The
Moloney-Murine Leukemia Virus (M-MLV) Reverse Transcriptase was chosen for its
higher stability and lower intrinsic RNase H activity, compared to AMV Reverse
Transcriptase. The traditional two-step RT-PCR was performed. 3 pg total RNA was
mixed with 2 pi of random decamers and nuclease-free water to a volume of 12 pi. The
sample was mixed, spinned, and heated at 85 °C for 3 minutes. The sample was then
placed on ice. To the sample were added 2 pi of lOx RT buffer, 4 pi of dNTPs mix, 1 pi
of RNase inhibitor, 1 pi ofM-MLV reverse transcriptase, and nuclease-free water to a
total volume of 20 pi. The sample was mixed gently and incubated at 42 °C for 1 hour.
The sample was then incubated at 92 °C for 10 minutes to inactivate the reverse
transcriptase. The cDNA was stored at -20 °C or was proceeded to the PCR (see
2.2.1.7.2).
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2.2.3 Real-time RT-PCR
2.2.3.1 Sample preparation
Muscles dissected from mice were flash frozen by immersion in liquid nitrogen and
stored in cryovials in liquid nitrogen prior to RNA extraction. Total RNA extraction was
performed using the PARIS kit (Ambion) according to the manufacturer's instructions.
The total RNA was eluted with 50 pi RNase-free elution solution by centrifugation, and
DNase treated (see 2.2.2.3). Isolated total RNA integrity was verified by an average
optical density (OD) OD260/OD280 nm absorbance ratio. 2 pg total RNA was reverse
transcribed with M-MLV reverse transcriptase in a volume of 20 pi, using random
decamers. Therefore, the concentration of 100 ng cDNA (reverse transcribed total RNA)
per pi was achieved. All reagents used for reverse transcription were obtained from the
RETROSCRIPT kit (Ambion). Finally, cDNA was diluted 1:2 with nuclease-free water
prior to using in real-time PCR.
2.2.3.2 Selection of primers for real-time RT-PCR
Primers were selected to bind specifically to mouse cDNA using Universal ProbeLibray
software (Roche Applied Science). The sequences of primers were shown in the
respective chapters. Primers were generated commercially by Invitrogen.
2.2.3.3 Optimisation of real-time PCR
Conditions of real-time PCRs were optimized in a MJ Gradient cycler with regard to
Taq polymerase, forward and reverse primers, and various annealing temperatures (55-
65 °C). RT-PCR amplication products were separated on a 4% agarose gel
electrophoresis. Optimised conditions were transferred on the real-time PCR protocols.
2.2.3.4 Real-time PCR
Real-time PCR mixture was prepared in a volume of 12.5 pi. containing lx iQ SYBR
Green Supermix (Biorad; 2x stock solution containing 100 mM KC1, 40 mM Tris-HCl
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pi I 8.4. 0.4 mM of each dNTP, iTag DNA polymerase 50 units/ml, 6 mM MgCh, SYBR
Green I, 20 nM fluoresein, and stabilizers), 100 pg of forward and reverse primers, and
nuclease-free water (Ambion). 50 ng Cdna was used as PCR template. The reactions
were performed in a 0.2-ml 98-well plate in the MyiQ cycler (Biorad). Each assay was
performed in triplets. The cycling conditions comprised 10 minutes of template
denaturation step at 95 °C, followed by 40 cycles of denaturation at 94 °C for 15 seconds
and primer annealing/extension step at the gene-specific primer temperature for 30
seconds. After the amplification and quantification programme, melting curve
programme was peformed at 60-95 °C with a heating rate of 0.1 °C per second. The
threshold cycle (Ct) for each transcript was defined as the point at which the
fluorescence rose appreciably above the background fluorescence, and determined by
MyiQ software (BioRad).
2.2.4 Cell culture
HeLa cells were maintained in Dulbecco's modified Eagle's medium (DMEM, GIBCO
BRL) containing 4,500 mg/L D-glucose and 2 mM L-glutamine supplemented with 10%
heat-inactivated fetal bovine serum (FBS), 0.1 mM non-essential amino acids (NEAA).
100 U/ml penicillin, and 100 U/ml streptomycin, at 37 °C with 5% CO2.
2.2.5 Transfection
Transient transfection was performed in HeLa cells using Lipofectamine 2000 Reagent
(Life Technologies). Cells were transfected with pcDNA3.1(+)C-hEEFl A2-myc which
was purified with GenElute Plasmid Miniprep kit (Sigma). The day before transfection.
the cells were trypsinised, counted, and plated in 24-well plates in 0.5 ml ofDMEM
containing 10% FBS and without antibiotics at 8 x 104 cells per well so that they were
90-95% confluent on the day of transfection. For each well of cells to be transfected, 0.8
pg of DNA was diluted into 50 pi ofOPT1-MEM I Reduced Serum Medium without
serum. 1.5 pi of Lipofectamine 2000 Reagent was diluted into 50 pi OPTI-MEM 1
Medium and incubated for 5 minutes at room temperature. The diluted DNA and the
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diluted Lipofectamine 200 Reagent were combined and incubated at room temperature
for 20 minutes to allow DNA-Lipofectamine 2000 Reagent complexes to form. Growth
medium was then removed from cells, and 0.5 ml ofmedium without serum was added
to each well, followed by adding of 100 pi of DNA-Lipofectamine 2000 Reagent
complexes directly to each well and mixing gently. The cells were incubated at 37 °C
with 5% CO2 for 4-5 hours. 0.5 ml ofDMEM with 20% FBS was added for a final
concentration of 10% FBS. The cells were incubated at 37 °C until 24 hours post-
transfection or until they were ready to assay for transgene expression.
2.2.6 Western blot analysis
2.2.6.1 Protein extraction
Tissues of interest were dissected from mice and immediately flash frozen by immersion
in liquid nitrogen, and stored at -70C. Tissues were homogenized in cold RIPA buffer
(150 mM NaCl, 10 mM Tris-HCl pH 7.2, 0.1% w/v SDS, 1.0% Triton X-100, 1% w/v
deoxycholate, and 5 mM EDTA) supplemented with lx Complete Antiprotease Cocktail
(Roche). Samples were centrifuged at 14,000 rpm at 4 °C for 5 minutes. Supernatants
were transferred to a new tube, quantified, and stored at -20 °C for further analysis.
2.2.6.2 Protein quantification
The Bradford protein assay was used to measure protein concentration, using the
Bradford DC Protein Assay detection kit (Biorad) according to the manufacturer's
instructions. 25 pi of Reagent A and 200 pi of Reagent B were mixed with 5 pi of
protein sample, and incubated at room temperature for 5 minutes. The absorbance was
measured at 595 nm using an EL312e Microplate Bio-Kinetics Reader (Bio-
Technologies Instruments). A standard curve was constructed by plotting absorbance
obtained from a range of bovine serum albumin (BSA) dilutions between 0-1.4 mg/ml,
and was used as a reference for determining the concentration of proteins.
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2.2.6.3 Sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE)
30-50 pg of protein from each sample was mixed with an equal volume of 2x Laemnli
sample buffer containing 2% w/v sodium dodecyl sulphate, boiled 100 °C for 2 minutes,
and separated by SDS-PAGE on 12.5% acrylamide gel with 4.2% stacking gel. The
Broad Range Prestained ladders (BioRad) were used as markers. Gels were run using a
Bio-Rad Protean III at 150 V and 20 mA for approximately 2 hours in Laemnli running
buffer, and subsequently electroeluted onto a polyvinylidene difluoride (PVDF)
Hybond-P membrane (Amersham Pharmacia Biotech) in Bjerrum and Schafer-Neilson
transfer buffer, using a BioRad Trans-Blot SD transfer apparatus at 20 V and 150 mA
for a minigel for 25-30 minutes.
2.2.6.4 Immunoblotting
After protein transfer, the blotting membrane was incubated overnight at 4 °C in
blocking buffer containing 5% w/v fat-free powdered milk and 0.1% v/v Tween 20 in
phosphate-bufferred saline (PBS). Membranes were rinsed with PBS and incubated in
the blocking buffer with the primary antibody (Table 2-1) for 1 -2 hours at room
temperature. The membranes were then washed three times with PBS containing 0.1%
v/v Tween 20. and bound antibodies were detected using an appropriate horseradish
peroxidase (HRP)-conjugated secondary antibody for 1 hour at room temperature. The
membranes were washed three times with PBS with 0.1% v/v Tween 20 and proteins
were visualized using an enhanced chemiluminescence (ECL or ECL plus) Western
blotting detection kit (Amersham Pharmacia Biotech). The membranes were exposed to
a MACO-X-RAY HS90 medical film and the film was developed using a Hyper
Processor (Amersham Life Science).
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Table 2-1 Antibodies used for immunoblotting
Antibody Dilution Source
eEF 1A2 1:500 Sheep polyclonal (Newbery, 2003)
Akt 1:100 Rabbit polyclonal (Abeam)
Phospho-Akt 1:100 Rabbit monoclonal (Abeam)
[3-actin 1:1000 Rabbit polyclonal (Sigma)
(3-tubulin 1:1000 Rabbit polyclonal (Abeam)
2.2.6.5 Data analysis ofWestern blots
Western blots were quantified using an enhanced chemiluminescent ECL or ECL Plus
(Amersham Pharmacia Biotech), a Hyper Processor machine (Amersham Life Science),
and Image J software. Band intensities were calculated, and background was subtracted.
2.2.7 Histological studies
2.2.7.1 Muscle preparations
Triceps and quadriceps were dissected from each mouse, and snap frozen in isopentane
cooled in liquid nitrogen prior to storage at -70 °C. 12-micron sections were cut mid-
belly in a cryostat and were attached to a glass slide prior to staining with haematoxylin
and eosin.
2.2.7.2 Microdissection of muscles
For neuromuscular junction studies, hindlimb and abdominal muscles were removed
from each mouse and were immersed in Normal Ringer Solution (NRS) supplemented
with O2 for 10 minutes prior to microdissecton. The muscle samples were pinned onto
silica dishes filled with NRS, and examined under a dual-lens stereo microscope. Under
the microscope, the major blood vessels and associated fascia were carefully removed.
Transverse abdominis (TA) and lumbrical muscle were then dissected to be a thin layer,
and ready for immunocytochemistry.
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2.2.7.3 Haematoxylin and eosin staining
Sections were immersed in the filtered I-Jarris Haematoxylin for 1 minute, and rinsed
with tap water until the water was clear. The sections were incubated in eosin stain for 1-
2 minutes, rinsed with tap water, and dehydrated in ascending alcohol solutions of 50%,
70%, 80%, 95% for 2 times, and 100% for 2 times, followed by clearing with xylene for
3-4 times. The glass slides were mounted in an organic mounting medium, pertex
(CellPath).
2.2.7.4 Succinic dehydrogenase (SDH) staining
Snap frozen section was incubated in the incubation medium (10 ml of 0.2 M Phosphate
Buffer, 270 mg Sodium Succinate, and 10 mg Nitro Blue Tetrazolium) for 60 minutes at
37 °C. The coverslips were then washed with three exchanges of dH20. Nitro Blue
Tetrazolium was removed with three exchanges of the acetone solution in increasing
then decreasing concentration of 30, 60, and 90% acetone in dH20. 90% acetone was
left covering the sections until a faint purplish cloud is seen over the section. The
sections were washed several times with dH20 and then mounted with a mounting
medium.
2.2.7.5 Measurement of the muscle fibre numbers and cross-
sectional areas
AH fibres in each haematoxylin-stained section were counted, and the cross-sectional
areas of all fibres were measured using the Image J software.
2.2.8 Immunofluorescence analysis
2.2.8.1 Immunostaining of neuromuscular junctions
Lumbrical and TA preparations for immunocytochemistry were fixed in 0.1 M PBS
containing 4% w/v paraformaldehyde for 30-40 minutes before labeling acetylcholine
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receptors by incubating in a-bungarotoxin (BTX) conjugated to 5 mg/ml tetramethyl-
rhodamine isothiocyanate (TRITC-a-bungarotoxin, Molecular Probes) for 20 minutes.
Muscles were blocked in 4% BSA and 0.5% Triton X in 0.1 M PBS for 30 minutes, and
incubated in a 1:200 dilution of primary antibodies directed against 165 kDa
neurofilament proteins (2H3, Developmental Studies Hybridoma Bank) and a 1:200
dilution of the synaptic vesicle protein SV2 (Developmental Studies Hybridoma Bank)
overnight. Muscles were then blocked in blocking solution for 30 minutes and incubated
in a 1:200 dilution of sheep anti-mouse antibody conjugated to the fluorescent label
FITC (Diagnostics Scotland). Muscles were whole-mounted in Vectashield
(Burlingame) on slides for subsequent imaging.
2.2.8.2 Immunofluorescence in HeLa cells
HeLa cells were cultured on glass coverslips, rinsed with PBS, and then fixed in cooled
methanol at for 10 minutes at -20 °C. The cells were then permeabilized with cooled
acetone for 1 minute at -20 °C. The coverslips were blocked with 3% bovine serum
albumin in PBS with 0.5% Tween-20 (PBS-T) for 30 minutes at room temperature, and
then incubated with primary antibodies for 1 hour at room temperature. Double labelling
for myc-tagged eEFl A2 and SMN was carried out by sequential incubations (1 hour)
with a monoclonal mouse anti-Myc antibody (Invitrogen) and FITC-conjugated anti-
mouse IgG antibody (Vector Laboratories), and then goat anti-SMN antibody (Abeam)
and Texas-Red-conjugated anti-goat secondary antibody (Vector Laboratories).
Antibodies were diluted in PBS to appropriate dilution: 1:5000 for anti-Myc antibody;
1:500 for anti-SMN antibody; 1:500 for secondary antibodies. Cells were rinsed once
and washed with PBS-T three times (5 minutes) between each antibody incubation. The
coverslips were mounted on slides using Vectashield with DAP1 (4'. 6-diamidio-2-
phenylindole; Vector Laboratories), and examined by immunofluoresence microscope
using conventional microscope Axioskop2 MOT (Carl Zeiss).
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2.2.9 Production of transgenic mice
2.2.9.1 Preparation of DNA constructs for microinjection
The transgene fragment was excised from pUC19 plasmid containing a transgene by
restriction endonuclease digestion. The transgene fragment was separated on a 0.8%
low-melting agarose gel in lx TAE gel, and the band was visualised under UV light and
removed with a sterile scalpel. The transgene fragment was electroeluted overnight from
the gel slice using the Elutrap® Electroelution System (Schleicher & Schuell
Bioscience), and eluted in TE buffer. From this step, in order to minimize dust
contamination in the further DNA preparation, non-fdtered tips were used, and all tips,
eppendorfs, and gloves were rinsed with sterile dEUO. The DNA was concentrated by
ethanol precipitation. The concentration of the DNA construct was determined by
running an aliquote on a mini agarose gel against known DNA standard. The DNA was
then diluted to 2 ng/pl in injection buffer, and stored at -20 °C for subsequent
microinjection.
2.2.9.2 Collection of fertilized oocytes
The mouse strain used to generate transgenic mice was C56BL/6J x CBA. Female donor
mice, aged of 4-8 weeks, were injected intraperitoneally with 10 IU of pregnant mare
serum gonadotrophin (PMSG, Intervet) three days prior to embryo collection and
microinjection. A day prior to microinjection, the donor mice were injected
intraperitoneally with 10 IU of human chorionic gonadotrophin (hCG, Intervet). In the
evening on the same day, each donor mouse was set up to mate with one proven stud
male, aged of 8 weeks - 8 months. On the morning of the day ofmicroinjection the
females were examined for the presence of a copulation plug in the vagina. To collect
the fertilized oocytes, mice were sacrificed by cervical dislocation. The mice were
positioned on their back and the abdomen was swabbed with 70% ethanol. A horizontal
incision was made in the mid-abdomen, and the ski was pulled off the abdomen. The
peritoneum was opened and the oviducts were removed and placed in a depression slide
with M2 medium. The oocytes were dissected out under a stereo-microscope, transferred
Chapter 2 - Materials and Methods 56
to M2 medium containing 400 mg/ml of hyaluronidase, and incubated for less than 3
minutes. The embryos were transferred into M2 medium with a transfer pipette and
washed for another three to four times in M2 medium. The embryos were then incubated
in Ml6 medium at 37 °C in 5% CO2 until ready for microinjection.
Donor mice were prepared by technicians at the Transgenic unit, and collection of
oocytes was performed by Dr. Brendan Doe.
2.2.9.3 Microinjection
Ten to twenty oocytes were suspended in a drop ofM2 medium on a depression slide
and the slide was palced onto the microscope stage. 1-2 pi ofDNA was transferred using
an Eppendorf microloader pipette into the needle holder. Microinjection was performed
under an inverse stereo microscope (Zeiss Axiovert 100). The embryo which had visible
pronuclear were held in position that the male pronucleus (a bigger one containing a
single nucleolus) was in the equatorial plane of the oocyte by gently suction with a
holding pipette. The injection needle (Femtotips, Eppendorf) was slowly inserted into
the pronucleus. The drawn out injection pipette was then gently pushed through the zona
and into the nucleus whereby the DNA was injected by gently pushing the pedal of the
micromanipulator (Narishige Ml 51). The injection needle was pulled out as soon as the
pronucleus was swollen noticeably. The fertilized oocytes which survived
micromanipulation were transferred to the oviduct of pseudopregnant recipients.
Microinjection procedure was performed by Dr. Brendan Doe.
2.2.9.4 Embryo transfer
The recipient females at the age of about 8 weeks to 6 months were mated with
vasectomised males the evening before the transfer. The next morning the females were
examined for the presence of a copulation plug. The females which were positive for the
plug were used for the embryo transfer. The recipients were anaesthetised by
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intraperitoneal injection with a mixture of 0.9 pi of a 100 mg/ml ketamine HC1 solution
and 0.1 pi of a 2% xylazine HC1 solution. The side of the lower part of the back was
shaved and swabbed with 70% ethanol, and a small transverse incision was made with
dissecting scissors to expose the ovary, oviduct, and uterus. The mouse was then placed
on the stage of stereo-microscope, and the opening of the oviduct (infundibulum) was
located. The embryos contained in a transfer pipette were injected into the infundibulum.
The fat pad, ovary, oviduct and uterus were then picked up and pushed back inside the
body wall, which was subsequently closed with one or two stitches. The skin was then
closed with wound clips. Mice were kept warm until the effects of the anaesthesia had
worn off and monitored to ensure that there were no post-operative complications.
2.2.9.5 Identification of progeny mice for transgene integration
All offspring were examined for integration of the transgene into genomic DNA at
weaning (3 weeks of age) by PCR of genomic DNA isolated from ear punches. Genomic
DNA was isolated using phenol: chloroform: isoamyl alcohol method (see 2.2.1.1.2).
Mice that had not incorporated the transgene were sacrificed by cervical dislocation.
2.2.10 Bioinformatics
BioEdit Sequence Alignment Editor: http://www.mbio.ncsu.edu/BioEdit/bioedit.html
Electronic PCR: http://www.ncbi.nlm.nih.gov/sutils/e-pcr/
Ensembl Genome Browser: http://www.ensembl.org/index.html
ExPaSy Proteomics Server: http://www.expasy.org/
Image J software: http://rsb.info.nih.gov/ij/
Mouse Genome Informatics (MGI): http://www.informatics.jax.org/
Primer 3 Input: http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi
Sanger Blast Search Service: http://www.sanger.ac.uk/DataSearch/blast.shtml
Sequence alignment program for DNA or proteins: http://www.ebi.ac.uk/clustalw/
Universal Probe Library: https://www.roche-applied-science.com/sis/rtpcr/upl/adc.jsp
VEGA Genome Browser: http://vega.sanger.ac.uk/index.html
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Chapter 3 Characterization of Wasted Mice
3.1 Introduction
The autosomal recessive wasted mutation gives rise to a set of features that include
progressive muscle wasting, weight loss, progressive paralysis, degeneration of anterior
horn cells of spinal cord, with abnormalities ofmotor nuclei in the brainstem, decreased
numbers of circulating lymphocytes, and early death of the wst/wst homozygotes by
approximately 28 days. The Eefla2 gene was found to partially deleted in mice with the
wst mutation (Chambers et al., 1998). Expression of eEFl A2 is tissue-specific, and
limited to the terminally differentiated cells of the brain, heart, and skeletal muscle. In
skeletal muscle in wild-type mice, eEFlAl and eEFlA2 are reciprocally expressed.
eEFlAl is expressed in early postnatal stages and diminished by postnatal day 25,
whereas eEFl A2 is not detectable at early stages but is strongly expressed at day 25. A
natural decline in eEFl Al and loss of eEFl A2 from the wst mutation mean there is no
translation elongation factor la in the wasted mouse, giving rise to a hypothesis that loss
of eEFl A2 may be a cause of muscle wasting in wasted mice.
3.1.1 Causes of muscle atrophy
Skeletal muscle atrophy that occurs in muscles of animals is a result of denervation,
immobilization, aging, starvation, and a number of disease states. Regardless of the
initiating event, skeletal muscle atrophy is characterized by a decreased in protein
content, fibre diameter, force production, and fatigue resistance. The different types of
conditions producing atrophy imply different types of molecular triggers and signaling
pathways for muscle wasting. Denervation, damage, or disease processes may reverse
the pattern of gene expression typical for the healthy mature muscle fibre. On the other
hand, the expression of some genes is relatively independent of the stage of maturation
and innervation of the muscle fibre (Pette and Vrbova, 1985; Eftimie et al., 1991). The
myogenic factors (MYFs), a class of transcription factors, play a role in the early steps
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of determination and differentiation as well as maintenance of the differentiated state. In
mature muscle, the MYFs, myogenin and MyoD are dramatically down-regulated
compared to levels in early developmental stages of muscle.
Loss of eEFl A2, however, occurs in wasted mice. To date, there is no evidence whether
muscle wasting in wasted mice is neurogenic or myopathic in origin. To address this
question, I conducted experiments to investigate the primary causes ofmuscle wasting in
wasted mice.
3.1.2 Muscle atrophy and Akt protein
Two recent studies have expanded knowledge about the mechanisms involved in the
development of skeletal muscle atrophy. These reports (Sandri et al., 2004; Stitt et al.,
2004), have provided direct evidence for a role of Aktl signaling as a modulator of the
expression of two important genes involved in the progression ofmuscle atrophy, the E3
ubiquitin ligases atrogin-1 or Muscle Atrophy F box (MAFbx) and the Muscle Ring
Finger-1 (MuRF-1), and their regulation by a family of transcription factors termed
Fork-head box O (FOXO). Exciting new evidence demonstrates that the expression of
atrogin-1 (MAFbx) and MuRF-1 is controlled by a signaling network that comprises
FOXOs and their regulation by Aktl. These new findings are important not only from
the atrophy standpoint, but also from the integration of cellular regulatory networks
perspective as they created a scenario in which a key molecule that is positively
involved in cellular growth via protein synthesis when in its active state, also negatively
regulates the opposite process (protein degradation). Such interactions suggest that the
dynamic regulation of skeletal muscle mass is not simply a balance between protein
synthesis and degradation but is a rather finely coordinated process. These findings have
also established a key role of PI3-K signaling growth factor/cytokine-mediated cell
survival, with Akt functioning as a direct link to the apoptotic machinery. Active Akt
directly phosphorylates pro-apoptotic BAD, resulting in its association with the 14-3-3
protein and consequent de-activation. The subsequent release of anti-apoptotic Bcl-2 and
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Bc1-xl. results in a shift away from programmed cell death towards cell survival (Datta et
al., 1997).
Skeletal muscle atrophy is a devastating condition seen in many catabolic diseases such
as cancer, sepsis, and denervation as well as in neuromuscular disorders such as ALS
(Lynch, 2001). Recent studies in mice and rats have shown a dramatic upregulation in
MAFbx and MuRF-1 in conditions causing muscle atrophy including denervation, and
have suggested that the transcriptional regulation ofMAFbx and MuRF-1 is controlled
by an Akt/Forkhead (FKHR)-dependent signaling pathway (Gomes et al., 2001; Lee et
al., 2004). In ALS patients, as seen in the ALS mouse model, skeletal muscle atrophy is
associated with an increase in MAFbx and a decrease in active Akt (Leger et al., 2006).
Whether or not the observations in other rodent models of human skeletal muscle are
similar to those observed in ALS patients and ALS transgenic mice requires
investigation.
While perturbations in normal signaling could reflect impairment within the muscle,
increases in protein content or activity could instead reflect a compensatory mechanism
to regulate the loss ofmuscle mass associated with denervation. In addition, these
changes could indicate an upregulation of anti-apoptotic pathways within the muscle,
thereby promoting not only cell survival within the tissue itself, but potentially targeting
the damaged motor neuron as well.
A recent study has shown that eEFlA is a potential binding partner ofAkt2 (Lau et al.,
2006). It is possible that muscle atrophy in wasted mice may lead to activation ofAkt
and its downstream proteins such as mTOR, resulting in promoting of protein synthesis
in order to compensate for ongoing muscle atrophy. The aim of this chapter was to
determine whether Akt, a downstream peptide of the PI3-K pathway, showed elevations
in protein expression and/or phosphorylation within progressively denervated skeletal
muscle in wasted mice.
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3.2 Results
3.2.1 Motor function in wasted mice
As loss of eEFl A2 might contribute to motor neuron degeneration, I examined wasted
mice aged from 20 day postnatal, when their motor function was still normal and no
disease symptoms were yet observed. I scored motor function in the hind limbs using a
rating scale (modified from Lambrecht et al., 2003) of 5 (normal function) to 0 (absence
ofmovement) as shown in the table 3-1.
Table 3-1 Neurological rating scale
Score Motor function
5 Normal function
4 Hind limbs are stretched but remain rigid when the mouse is lifted by its
tail, normal walking
3 No stretching of hind limbs when lifted by tail, normal walking
2 Rigid hind limbs when lifted by tail, ataxic or knuckling walking
1 Rigid hind limbs when lifted by tail, hind limb movement but unable to
walk
0 Rigid limbs when lifted by tail, total absence ofmovement
3.2.1.1 Progressive paralysis after weaning in wasted mice
Wild-type mice showed normal motor function in the hind limbs for the entire duration
of the analysis, as shown in table 3-2. In contrast, all six wasted mice showed signs of
paralysis beginning at weaning (score 4 + 0) and progressed to severe paralysis with an
absence ofmovement (score 0.33 + 0.58, P < 0.005) at age of 27 days and died by 28
days postnatal. Ataxic walking was observed in wasted mice from age of 23 days (P <
0.005). Figure 3-1 shows the neurological outcome and neurological score of wasted
mice compared to those of age-matched wild-type mice.
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Table 3-2 Neurological rating scores of hind limbs ofwasted mice and wild-
controls.
D20 D21 D22 D23 D24 D25 D26 D27
Control 1 5 5 5 5 5 5 5 5
Control 2 5 5 5 5 5 5 5 5
Control 3 4 5 5 5 5 5 5 5
Control 4 4 5 5 5 5 5 5 5
Control 5 5 5 5 5 5 5 5 5
Control 6 5 5 5 5 5 5 5 5
Mean 4.67 5.00 5.00 5.00 5.00 5.00 5.00 5.00
S.D. 0.52 0 0 0 0 0 0 0
wst/wst 1 5 4 3 3 3 2 2 1
wst/wst 2 4 4 3 3 2 2 1 0
wst/wst 3 4 4 4 2 2 2 2 0
wst/wst 4 4 4 4 3 2 2 2 0
wst/wst 5 5 4 3 3 3 2 1 1
wst/wst 6 4 4 3 2 2 2 2 0
Mean 4.33 4.00 3.33 2.67 2.33 2.00 1.67 0.33
S.D. 0.52 0 0.52 0.52 0.52 0 0.52 0.52
P value vs. controls * 0.31 ^ ■ - < U.UID w
* Mann-Whitney test.
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Figure 3-1 Neurological score, (a) 24-day-old wild-type mouse with score 5.
(b) 21-day-old wasted mouse with score 4. (c) 24-day-old wasted mouse with
score 3. (d) Means of neurological scores in wasted mice compared to those of
age-matched wild-type mice.
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3.2.2 Muscle pathology in wasted mice
Mice were culled by cervical dislocation and muscle tissue was separated from bone and
immediately frozen in liquid nitrogen. Segments ofmuscle from wild-type and wasted
mice were snap frozen in ice-cooled isopentane and 12-um sections were cut in a
cryostat before staining.
3.2.2.1 Decrease in the cross-sectional area of fibres in wasted
muscle
The average fibre area in the quadriceps muscle of wild-type and wasted mice was
calculated by counting 200-1,000 fibres in the transverse section ofmuscles from three
25-day mice for each genotype, and dividing the total area of the counted fibres by fibre
number. Fibre atrophy in the wasted muscles was documented by the overall decrease in
the cross-sectional area of fibres (Figure 3-2a). The muscle fibre area in wasted mice
2 • ")
was 176 + 7 pnT, whereas the muscle fibre area in wild-type controls was 249 + 17 pm"
(P < 0.005). To underline this finding, analysis of fibre size differences showed a
significant decrease in total fibres per field in the muscles of 25 day-old wasted mice as
shown in table 3-3 (P < 0.0001), and a significant smaller fibre diametre in wasted
muscles (16.9 + 0.9 um in wasted muscles, 20.6 +1.1 um in wild-type muscles, P <
0.0001), as shown in figure 3-2b.
Table 3-3 Overall fibre atrophy in wasted mice documented by an increase
in total fibre number per field (40x), P < 0.0001.
Muscle Fibre Analysis Wild Type Wasted
Average Total fibres/Field 84 120
Minimum diameter (pm) 18.3 15.7
Maximum diameter (pm) 22.5 19.1























Figure 3-2 Analysis of fibre size differences, (a) Average fibre area in
quadriceps of wild-type and wasted mice (* P < 0.005). (b) Average fibre
diameter in quadriceps ofwild-type and wasted mice (* P < 0.0001).
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3.2.2.2 Muscle atrophy in wasted mice has features of neurogenic
atrophy
Hematoxylin and eosin-stained cross-sections of triceps and quadriceps from three
wasted and wild-type 25 day-old mice were analysed. In addition to the overall decrease
in the cross-sectional area of fibres in wasted mice, I found that some pathologic
processes were found in the muscle. The muscle fibres of wild-type mice were of
relatively uniform size and shape, with nuclei located in the periphery of the cells
(Figure 3-3a). In contrast, the muscles of wasted mice showed small angular fibres and
pyknotic nuclear clumps, which are a characteristic feature of neurogenic atrophy
(Figure 3-3b-d ). The small angular fibres were often basophilic in H&E stains. Multiple
small groups of atrophic fibres were also demonstrated. The findings of atrophic groups
of angular fibres suggested that the process was in the early stage of denervation.
Wasted muscle pathology showed a range of severity. Pyknotic nuclear clumps were
clumps of myonuclei, which are an end product of denervation atrophy. The contractile
apparatus of the remainder ofmyofibres largely disappeared. The finding of pyknotic
nuclear clumps in muscles of wasted mice suggests that denervation exists without
reinnervation. These pathologic findings were demonstrated in both upper limb and
lower limb muscles.
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Figure 3-3 Hematoxylin and eosin-stained cross-sections of muscles of 25-day-old mice,
(a) Quadriceps of wild-type mouse (40x). (b, 40x and c, 20x) Quadriceps of wasted
mouse, showing angulated atrophic fibres (arrowheads), (d) Triceps of wasted mouse
(60x), showing severe fibre atrophy with prominent pyknotic nuclei (arrowheads). Some
fibres show severe loss of contractile apparatus (arrows).
3.2.2.3 Regenerating muscle fibres were found in muscle of wasted
mice
Hematoxylin and eosin-stained cross-sections of quadriceps from 25 day-old wasted
mice occasionally showed centralized nuclei as shown in figure 3-4, whereas they were
not found in wild-type muscle. Although this finding was variable, it is worth
mentioning because centralized nuclei are typical of regenerating muscle fibres, which
might have been thought not to happen in muscle of wasted mice.
3.2.2.4 Muscle from wasted mice showed an increase in
mitochondrial staining
Succinate dehydrogenase (SDH) staining of quadriceps from 25 day-old wasted and age-
matched wild-type mice was used to study mitochondrial dysfunction. SDH stain is the
most sensitive and specific stain for mitochondrial proliferation in muscle fibres.
Increased SDH staining of muscle fibres indicates abnormality in mitochondrial
function. I found that muscle fibres from wasted mice stain darkly for SDH compared
with muscle from wild-type mice, as shown in figure 3-5. Increased SDH staining could
be found in regenerating muscle fibres. This finding helps support the above finding of
centralized nuclei in wasted muscle fibres and suggests that there is a regenerative
potential in wasted muscle, although mitochondrial disease could not be excluded.
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Figure 3-4 Hematoxylin and eosin-stained cross section of quadriceps of two 25-day-old
mice, (a) 40x and (b) 60x, showing centralized nuclei typical of regenerating muscle
fibres (arrows).
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Figure 3-5 Succinyl dehydrogenase-stained cross sections of quadriceps of 25-day-old
mice, (a) Wild-type mouse, (b and c) Wasted mouse, showing an increase in SDH
staining.
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3.2.3 Abnormalities of neuromuscular junctions in wasted mice
To determine whether the degenerative process involves terminal axons, labeling of
NMJ of skeletal muscles, including transverse abdominis (TA) and lumbricals, was
performed. Muscles from wild-type and wasted mice were microdissected and fixed in
4% paraformaldyhyde in PBS before labeling postsynaptic acetylcholine receptors with
a-bungarotoxin (BTX) conjugated to tetramethylrhodamine isothiocyanate (TRITC-a-
bungarotoxin). Muscles were then incubated overnight in primary antibody raised
against 165-kDa isoform of neurofilament proteins and the synaptic vesicle protein SV2
and visualized with sheep anti-mouse FITC-conjugated secondary antibodies.
Neuromuscular junctions were imaged using a laser scanning confocal microscope.
Microdissection and immunostaining were performed by myself and Dr. Thomas
Gillingwater.
3.2.3.1 Progressive retraction of motor nerve terminals in wasted
mice associated with muscle denervation
Immunocytochemical staining of neurofilament middle subunit (NF-M), SV2, and
TRITC-a-BTX labeling ofNMJs of TA and lumbricals in 23 and 25 day-old wild-type
mice showed normal NMJs characterized by being plaques with branched structures
(pretzel-shaped) in which presynaptic and postsynaptic specializations are closely
associated (Figure 3-6a ). By contrast, a lack of overlying terminal axons was observed
in some synaptic areas ofwasted mice, which further indicated the presence of a muscle
denervation process, as shown in figure 3-6b and 3-6c. In addition to vacant motor
endplates, other synaptic areas displayed striking abnormalities, including reduction of
branched subneural apparatus, changes of terminal axons or both (Figure 3-6d).
Sometimes the terminal axon collaterals were very thin and terminated in a "retraction
bulb" swelling (Figure 3-6d). Evidence ofprogressive muscle denervation was observed
in the TA muscles of wasted mice as young as 17 days old.
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Figure 3-6 Denervated motor endplates and changes of terminal axons. Immunostaining
of neuromuscular junctions on preparations ofTA muscles with antibodies against
neurofilament/SV2 (green) and counterstaining with TRITC-a-BTX (red), (a) 25-day-
old control, (b and c) 23-day-old wasted mouse, showing a lack of overlying terminal
axons, (d) 23-day-old wasted mouse, showing reduction of branched subneural
apparatus. The arrow indicates a thin axon terminating in a "retraction bulb". Scale bar =
100 pm (a, b), = 20 pm (c,d).
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3.2.3.2 Accumulation of neurofilaments in synaptic terminals of
neuromuscular junctions in wasted mice
Synaptic terminals filled with NF-M were present in wasted mice but not in the controls
of the same age (Figure 3-7). An accumulation ofNF-M in wasted mice suggested that
an aberrant cytoskeletal organization of terminal motor axons occurred in wasted mice.
Surprisingly, no axonal sprouting was detectable in NMJs examined, despite the
presence of denervated NMJ intermixed with accumulation ofNF-M in synaptic
terminals. These results indicate an abnormal organization of synaptic terminals
associated with a defect of axonal regeneration in wasted mice.
Figure 3-7 Accumulation of neurofilaments in terminal axons of wasted mice, (a) 23-
day-old TA of a control mouse, (b) 23-day-old TA of a wasted mouse, revealing
terminal axons filled with neurofilaments (arrow). The arrowhead indicates thinning of a
distal axon. Scale bar = 20 pm.
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3.2.4 Expression of nerve-regulated genes in muscle of wasted mice
Neurodegenerative diseases are less clear-cut with regard to molecular causes and
physiological effects. Genes have been assigned to some forms of familial amyotrophic
lateral sclerosis and spinal muscular atrophy. However, the ubiquitous expression of
these genes does not give a hint as to why the nervous system is preferentially affected.
This part ofmy thesis deals with wasted mice that could represent an animal model for
human motor neuron diseases. I studied genes for the al subunit of acetylcholine
receptor (AchRal), for the myogenic factor myogenin, and for the muscular chloride
channel C1C-1, the expression of which in normal skeletal muscles is developmentally
regulated and nerve-dependent.
Gene expression was evaluated by real-time quantitative RT-PCR using SYBR green 1
kit on total RNA extracted from the muscle quadriceps of 25 and 28 day-old wasted and
wild-type mice. As the conventional use of a single gene for normalization leads to
relatively large errors (Vandesompele et al., 2002), the measures herein were normalized
to RNA levels of two reference genes, P-actin (a structure-related gene) and GAPDH (a
metabolism-related gene). Primer sequences are presented in Table 3-4.
3.2.4.1 Confirmation of primer specificity
The specificity of real-time PCR products was documented with 4% high resolution
agarose gel electrophoresis and resulted in a single product with the desired length. In
addition a melting curve analysis was performed at temperatures from 55 to 95 °C with a
heating rate of 0.1 °C per second and a continuous fluorescence measurement, which
resulted in single specific melting temperature as follows: AchRal, 82.5 C; myogenin,
89.2 °C; C1C-1, 83.5 °C; p-actin, 85.5 °C; and GAPDH, 85.1 °C. No primer-dimers were
generated during the 40 real-time PCR amplification cycles. Figure 3-8 show the results
ofmelt curve analysis.
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Table 3-4 Real-time RT-PCR Primers
Gene Orientation Nucleotide sequence (from 5' to 3') Size of the
name amplicon (bp)
AchRal Forward ACCTGGACCTATGACGGCTCT 67
Reverse AGTTACTCAGGTCGGGCTGGT
Myogenin Forward CTACAGGCCTTGCTCAGCTC 200
Reverse AGATTGTGGGCGTCTGTAGG
C1C-1 Forward CTGCATTTGGAAGGCTGGTAGGAG 161
Reverse AATGACGGCTGTGGAGACTGTGTG
P-actin Forward CCCTGTATGCCTCTGGTCGT 103
Reverse ATGGCGTGAGGGAGAGCAT
GAPDH Forward TGAAGCAGGCATCTGAGGG 102
Reverse CGAAGGTGGAAGAGTGGGAG
3.2.4.2 Real-time PCR amplification efficiencies and linearity
To ensure comparability between the five (three target genes and two reference genes)
real-time PCR assays, I determined the PCR efficiency of each individual assay by
measuring serial dilutions of 100 ng cDNA from a wild-type muscle sample in triplicate
Only Ct values less than 40 were used for calculation of the PCR efficiency from the
given slope in MyiCycler software according to the equation: PCR efficiency (E) = (10l"
l/slope]
— 1) x 100. Figure 3-9 shows some examples of the real-time PCR efficiencies, in
which Ct cycles versus cDNA (reverse transcripted total RNA) concentration input (n =
3) were plotted to calculate the slope. All investigated transcripts showed high real-time
PCR efficiency ofmore than 98%, with high linearity (Pearson correlation coefficient r
>0.95).
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Figure 3-8 Melting curve analysis and high-resolution gel electrophoresis resulting in
single product specific melting temperature for AchRal (a), myogenin (b), C1C-1 (c), [3-
actin (d), and GAPDH (e). The plots displayed the negative first derivative of the
fluorescence (-dF/dT) against temperature
Chapter 3 - Characterisation of wasted mice 77
Correlation Coefficient: 0.988 3ope: -3.178 Intercept: 24.826 Y= -3.178 X 4 24.826















Log Starting Quantity, nanograms
a
Correlation Coefficient: 0.950 3cpe: -3.099 trtercept: 25.47D Y=-3.099X+35.47Q o Unknowns
PCR Efficiency: 110.2 % • Standards
Log Starbng Quanbty, nanograms
Figure 3-9 Determination of real-time PCR efficiencies of reference gene, GAPDH (a),
and target gene, AchRal (b).
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3.2.4.3 Intra-assay variation
To confirm the accuracy and reproducibility of real-time PCR, the intra-assay precision
was determined in three repeats within one MyiCycler run. The calculation of test
precision was based on the Ct variation and the Ct mean value. The table 3-5 shows
intra-assay variation was less than 1.5% for all assays.
Table 3-5 Intra-assay variation of real-time RT-PCR
Mean (n = 3) Ct variation (%)
AchRal control 32.067 0.14
sample 31.467 0.26
Myogenin control 30.133 0.32
sample 30.533 0.32
C1C-1 control 28.100 0.28
sample 30.667 0.09
P-actin control 26.933 0.97
sample 27.133 1.16
GAPDH control 23.067 1.42
sample 22.500 0.48
3.2.4.4 Expression of the genes encoding AchRcrt and Myogenin in
wasted mice
The expression ofmany muscle-specific genes is dependent on development and
innervation. In mature muscle, myogenin is drastically down-regulated compared to the
level in early developmental stages ofmuscle. In the same way, much lower
concentrations ofmRNAs for al subunits of AchR are found in healthy mature muscle
than in myotubes. Denervation may reverse the pattern of gene expression. The principal
patterns of genes expression typical for denervated muscle were confirmed for the wild-
type mouse (Klocke et al., 1994). For the gene expression analysis in wasted mice, I
selected P-actin as a reference gene because its expression is relatively independent of
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the state ofmaturation and innervation of the muscle fibres (Eftimie et al., 1991; Pette D
and Vrbova G, 1985), and used GAPDH, a common housekeeping gene, as a second
reference gene to support the results.
3.2.4.4.1 Wasted mice showed an upregulation of AchRal and myogenin genes
As the above studies suggested that muscle atrophy in wasted mice might be a result of
denervation, to provide further support for these findings I investigated the expression of
denervation-sensitive genes, AchRal and myogenin, in hindlimb muscle, quadriceps,
from asymptomatic (20 days old) and symptomatic (25 days old) wasted mice, and age-
matched wild-type controls (n = 3 for each group). Figure 3-10 shows that the transcripts
ofAchRal in quadriceps of 25 day-old mice are significantly upregulated 4.33-fold
above the levels in wild-type mice (P = 0.0159). Interestingly, the upregulation of
AchRal was also detected in wasted mice at age of 20 days old when no motor
abnormalities were found, and the levels of expression were 32-fold higher than RNA
from muscles ofwild-type mice (P = 0.0004).
In a similar fashion, the expression of myogenin in 25 day-old wasted mice was elevated
10-fold higher than in wild-type mice (P = 0.0013), as shown in figure 3-10. In 20 day-
old mice, the levels ofmyogenin expression were 2.35-fold higher than RNA from
quadriceps ofwild-type mice (P = 0.0091). When normalized to the levels ofGAPDH
expression, the levels ofAchRal and myogenin followed the same pattern as that of [)-
actin gene (Figure 3-11). The positive correlation between AchRal and myogenin may
reflect a mechanistic relationship as myogenin is a transcription factor which is known
to control the expression of the AchRal gene (Eftimie et al., 1991; Piette et al..] 990).
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3.2.4.4.2 Downregulation of CIC-1 genes in wasted mice
The muscular chloride channel CIC-1 is another denervation-sensitive gene. In contrast
to AchRal and myogenin, CIC-1, which regulates excitability, is only found in mature
skeletal muscle, not in myotubes, and is downregulated upon denervation. Whereas
levels of gene expression for AchRal and myogenin were elevated in wasted mice,
those for CIC-1 were lowered. Normalized to the expression levels of P-actin, those of
CIC-1 in wasted mice were 5- and 2.63-fold lower than in wild-type mice at age of 25 (F
= 0.001) and 20 (P = 0.0234) days old, respectively (Figure 3-10). Similar patterns were
demonstrated when normalized to the expression levels ofGAPDH, as shown in figure
3-11.

































Figure 3-10 Expression levels of AchRal, myogenin, and CIC-1 genes in
quadriceps of 25-day-old (a) and 20-day-old (b) wasted mice, normalized to
those of (3-actin. Asterisks denote statistical significance for comparisons
(Unpaired /-tests).
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Figure 3-11 Expression levels ofAchRal, myogenin, and CIC-1 genes in
quadriceps of 25-day-old (a) and 20-day-old (b) wasted mice, normalized to
those ofGAPDH. Asterisks denote statistical significance for comparisons
(Unpaired /-tests).
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3.2.5 Skeletal muscle atrophy in wasted mice reveals an increase in
Akt protein
3.2.5.1 Western analysis of protein
Wasted and wild-type mice were culled at 25 days old, when rigidity and ataxic walking
are prominent. Figure 3-12 demonstrate the Western blot images and graph values of the
levels ofAkt expression for each animal. All of the wasted samples show an elevation of
Akt protein to varying degrees, compared to those of age-matched wild-type mice. The
same findings were seen for the expression of Akt-P, as shown in figure 3-13.
At the age of 25 days old, levels of Akt in wasted mice (0.497 + 0.105) were
significantly different from their age-matched controls (0.147 + 0.053). with P < 0.05
(Figure 3-14). Levels of Akt-P expression in 25-day-old wasted mice were 0.386 +
0.052, compared with those of wild-type controls of 0.054 + 0.006, with P < 0.005
(Figure 3-14).
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Figure 3-12 Akt protein expression levels in 25-day-old wasted mice. Western blot
images (a) and graph values (b) are of four age-matched wild-type littermates (C 1-
C4) and wasted mice (W1-W4).
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b.
Figure 3-13 Akt-P protein expression levels in 25-day-old wasted mice. Western blot
images (a) and graph values (b) are of four age-matched wild-type littermates (Cl-
C4) and wasted mice (W1-W4).


















































Figure 3-14 Expression levels ofAkt (a) and Akt-P (b) in 25-day-old wasted mice.
Values are presented as means + S.E.M (n = 4 per group). Asterisks denote P < 0.05
(a), and P < 0.005 (Unpaired /-test).
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3.3 Discussion
3.3.1 Causes of muscle atrophy in wasted mice
The causes ofmuscle atrophy and how the loss of eEFl A2 in wasted mice leads to
muscle atrophy have not been identified. I have demonstrated here and found several
clues of evidence that suggest that muscle atrophy in wasted mice is neurogenic in
origin. It has been previously shown that the loss of eEFl A2 in muscle of wasted mice
leads to a disproportionate decline in muscle mass as wasted mice deteriorate (Newbery
et al., 2005). That this change was due to fibre atrophy in the wasted muscles was
documented here by the overall decreased in the cross-sectional area of fibres and in the
decreased diameter.
The finding of angulated atrophic fibres in muscle of wasted mice suggests the early
stage of denervation. If a motor unit that was originally innervated by a type l nerve
loses its innervation, a number of isolated atrophic fibres will be initially scattered about
a small region of the muscle. Pyknotic nuclear clumps that are found in the same
muscles that present angulated fibres suggests the degenerative process is ongoing, even
that some fibres were getting into the late stage of fibre denervation. In human, these
findings of neurogenic changes can occur in disorders that affect motor neurons,
including anterior horn cells (eg. motor neuron disease), motor neuropathy, peripheral
neuropathy, and disorders that affect intramuscular nerve twigs. In wasted mice, these
findings are consistent with the previous publications that showed vacuolation in
anterior horn cells (Lutsep and Rodrigeuz, 1989; Newbery et al., 2005). Grouped
atrophic muscle fibres characteristic of muscle denevation were also found in a
transgenic mouse model of SMA (Frugier etal., 2000) and ALS (Gurney et a/., 1994;
Ripps et al., 1995; Wong et al., 1995; Bruijn et al., 1997).
The examination of wasted mice occasionally revealed centralized nuclei typical of
regenerating muscle fibres. Although they can be found in myopathy, the number of
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centralized or internal nuclei in such a condition would be marked. The increased SDII
staining in wasted muscle demonstrated here may give another supporting clue for
regenerating fibres in wasted muscle. Mitochondrial proliferation is one of the striking
responses observed in skeletal muscle exposed to a variety of physiological conditions
(Freyssenet et al., 1996; Hood et al., 2000). It has been demonstrated that skeletal
muscle regeneration is accompanied by a dramatic stimulation ofmitochondrial
biogenesis concomitant with the onset ofmuscle differentiation (Duguez et a/., 2002).
The signals involved in the stimulation ofmitochondrial biogenesis during muscle
regeneration remain to be determined, but they most likely result form the combinatorial
interplay of different molecular events. For example, it has been shown in transgenic
mice expressing a locally acting isoform of insulin-like growth factor-1 (mlgf-l) that is
expressed in skeletal muscle that mlgf-l may act as a survival factor by prolonging the
regenerative potential of younger muscle (Musaro et al., 2001). Skeletal muscle atrophy
occurs as a result of a variety of conditions such as aging, denervation, immobilization
and starvation. Regardless of the initiating event, muscle atrophy is characterized by a
decrease in protein content, fibre diameter, force production, and fatigue resistance. It is
interesting that wasted mice in which loss of eEFl A2, a protein involved in translation
step of protein synthesis is found, and in which eEFlAl is undetectable after 21 days of
age, may still have the potential to regenerate muscle fibres. The response of skeletal
muscle to denervation is complex. On the one hand, as also seen here in wasted mice,
individual muscle fibres undergo significant atrophy, and there is considerable
disassembly of the contractile apparatus, along with significant myonuclear loss. On the
other hand, there is a considerable increase in the satellite cell population within days of
denervation (Hanzlikova et al., 1975; McGeachie and Allbrook et al., 1978; Ontell,
1974; Viguie et al., 1997) as well as the formation of new muscle fibres (Borisov et al.,
2001; Dedkov et al., 2001). In denervated muscle in rat, levels of eEFl A1 protein
remain very low for the first 10 days after denervation (Khalyfa et al., 2003). During this
period, the satellite cell population associated with the denervated muscle fibres roughly
doubles (Snow, 1983), and the muscle fibres themselves begin to show signs of atrophy.
By 30 days after denervation, the level of eEFl Al protein (normally expressed at very
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low levels at this age) have shown a significant increase. However, this observation in
rat cannot be applied to wasted mice in which the expression of eEFl A1 protein
progressively declines in atrophic muscle, although it is still detectable at low levels at
28 days old (Khalyfa et al., 2001). Even though it is expressed at low levels after
weaning, the activity of eEFl Al protein in muscle of symptomatic wasted mice may
account for protein synthesis in such regenerating muscle fibres.
To determine whether the degenerative process also involved motor axons, labeling of
NMJ of skeletal muscles was performed. A lack of terminal axons was observed in some
synaptic areas ofwasted mice studied, which further indicates the presence of a muscle
denervation process. Moreover, terminal axons were filled with NF-M as determined by
immunolabeling. Synaptic terminals filled with NF were already present in 17-day-old
wasted mice but not in controls, indicating that this change occurs early in the
development ofwasted phenotype. Surprisingly, no axonal sprouting was detectable,
despite the presence of denervated NMJ intermixed with NMJ showing terminal axons
filled with NF. These results indicate an abnormal organization of synaptic terminals
associated with a defect of axonal regeneration in wasted mice. These findings in wasted
mice are similar to those in Smn mutant mice, a mouse model of spinal muscular atrophy
(SMA) (Cifuentes-Diaz et al., 2002), but different from those found in SOD0344
transgenic mice, a mouse model ofALS characterized by motor neuron degeneration
(Gurney et al., 1994). No terminal axon filled with NF and numerous axonal sprouts
were observed in the ALS model, indicating that NMJ changes are not only specific to
Smn mutant mice, but also in wasted mice. The accumulation of NF in terminal axons in
wasted and Smn mutant mice may have common pathogenic processes. Whether the
accumulation ofNF is a primary effect of the loss of eEFl A2 or SMN function or a
secondary event via an unidentified pathway remains to be investigated. Cytoskeletal
components play a major role in axonal growth and plasticity. Abnormalities of
accumulation ofNF in terminal axons of wasted mice may contribute to the defects in
terminal axon growth and plasticity, as suggested by the retraction ofmotor nerve
terminals and the defect in axonal sprouting. The resulting aberrant cytoskeletal
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organization at the NMJ ofwasted mice may contribute to the loss ofmotor neuron
function. Moreover, the relatively marked degenerative changes in terminal axons
contrast with the mild abnormalities in anterior horns of spinal cord during the early
stage ofwasted phenotype, as shown by the presence of gliosis without reduction of
motor cell bodies in 19 day-old wasted mice (Newbery et al., 2005), suggesting that
degeneration ofmotor neuron cell bodies may result from a dying-back axonopathy
starting from terminal axons.
To further support the consistency ofmy results, the levels of gene expression of nerve-
regulated genes were studied in quadriceps ofwasted mice. I show here that the
neuromuscular disease in wasted mice leads to drastic upregulation of the genes for
AchRal and for the myogenic factor myogenin. The disease also leads to mild to
moderate reduction of the muscular chloride channel C1C-1 transcripts. Myogenin is a
transcription factor that is shown to control the expression of the AchRa gene (Eftimie et
al., 1991; Gunning et al., 1983), and, like other myogenic factors, is itself regulated by
electrical activity. In normal muscle fibres, the effect of membrane depolarization is
mediated by Ca24 fluxes and the activation of protein kinase Ca (PKCa). Activated
PKCa phosphorylates and thereby inactivates myogenin. thus suppressing transcription
of the AchRa gene (Huang et al., 1994; Huang et al., 1993; Huang and Schmidt, 1994;
Huang et al., 1992). As mRNA levels for myogenin and AchRa are higher both in
immature and in denervated muscle fibres than in innervated adult muscle IIbres. they
indicate either regeneration or physiologic denervation. The same gene regulation holds
for the downregulation of the expression of C1C-1 in wasted mice. C1C-1 mediates the
Cf conductance of the plasma membrane. Not only does C1C-1 control the excitability
of adult muscle, but its own expression is dependent on actual muscle activity (Klocke et
al., 1994). Thus, it supports the findings in muscle pathology and in changes of gene
expression in wasted mice that there is concomitant ongoing denervation and muscle
fibre regeneration during the degenerative process.
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3.3.2 Muscle atrophy in wasted mice and Akt protein
The severe and progressive muscle wasting resulting from ongoing denervation is a key
clinical feature ofmotor neuron diseases. Perturbations have been seen in the PI3-K
pathway in neural tissue of both human and murine models ofATS (Wagey et al., 1998.
Hu et al., 2003a, Hu et al., 2003b), yet very few studies have examined biochemical and
molecular changes occurring within the muscle. I therefore chose to examine skeletal
muscle from wasted mice, a potential murine model of progressive denervation, to
determine if Akt and its phosphorylated protein, a key downstream peptide of PI3-K
pathway, were affected in the diseased muscle.
As hypothesized, a significant upregulation of Akt was found in the skeletal muscle of
wasted mice. At the severe symptom period and at end-stage, levels of both Akt protein
and its phosphorylated form were significantly higher in wasted mice than values
observed in age-matched wild-type controls. PI3-K signaling has been shown to be
involved in multiple cellular functions, including muscle growth and cell survival. It is
possible that these changes in Akt may reflect an attempt by the muscle to target
downstream effectors responsible for these functions.
Together with the immunohistochemistry studies in NMJs of wasted mice in chapter
three, that showed a progressive muscle denervation, the observed increases in Akt and
phosphorylated Akt appear in conjunction with increases in denervation, suggesting that
the muscle may be upregulating Akt in response to continual denervation, and the rise in
Akt may contribute to maintenance ofmuscle mass until the point where excessive
denervation and resultant myofibre death overpower its function.
The elevation in phosphorylated Akt implies that factors upstream in the signaling may
be altered as well. Significant increases in PI3-K activity have been found in short-term
denervated rat hind limb (Bertelli et al., 2003). Various trophic factors have also been
shown to be elevated in muscle in a number of models of denervation. An upregulation
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of local growth factors such as 1GF-1, resultant from the progressive denervation, could
be responsible for triggering the PI3-K. signaling cascade, thereby targeting Akt.
However, Bertelli and colleagues (Bertelli et al., 2003) found that phosphorylated Akl
levels were reduced in the denervated muscle when compared to control tissue, even
with increased P13-K activities. Other experiments also revealed decreased Akt protein
and phosphorylation content in denervated rat hind limb, versus sham-operated controls
(Wilkes and Bonen, 2000). In human, skeletal muscle atrophy in ALS has been revealed
to show a reduction in Akt activity (Leger et al., 2006). These results appear to
contradict my current findings, but differences could exist due to different models of
denervation. For example, some studies examined changes in rat skeletal muscle at only
3 minutes (Wilkes and Bonen, 2000) and 4 hours (Bertelli et al., 2003) after acute
denervation via removal of a portion of sciatic nerve. At such immediate time points, it
is possible that the findings could represent a temporal sequence. PI3-K activity appears
to have been stimulated directly upon denervation (Bertelli et al., 2003). but a 4 hour
window may not allow enough time to observe commensurate results downstream at
Akt.
Alternatively, in wasted mice, myofibre denervation is an ongoing process which could
result in continual signaling to upregulate PI3-K and downstream targets such as Akt. As
more fibres become denervated with disease progression, an increased release of trophic
factors could occur, resulting in increased PI3-K activity and gradual elevations in
downstream Akt and phosphorylated Akt, as the findings in wasted mice suggest.
Apoptosis has been shown to be a component of denervation-induced atrophy (Allen et
al., 1997, Schoser et al., 2001) and Akt has been shown to phosphorylate proteins
involved in both apoptotic and atrophic signaling pathways, such as caspase 9 or FOXO
(Toker, 2000, Sandri et al., 2004, Stitt et al., 2004). Phosphorylation of these proteins
results in their de-activation, thereby contributing to the suppression of both
programmed cell death and catabolic pathways simultaneously.
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Levels of Akt and its phosphorylated protein in wasted mice could also he elevated in an
attempt to regulate muscle mass, as the role of Akt in protein synthesis has also been
substantially documented. Different Akt content and activity has been found to exist
between individual muscle cells, and during muscle regeneration, endogenous Akt
phosphorylation and activity were upregulated only in innervated, not denervated fibres
(Pallefaccina et al., 2002). If so, the findings ofmoderate to high Akt intensity in my
current study may represent a small number of innervated fibres remaining within a
localized cluster of denervated areas. This could represent an upregulation of processes
in an attempt to regulate losses within specific motor units, targeting not only denervated
hut remaining innervated fibres as well.
Maintenance ofmuscle mass requires a balance between hypertrophic and atrophic
pathways. While Akt has been previously been shown to activate protein synthetic
pathways, recent evidence suggests a role for Akt in the suppression of atrophy through
FOXO. Studies have recently demonstrated that inhibition of FOXO factors via Akt-
mediated phosphorylation results in a downregulation ofMAFbx and MuRF-1 (Sandri et
al., 2004, Stitt el al., 2004) with subsequent suppression of atrophic protein degradation
(Sacheck et al., 2004).
It is unclear whether an increase in Akt and its phosphorylated proteins in skeletal
muscle of wasted mice are operating to target imperative biological processes, or if they
are instead only a result of the disease state of the muscle. Further studies will aid in the
further understanding of the role of Akt in progressively denervated muscle, potentially
via identification of relevant downstream targets.
Chapter 3 - Characterisation of wasted mice 94
Chapter 4 Transfection of HeLa cells to study
redistribution and colocalisation of eEF1A2 and SMN:
Analysis by Quantitative Immunocolocalisation
4.1 Introduction
The eEFIA protein is one of the most abundant proteins in mammalian cells and plays a
pivotal role in protein synthesis. eEFIA is present mainly in the cytoplasm of cells, but a
small proportion of eefla molecules has been previously identified in the nucleus
(Colling et al., 1994, Janssen et al., 1994, Barberse et al., 1995, Billaut-Mulot et al.,
1996, Sandres et al., 1996). It has been reported that ZPR1 binds to eefla in human
A431 epidermal carcinoma cells (Gangwani et al., 1998). ZPR1 is located in the
cytoplasm of quiescent mammalian cells. Treatment with mitogens, including EGF,
causes the redistribution of ZPR1 from the cytoplasm to the nucleus (Galcheva-Gargova,
et al., 1996). EGF stimulation ofA431 cells also triggers the formation ofZPR 1 /eEFIA
complexes and the the translocation of both ZPR1 and eEFIA from the cytoplasm to the
nucleus. There are two isoforms of eEFIA, eEFlAl and a highly homologous (92%)
isoform, eEFl A2. The function of eEFIA in the nucleus has not been identified. The
redistribution of eEFIA in proliferating cells suggest that this protein, either eEFl A1 or
eEFl A2 isoform, may be involved in a signaling pathway that communicates mitogenic
signals from the cytoplasm to the nucleus.
Although a few report reports described a nuclear localization for eEFIA, some studies
have been unable to show shuttling or nuclear localization of eEFIA (Calado et al.,
2002, Bohnsack et al., 2002). It has been demonstrated that eEFIA interacts with
exportin-5 (Exp-5) and Exp-5 mediates nuclear export ofeEFIA, causing eEFIA to be
strictly excluded from nuclei.
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The nuclear localization of eEFl A isoforms and involvement of eEFl A in the nuclear
processes remain to be established. Studies have shown that both eEFl A isoforms are
expressed in neurons (Lee et al., 1995, Lee et al., 1993) and in pheochromocytoma cells
(PC 12) (Petroulakis and Wang, 2002). In PC 12 cells, a preferential synthesis of eEFl A1
over eEFl A2 has been demonstrated upon nerve growth factor (NGF) stimulation. As
the absence of eEFlA2 is implicated in neurodegeneration in the mouse mutant, wasted,
it would be interesting to investigate the redistribution of eEFl A2 in cells in the starved
condition and upon mitogenic stimulation.
In addition to the interaction of ZPR1 and eEFl A, studies have shown that SMN co-
immunoprecipitates with ZPR1. Immunoprecipitation of SMN and ZPR1 was drastically
reduced when cells were grown in the absence of serum and was restored upon serum
refeeding (Gangwani et al., 1998). One hallmark of spinal muscular atrophy is the
failure of SMN to localize within the nuclear bodies (Gangwani et al., 2001). It is not
known whether eEFl A2 is in the same ZPR1-SMN pathway, or whether or not the entire
complex is translocated into the nucleus together. I therefore conducted transfection
experiments and studied colocalization of eEFl A2 and SMN using quantitative
immunocolocalization.
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4.2 Results
4.2.1 Construction of epitope-tagged hEEF1A2 expression plasmid
The strategy for this study was to clone a human eEFlA2 cDNA amplified by PCR from
the I.M.A.G.E cDNA clone into the expression vector pcDNA3.1(+)C-myc-Ehs,
following by transfection and immunofluorescence analysis.
4.2.1.1 PCR amplification of the human eEF1A2 cDNA from pOTB7-
hEEF1A2
PCR primers (Table 4-1) were designed to amplify the human eEFl A2 full-length
cDNA from the I.M.A.G.E clone, pOTB7-hEEFl A2. The Hindlll restriction site was
introduced into the 5' end of the forward primer and the Xhol restriction site was
introduced to the 5' end of the reverse primer in order to subclone the insert into the
HindlW and Xhol sites of the vector.
Table 4-1 Primers for amplification of the full-length human eEFl A2 cDNA. The
underlines indicate Hindlll andTTzoI sites for the forward and reverse primers,
respectively.
Primer name Primer sequence (5' to 3')
hEFl 2c forward CGC GCA AGC TTA ATG GGC AAG GAG AAG ACC CAC ATC
hEF12c reverse GGC GTT CTC GAG CG CTC TTC TTC TCC ACG TTC TTG
Double strand cDNAs of 1,357 bps were synthesized by PCR at 94 °C for 2 minutes for
a pre-heat step, followed by 94 °C for 1 minute, 55 °C for 45 minutes, and 72 °C for 1
minute for 34 cycles. The resulting PCR products were visualized on an agarose gel and
purified. The PCR products were then digested with Hindlll and Xhol, and gel purified
before subcloning into the Hindlll/Xhol site of pcDNA3.1(+)C plasmid.
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4.2.1.2 Preparation of the expression vector pcDNA3.1 (+)C-myc-His
The 5,500-bp expression vector pcDNA3.1(+)C, which contains the Myc epitope, was
digested with Hindlll and Xhol restriction enzymes. As these two restriction sites were
close together, the vector was dephosphorylated with shrimp alkaline phosphatase to
decrease the non-recombinant background caused by incomplete digestion with one of
the enzymes, which was undetectable by gel analysis. Following digestion and
dephosphorylation, the vector was gel-purified prior to insert ligation to reduce residual
nicked and supercoiled plasmid.
4.2.1.3 Cloning of the full-length human eEF1A2 cDNA into the vector
pcDNA3.1(+)C-myc-His
The 1,357-bp full-length human eEFl A2 cDNA was cloned into the HindlU/Xhol sites
of pcDNA3.1 (+)C-myc-His plasmid at a 3:1 or 5:1 insert to vector ratio at room
temperature with an overnight incubation. Transformation was performed in the E.coli
strain JM109 as described in 2.2.1.13. Selection for transformation was accomplished by
plating on medium containing ampicillin.
4.2.1.4 Screening and analysis of the transformants
After cloning, transformed E.coli colonies were screened by colony PCR, using insert-
specific promers, and restriction digestion analysis to identify the desired construct.
Table 4-2 shows the sequences of the primers used for colony PCR, and figure 4-1
shows the images of right PCR products obtained from colony PCR. and of the result of
restriction digestion with Hindlll and Xhol restriction enzymes, confirming the success
of cloning. Figure 4-2 shows the map of the pcDNA3.1(+)C-hEEFl A2-myc, which was
ready for transfection.
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Table 4-2 Human eEFlA-2 cDNA-specific primers for colony screening
Primer name Primer sequence (5' to 3') Size of the amplicon (bp)
hEF 12sc_ forward TCA TCG GCC ACG TGG ACT CC 311
hEF12sc_reverse CGA TCA GCA CTG CGC AGT CC
Figure 4-1 Images of gel elecrophoresis showing the right product of restriction
digestion analysis (a), and of colony screening (b).
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Figure 4-2 Map of the pcDNA3.1(+)C-hEEFlA2-myc. The full-length
human eEFl A2 cDNA is located between the HindlU and Xho\ sites.
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4.2.1.5 Sequencing of the pcDNA3.1(+)C-hEEF1A2-myc
The pcDNA3.1(+)C-hEEFl A2-myc was partially sequenced across the insert to ensure
that no mutation was introduced in the PCR process of insert preparation. The T7
promoter/priming site and BGH reverse priming site located in the pcDNA3.1(+)C-myc-
His were simply chosed for primer designing, as shown in table 4-3.
Table 4-3 Sequencing primers for the pcDNA3.1 (+)C-hEEF 1 A2-myc
Primer name Primer sequence (5' to 3')
T7 promoter/priming_forward TAA TAC GAC TCA CTA TAG GG
BGH primingreverse TAG AAG GCA CAG TCG AGG
The sequenced result was aligned to the reference human eEFl A2 cDNA sequence,
NM 001958, and demonstrated 100% identity, as shown in figure 4-3.
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Figure 4-3 Alignment of the partially sequenced pcDNA3.1 (+)C-hEEF 1A2-myc to
the reference sequence of human eEFlA2 cDNA, NM 001958.
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4.2.2 Transient transfection of HeLa cells and calculation of
transfection effieciency
HeLa cell culture and transient transfection were performed as described in 2.2.4 and
2.2.5. To determine the best ratio of the pcDNA3.1(+)C-hEEFl A2-myc plasmid to
Lipofectamine 2000 reagent so as to achieve the highest transfection efficiency, the ratio
of the plasmid to the transfection reagent was set as shown in table 4-4.
Table 4-4 Ratio of the pcDNA3.1(+)C-hEEFlA2-myc plasmid to Lipofectamine
2000 reagent for transfection
Amount of plasmid Amount of transfection reagent (pi) for each ratio
(ftg) 1:1 1:2 1:3
0.8 0.8 1.6 2.4
1.0 1.0 2.0 3.0
1.2 1.2 2.4 3.6
1.6 1.6 3.2 4.8
For calculation of transfection efficiency, regions were chosen in the middle of each
slide quarter. Micrographs of these areas were taken at 20x magnification, and the
images were recorded for further analysis using ImageJ software. eEFl A2-myc-
expressing cells were counted in each of the areas and then all DAPI-stained nuclei were
counted within the same areas. The relative percentage of eEFlA2-myc-expressing cells
per 20x area was determined by dividing the number of the eEFl A2-myc-positive cells
by the total number of DAPI-stained nuclei times 100. The average percentage of
transfected cells was then calculated using the data from each area of the slides, as
shown in figure 4-4. Although there was no statistically significant difference, compared
with the manufacturer's recommended ratio of 1:2 (P = 0.5), the 1:3 ratio of 0.8-ug
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plasmid provides a potential to gave the highest transfection efficiency at 19.5 + 4.1%
(mean + SEM), and this ratio was used for further transfection experiment.
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Figure 4-4 Transfection efficiency, (a) A representative image of transfection at the rati
1: 3 of plasmid (0.8 pg) to transfection reagent, (b) Graph comparing transfectic
efficiency for each ratio of each amount of the plasmid.
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4.2.3 Immunofluorescence analysis
HeLa cells grown at 37 °C in DMEM with 10% calf serum (control) were incubated in
serum-free medium for 24 hours (starved), and then treated with either 10% calf serum
for 12 hours or 100-nM epidermal growth factor (EGF) for 15 minutes at 37 °C. The
cells were examined by conventional immunofluorescence microscopy using a mouse
monoclonal antibody to the c-Myc epitope. DNA was stained with DAPI. No fluorescent
signal was detected when the cells were incubated with primary or secondary antibody
only.
4.2.3.1 Cytoplasmic localisation of eEF1A2 in control and starved HeLa
cells
As described in previous studies, eEFIA is an abundant protein that is present mainly in
the cytoplasm of the cells (Edmonds et al., 1996). By transfecting the HeLa cells with
the plasmid pcDNA3.1(+)C-hEEFlA2-myc and using a specific antibody against the c-
Myc epitope, I found that eEFlA2 (green), an isoform of eEFIA, is mainly located in
the cytoplasm of the cells, as shown in figure 4-5. In serum-starved cells, eEFl A2 was
still confined in the cytoplasm, as shown in figure 4-6.
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Figure 4-5 Cytoplasmic localization of eEFlA2 in the cytoplasm of HeLa cells grown in
the presence of serum. Fluorescein (green) and DAPI (blue) represent eEFl A2 and
DNA, respectively.
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Figure 4-6 Cytoplasmic localization of eEFl A2 in 24-hour serum-starved HeLa cells.
Images on the left and right panels were taken from different transfection slides.
Fluorescein (green) and DAPl (blue) represent eEFlA2 and DNA, respectively.
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4.2.3.2 Redistribution of eEF1A2 to the nucleus in serum-treated and
mitogen-activated HeLa cells
While eEFlA2 was not detected in the nucleus of serum-starved cells, 1 compared
eEFl A2 localization in serum-treated (Figure 4-7) and EGF-activated cells (Figure 4-8).
Diffuse cytoplasmic staining was detected for both serum-treated and EGF-activated
cells. Elpon treatment with serum or EGF, a fraction of the eEFl A2 molecules was
observed to redistribute from the cytoplasm to the nucleus. The punctate distribution of
eEFl A2 in the nucleus may suggest that this isoform of eEFl A accumulate within
nucleoli of the mitogen-treated cells.
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Figure 4-7 Redistribution of eEFlA2 from the cytoplasm to the nucleus in serum-treated
FleLa cells. Images on the left and right panels were taken from different transfection
slides. Fluorescein (green) and DAP1 (blue) represent eEFlA2 and DNA, respectively.
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Figure 4-8 Redistribution of eEFlA2 from the cytoplasm to the nucleus in EGF-treated
HeLa cells. Images on the left and right panels were taken from different transfection
slides. Fluorescein (green) and DAP1 (blue) represent eEFlA2 and DNA, respectively.
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4.2.4 Quantitative Immunocolocalisation
Immunocolocalisation of eEFlA2 with SMN in HeLa cells was studied by using double-
labelling immunostaining and a new quantitative test of colocalisation by intensity
correlation analysis (ICA). Double-labelling ofmyc-tagged eEFl A2 and SMN was
carried out by sequential incubation with a monoclonal mouse anti-Myc antibody and
FITC-conjugated anti-mouse IgG secondary antibody, and then goat anti-SMN antibody
and Texas-red-conjugated anti-goat secondary antibody. As conventional colocalisation
is based on a dye-overlay method, this technique only provides an indication of
coexistence of two proteins in the same regions. It does not address whether the intensity
of staining for the two proteins varies in synchrony, as would be expected if they are
components of the same complex. A limitation of the dye-overlap method is that when
one protein target is distributed across most of the cell, a second protein will be
identified as colocalised even when its distribution is totally random with respect to the
first. I used a newly developed method to test for protein colocalisation by staining
intensity correlation analysis (Li et al., 2004). The ICA imaging was performed
according to the standard method as described by Li et al. (2004). HeLa cells were
imaged on a Zeiss Axioskop upright fluorescence microscope. All comparisons were
made from pairs of single deconvolved image. The Image-J plug-in software was used to
do the ICA analysis. Interpretation of the ICA analysis is based on an ICA plot and an
intensity correlation quotient (ICQ). The ICA plot is a scatterplot of normalized dye A
versus dye B staining intensities, which provides clues to their staining relationship by
representing as the product of the differences from the mean (PDM), i.e. for each pixel.
The PDM value is calculated by (dye A intensity - mean dye A intensity) x (dye B
intensity - mean dye B intensity). The ICQ, a statistically testable quotient, is generated
by subtraction 0.5 from the PDM value (to distribure the quotients to the -0.5 to +0.5
range), and used to provide an overall index of whether the staining intensities are
associated in a random, a dependent or a segregated manner. With random staining ICQ
= ~0; dependent staining 0 < ICQ < +0.5, and for segregated staining 0 > ICQ > -0.5. If
myc-tagged eEFl A2 and SMN were parts of the same complex then their staining
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intensities should vary in synchrony, whereas if they were on different complexes of
structures they would exhibit asynchronous staining, termed dependent and segregated
staining, respectively.
4.2.4.1 eEF1A2 associates with SMN in the cytoplasm
I have previously demonstrated that myc-tagged eEFlA2 is widely distributed in the
cytoplasm of HeLa cells, both in normal and serum-starved conditions. To determine
colocalisation of eEFl A2 with SMN, a visual inspection of the fluorescence staining
pairs suggested colocalisation of the proteins in the cytoplasm (Figure 4-9). I used the
ICA method to test a staining relationship between myc-tagged eEFl A2 and SMN. As
shown in figure 4-10, the products of difference from mean (PDM) plots were highly
skewed toward positive values (Figure 4-10, centre and right panels), consistent with a
dependent staining pattern. Furthermore, the calculated ICQ values, as shown in figure
4-11, were consistently positive and significant (+0.185 + 0.03; P = 0.0034; n = 5),
indicating that the intensities in two images, green and red, varied in synchrony (i.e. they
were dependent). The ICQ is based on the non- parametric sign-test analysis of the PDM
values and is equal to the ratio of the number of positive PDM values to the total number
ofpixel values. Therefore, in any image where the intensities vary together, the PDM
will be positive. This analysis provided compelling evidence that staining for myc-
tagged eEFl A2 varied in synchrony with that for SMN, consistent with the formation of
a complex with the cytoplasm of HeLa cells.
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Figure 4-9 HeLa cells stained with anti-myc antibody and anti-SMN antibody. The left
panels show merged images of each analysed cell, using intensity correlation analysis.
The centre and right panels show gray-scale images after background subtraction and
threshold adjustment for intensity correlation analysis.
myc-EEFlA2 SMN
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Figure 4-10 Intensity correlation analysis. Each row (a-e) represents the ICA plots of the
cells, a-e, in figure 4-9. For the centre and right panels, the y-axis is the PDM (products
of differences from mean) values, and the x-axis is the green (eEFl A2) or red (SMN)
intensity. The left panel shows the frequency scatter plots of eEFl A-2 intensity (y-axis)
versus SMN intensity (x-axis). The ICQ = +0.097, +0.152, +0.183, +0.222, and +0.271
for a, b, c, d, and e, respectively.
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Figure 4-11 Graphs representing quantitative immunocolocalisation, showing the
intensity correlation quotient, analysed by the ICA method, of the cells a-e in figure 4-9
and 4-10. The mean ICQ equals +0.185 + 0.03 (mean + SEM, Student's t test).
4.2.4.2 eEF1A2 and SMN in the nucleus of serum-treated HeLa cells
In an attempt to determine whether the eEFl A2 colocalised with SMN in the nucleus of
serum-treated or EGF-activated cells, only some cells were seen both myc-tagged
eEFl A2 and SMN in the same nuclei. The representative analyses were shown in figure
4-12. The average ICQ for colocalisation in the serum-treated cells was +0.112. This
was inconsistent. Although in some treated cells there was evidence of a dependent
relation between eEFlA2 and SMN (Figure 4-12a and b; ICQ = +0.271), some cells
showed a random relation (Figure 6-12d and e; ICQ = -0.047). In the nucleus of treated
cells, a poor staining intensity relation was observed, as shown in figure 4-12c and f. No
high pixel intensity of myc-tagged eEFlA2 was seen at both low and high SMN staining
intensities. This could be a limitation of the ICQ method, e.g. perhaps an inability to
resolve colocalisation in components of small organelles.
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Figure 4-12 Intensity correlation analysis of representative immunostaining images of
two serum-treated HeLa cells stained with anti-myc antibody and anti-SMN antibody.
The iii and iv panels of the row a and d show gray-scale images after background
subtraction and threshold adjustment. The i panel of the row a and d shows merged
images of each analysed cells. For the iii and iv panels of the row b, c, e and f, the y-axis
is the PDM (products of differences from mean) values, and the x-axis is the green
(eEFl A2) or red (SMN) intensity. The ii panel shows the frequency scatterplots of
eEFlA-2 intensity (y-axis) versus SMN intensity (x-axis). The rows (b) and (e) represent
the ICA plots of the whole cell areas. The ICQ values of the row (b) equal +0.271, and
of (e) equals -0.047. The rows (c) and (f) represent images of the intranuclear areas (the i
panel) and the ICA plots of the intranuclear areas (the ii-iv panels) of the cells in (a) and
(d), respectively. Note the diffuse pixel intensities in (c) and (f).
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4.3 Discussion
The eEFlA2 protein is preferentially located in the cytoplasm of cells. I demonstrated
that a fraction of eEFl A2 redistributes to the nucleus after treatment with serum and a
mitogen, EGF. Immunoflurescence analysis revealed that the nuclear eEFl A2 exhibited
a punctuate appearance. This finding was consistent with previous studies that described
the nuclear localization of the eEFl A protein family (Billaut-Mulot et al., 1996, Sanders
et al., 1996, Gangwani et al., 1998). However, some studies were unable to demonstrate
nuclear localization of eEFl A (Bohnsack et al,. 2002, Calado et al., 2002). Exp5 is
shown to be a functional nuclear export receptor for eEFl A. It is a tRNA binding
protein, and this complex actively suppresses nuclear translation by promoting nuclear
export of eEFl A. The reason for these opposite findings might be differences in cell
culture condition. In Calado et al (2005), HeLa cells were grown in steady-state in the
presence of 10% calf serum, whereas in other studies including my experiment, the cells
were stressed by serum starvation prior to refeeding with serum or stimulating with
mitogens. It is possible that redistribution of eEFl A2 to the nuclei of stressed cells was
stimulated by serum or mitogens to compensate intranuclear translation or other
processes of tRNA processing. It has also been claimed recently that a significant
proportion (10-15%) of cellular protein synthesis takes place in the nucleus, and
occasionally reports of nuclear pools for some translation factors were proposed to
support that claim (Iborra et al., 2001).
Like eEFl A2, SMN is present in both the cytoplasm and the nucleus, where it
accumulates in punctate structures including gem and Cajal bodies (Liu and Dreyfuss,
1996; Matera and Frey, 1998; Young et al., 2000). By using double-labeling
immunostaining and a quantitative analysis of staining dependency, I found that eEFl A2
and SMN exhibited a moderately strong staining intensity correlation (Figure 4-10). This
indicates that eEFl A2 and SMN vary in synchrony and suggests that a proportion of
cytoplasmic eEFl A2 colocalizes with SMN. SMN has been demonstrated to interact
with ZPR1 and the SMN/ZPR1 complex redistributes to and colocalizes to subnuclear
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structures (Gangwani et al., 2001). It has been postulated that upon EGF stimulation,
ZPR1 binds to eEFl A and SMN in the cytoplasm and redistributes to the nucleus
(Matera and Hebert, 2001). Immunoprecipitations with anti-SMN antibodies has been
shown to pull down two unidentified bands with mobilities very similar to those of
ZPR1 and eEFl A (Charroux et al., 2000). Based on quantitative immunocolocalization
as described above, it is possible that eEFlA2 could be part of the so-called SMN
complex.
I next examined the association of eEFlA2 with SMN in the nucleus of serum-treated
cells. Unfortunately, there were no satisfactory ICA results to determine their relation.
This is possible that a fraction of cytoplasmic eEFl A2 that is translocated into the
nucleus is small, and only a tiny proportion of this fraction may colocalize with SMN, or
that interaction between eEFlA2 and SMN in the nucleus exists only in a particular
stage of the cell cycle.
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Chapter 5 Construction and Characterization of muscle-
specific human EEF1A2 transgene
The aims of this study are to construct transgenic mice expressing muscle-specific
human eEFl A2 and to determine the phenotype that results from loss of eEFl A2 in
neurons.
5.1 Construction of muscle-specific human EEF1A2 transgene
5.1.1 Introduction
Elomozygous wst/wst mice develop severe muscle wasting and degeneration ofmotor
neurons, beginning at 3 weeks after birth and die by age of 28 days. In humans, muscle
wasting is a common and clinically important outcome of several neurological disorders,
which include diseases of the central nervous system such as motor neuron disease
(MND) and spinal muscular atrophy (SMA), and ofmuscle itself such as Duchenne
muscular dystrophy. A deletion in the promoter and first exon of the Eefla2 gene,
resulting in the absence ofEefla2 mRNA, was identified in wasted mice (Chambers et
al., 1998). Unlike eEFlAl, eEFlA2 is specifically-expressed in neuron, heart, and
skeletal muscle, which are largely composed of long lived terminally differentiated cells.
Using an immunoflurorescene study, our publication has demonstrated very thin motor
axon collaterals terminating in a retraction bulb swelling, and abnormal motor end plate
occupancies (Newbery et al. 2005).
A human EEFlA2-containing PI-derived artificial chromosome (PAC) has previously
been constructed by Dawn Loh (Loh, 2003) and was used to generate transgenic mice.
The human EEF1A2 PAC was found to correct the wasted phenotype since the body
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weights of transgenic wasted mice were similar to their wild-type littermates. This was
also reflected in the correction of spleen and thymus atrophy in the transgenic wasted
mice. In addition, none of the transgenic wasted mice showed any sign of tremor or
paralysis, and lethality was also rescued.
Herein, I constructed a muscle-specific human EEF1A2 transgene in order to produce
transgenic wasted mice specifically expressing human eEFlA2 in muscle, and to
evaluate the phenotype to see whether loss of eEFl A2 in neuron and heart but presence
in muscle lead to muscle wasting and other neuromuscular abnormalities.
5.1.2 Strategy
In order to evaluate the phenotype that results from tissue-specific expression of
eEFl A2 in muscles but not neuron, transgenic mice carrying a human EEF1A2 gene that
was driven by the muscle-specific promoter were generated.
Human EEF1A2 gene has been mapped to chromosome 20q 13.3 (Lund et al., 1996).
The coding regions of the human EEF1A1 and EEF1A2 are very similar, whereas the
level of similarity in the 5'UTRs, 3'UTRs, introns, and upstream promoter regions is
very low (Knudsen et al., 1993). To avoid the isolation of genomic DNA from either
EEF1A1 or pseudogenes, the pUC19-EEFlA2 plasmid, constructed by Julia Boyd in our
group by subcloning the human EEF1A2 gene from the PAC-EEF1A2, made by Dawn
Loh, into pUCl 9 was used to isolate the human EEF1A2 gene. The gene coding for the
human eEFl A2 has been isolated and sequenced, and the structure and the activity of its
promoter has been characterized (Bischoff et al., 2000). The human EEF1A2 spans
approximately 10 kb and consists of eight exons. The transcription initiation site is
located at the position 1780-2030, immediately upstream of the first exon, and the
predominant transcription initiation site is localized to an adenine nucleotide 166 bp
upstream to the initiator codon or AUG. The core promoter region sufficient to drive
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transcription ranges from the position -16 to +92. These regions were removed and
replaced with the muscle-specific promoter.
Transgenic mice were produced containing the full-length coding region of human
EEF1A2 gene driven by the human skeletal muscle actin (HSA) promoter. The efficacy
of the HSA promoter to drive gene expression was first characterized by Brennan and
Hardeman, who reported the advantages of this promoter to be its tissue specificity,
developmentally correct expression, level of expression, and the fact that a-skeletal actin
gene is expressed naturally in all types of skeletal muscle (Brennan and Hardeman,
1993). This promoter has been used previously to successively generate transgenic mice
with muscle-specific expression (Crawford et al., 2000; Spencer et al., 2002; Spencer
and Mellgren, 2002; Kent et al., 2004). Reports of transgenic studies using the quail
troponin I gene, the rat MLCl/3f gene, the mouse muscle creatine kinase gene, the rat
myosin light chain 2 gene, and the a-myosin heavy chain gene have looked at the ability
of gene promoter to direct striated muscle-specific, and in some cases developmentally
correct, expression. The level of expression achieved by these transgenes has not been
quantified in the context of the normal expression of the endogenous gene. In contrast,
the -2000 to +239 region of the EISA gene is a highly tissue-specific promoter known to
be capable of directing expression of up to 53% of the endogenous gene in adult skeletal
muscle. Additionally, it has the advantage over other isoforms of the contractile protein
multigene families that a-skeletal actin is expressed in all skeletal muscle types. During
development, a-cardiac actin is the predominant isoform of sarcomeric a-actin in mice,
and it is only post-partum that there is a switch to a-skeletal actin (Gunning et al., 1987;
Brennan and Hardeman, 1993). Thus, by using the a-skeletal actin promoter, any
possibilities that embryonic expression ofEEF1A2 might interfere with development
was minimized. The promoter and the first exon of the HSA gene (from -2000 to +239,
relative to the transcription initiation site) were isolated from pHSA2000CAT plasmid
(kindly provided by Edna Hardeman).
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5.1.3 Results
5.1.3.1 Isolation and preparation of human a-skeletal actin promoter
Three parameters of regulation of the human a-skeletal actin, which include level of
expression, tissue specificity, and developmental regulation, are mediated by sequences
within the region -2000 to +239 of the promoter (Brennan and Hardeman, 1993). These
three aspects of the regulation are located in the pHSA200CAT plasmid that, as shown
in figure 5-1, was used for isolating the promoter for this project. The 2, 372-bp
fragment used for constructing the transgene was isolated by PCR. PCR was chosed as a
method to isolate the fragment instead of restriction endonuclease digestion because of a




Figure 5-1 pHSA2000CAT plasmid
In the pHSA200CAT plasmid, a 2,372-bp fragment starting at a Hindlll site 2,000 bp
upstream from the site of transcription initiation contains the first exon and 271 bp of the
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first intron and ends at the HindiII site. PCR primers were designed to generate HindlU
and AgeI sites at the 5' and 3' terminus of the fragment, respectively (Table 5-1).
Table 5-1 Primers for HSA insert amplification. Hindlll and AgeI restriction sites
are indicated in bold for the forward and reverse primers, respectively.
Primer name Orientation Nucleotide sequence (from 5' to 3')
HSAins Forward CGC GCA AGC TTT CTG TAA GGA AAG GT
Reverse GGC GTT ACC GGT AAA GCG CGT GTG GCT
To reduce the risk of the potential for introducing mutations when using PCR for insert
preparation, I used enzymes with high fidelity obtained from Expand High Fidelity PCR
system (Roche). The System contains Taq DNA polymerase and Tgo DNA polymerase
with proofreading activity. The 5'-3' polymerase activity of Taq DNA polymerase and
the 3'-5' exonuclease or proofreading activity of Tgo DNA polymerase provided
improved results, compared to Taq DNA polymerase without Tgo DNA polymerase.
The PCR condition and cycling are shown in chapter 2, Materials and Methods.
By using this protocol, a single band of the correct size was visualized on agarose gel
electrophoresis. The PCR products were purified from primers, nucleotides, polymerase,
and salts using QIAquick PCR Purification kit prior to restriction digestion with Hindlll
and AgeI. The human a-skeletal actin promoter inserts derived from PCR were prepared
for cloning by restriction digestion with HindlU and AgeI, followed by gel purification.
5.1.3.2 Isolation and preparation of the vector containing human
EEF1A2
The 21,543-bp pUC19 plasmid (Figure 5-2) carrying human EEF1A2 and its promoter
was used to prepare the vector for subsequent cloning. Originally, the 18,891-bp human
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EEF1A2 gene and its promoter were cloned into the Hindlll and Kpnl sites of the
plasmid pUC19. After analysis of restriction sites of this plasmid, the Agel site was a
unique site that was located at the position 102-bp upstream to the second exon. Thus,
the 7,751-bp fragment containing the promoter of human EEF1A2 was removed from
this plasmid by restriction digestion using the enzyme HindiII and AgeI. The 13,783-bp
pUC19 carrying human EEF1A2 gene without the promoter was separated from the
promoter after restriction digestion by gel electrophoresis, and purified by gel
purification prior to ligation and transformation.
11,140 bp
►7.7-kb fragment removed &■*-
replaced by HSApro
pUC19-EEF1A2
Figure 5-2 Diagram of the pUC19-EEFlA2 used for preparation of the vector for
subsequent cloning
When recovering DNA from the gel slice, 10 mM Tris-HCl, pH 8.5 was used an elution
buffer instead ofwater or TE because DNA might degrade in absence of a buffering
agent when using water, and EDTA in TE might inhibit subsequent enzyme reactions,
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which might be a cause of unsuccessful transformation that occurred sometimes in this
experiment.
5.1.3.3 Cloning of the human a-skeletal actin promoter into the pUC19-
EEF1A2 vector
The 2.3-kb fragment of the human a-skeletal actin promoter was ligated to the Hindlll-
Agel sites of the 13.7-kb pUC19-EEFlA2 vector, upstream to the human EEF1A2
sequence. Several ligation conditions were preformed in order to give successful
transformation. The condition that gave a desired result was performing incubation at 4-
6 °C overnight.
5.1.3.4 Screening and analysis of the construct
Transformed E.coli colonies were screened for inserts by direct colony PCR using HSA-
specific primers, as shown in Table 5-2. The PCR condition and cycling are shown in
chapter 2, Materials and Methods.
Table 5-2 Primers for direct colony PCR screening.
Primer name Orientation Nucleotide sequence





GAT GAC TAC AAG GTG GAC TG
ACT ATG TGT GTC CCT CTC CT
277
Large scale preparations of the pUC19-HSA-EEFlA2 plasmid were prepared from the
positive colonies. The construct was sequenced to screen for mutations, and restriction-
digested to screen for the intact integrity of the transgene and to ensure the presence of
intact restriction sites for subsequent isolation. Sequencing of the construct was
performed on the whole sequences of the human a-skeletal actin promoter, using
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primers presented in table 5-3. Figure 5-3 shows where the primer sequences are on the
construct. For the human EEF1A2 gene, sequencing was performed on the coding
sequences from the exon 2 to the exon 8, and the polyadenylation site and signal
sequences, using primers shown in table 5-4. Both forward and reverse strands of the
transgene construct were sequenced.
Table 5-3 Primers for PCR sequencing ofHSA region of the pUC19-HSA-
EEF1A2. Four nucleotide sequences for both forward and reverse primers were designed
to span around 800 bps for accurate sequencing.
Primer name Orientation Nucleotide sequence
(from 5' to 3')
seqHSA F1 ATG CTT CCG GCT CGT AT
F2 ATG TCC CTG AGT TCA TC
F3 AGT GCG TCC TAC AGG AG
F4 GAG ACA CTC CAT ATA CG
seqHSA R1 GGA TGT GCT TAA GTG CT
R2 GTT CCC CTC CTG TAG GA
R3 CGT ATA TGG AGT GTC TC
R4 ACC ACG ATG TTG ATG TG
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Figure 5-3 Locations of the primers for HSA sequencing. Forward primers are in
bold, and reverse primers are underlined.
Table 5-4 Primers for PCR sequencing of the coding sequences, exon 2 to exon 8,
of the pUC19-HSA-EEFl A2. The primer segE8 were designed to cover the
polyadenylation site in addition to exon 8.
Primer name Orientation Nucleotide sequence
(from 5' to 3')
seqE2 F GAG ACA CTC CAT ATA CG
R GAG ATG CCA AGC CTG GCC AC
seqE3 F CTG TAA CAA GCA GCT CGC AC
R GAG CCA GAC TGG GTG AGG G
seqE4 F GGA GAG GCC TGG AAG TGA G
R GTG CCA CCT GCC GGT GCC TCG
seqE5 F AGC AGT ACT CCT GGA AGC A
R AGA GAT TGG AGA CAG CCC
seqE6 F CTT TGT TGG TTT CCA GGC TC
R GAC AGT CCT GCT GCT GTC C
seqE7 F CCT CCA GTC AGC ACT CCG G
R CTG CCA TGC TCT GGG CCA AGC
seqE8 F CGT GTT CCG AGG ACA TTC C
R CAG GGA GTG AAG GAT GCT G
There were no mutations found in any of the regions sequenced. The results of
sequencing are given in Appendix 1. Figure 5-4 shows the schematic diagram of
pUC 19-HSA-EEF1A2.
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hEEF1A2 HSApro
11,140 bp •>«"—2,372 bp
16,155 bp
Figure 5-4 Diagram ofpUC19-HSA-EEFl A2. The 13,512-bp Hindlll-Kpnl
fragment includes the 2,372-bp Hindlll-Agel fragment ofHSA promoter and the 11,140-
bp Agel-Kpnl fragment of human EEF1A2. pA (in red) denotes the polyadenylation site
and signal sequence, shown as a nucleotide sequence in the diagram. Restriction sites
represented by H, HindiII; X, Xbal; XH, Xhol\ A, AgeI; K, Kpnl.
For restriction mapping, the unique restriction endonucleases, Hindlll, Kpnl, Xhol, Xbal,
and AgeI, were located only in the transgene sequences, and used for restriction
digestion. The result of restriction digestion showed that, as shown in figure 5-5, the
integrity of the transgene was intact.
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Figure 5-5 Photograph of restriction mapping. pUC19-FISA-EEFlA2 was digested
with the restriction enzymes represented by H, Hindlll; K, Kpnl; Xh, Xhol; X, Xbal; A,
Age I. The 13,512-bp HSA-EEF1A2 transgene was yielded by FI/K digestion. Digestions
with other restriction enzymes also gave the right-size products. Two markers, Ml and
M2, were used to determine the size of products. Predicted digestion-product sizes: H/K,
13,512 and 2,643 bp; Xh/k, 11,467 and 4,688 bp; X, 10,866 and 5,289 bp; A/H, 13,783
and 2,372; H, 16,155 bp.
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5.2 Generation of transgenic mice
5.2.1 Preparation of DNA construct for microinjection
The 16,155-bp pUC19-HSA-EEFl A2 plasmid was digested with HindWI and Kpn\ to
isolate a 13,512-bp fragment that included the HSA promoter, the EEF1A2 gene from
exon 2 to exon 8 including their introns, and the polyadenylation site and signal
sequences. The 13,512-bp transgene was separated by 0.8% agarose gel electrophosis.
The band of the transgene was cut from the gel and further purified by electroelution
using Elutrap Starter kit (Schleicher & Schvell). The fragment was then concentrated by
ethanol precipitation. The concentration of the purified transgene was measured using an
UV spectrophotometer. The transgene was then diluted to a concentration of 2 ng/ul
with injection buffer, and its concentration was confirmed by comparing with Hindlll-
digested X phage on an agarose gel. The male pronucleus of fertilized C57BL/6J
embryos was microinjected by Brendon Doe. The embryos were then transferred into the
oviduct of the pseudo-pregnant mice to complete their gestation.
5.2.2 Analysis of progeny mice for transgene integration
A total of 38 offspring were obtained. Of these, one died. The offspring were screened
for the presence of the transgene by PCR analysis of genomic DNA isolated from ear
clips at three weeks of age using the phenol: chloroform: isoamyl alcohol method. The
primers were designed to detect the sequence of the HSA-EEF1A2 junctions, as shown
in figure 5-6. In addition, the second PCR was used to identify the exon 5 of human
EEF1A2 gene in order to confirm the presence of transgene in case the HSA-EEF1A2
junction region could not be easily amplified, as shown in Table 5-5.
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1 2 3 4 5 6 7 8
HSA-EF12jn primer pair huExon5 primer pair
Figure 5-6 Diagram of the HSA-EEF1A2 constructs used as transgenes showing
sites in designing screening primers.
A third assay that detected an endogenous mouse beta-globin gene was designed in order
to demonstrate that the DNA preparations were amenable to PCR (Table 5-5). Mice
were tested with both assays so that no transgenic founder was mistakenly discarded
because ear clip DNA was not suitable for PCR.
Table 5-5 Primers used for screening HSA-EEF1A2 transgenic mice
Primer name Orientation Nucleotide sequence Size of the
(from 5' to 3') amplicon (bp)
HSA-EF12jn F GCC GAG AGT AGC AGT TGT A 313
R GAT GTT GAT GTG GGT CTT C
huExon5 F AGC AGT ACT CCT GGA AGC A 344
R AGA GAT TGG AGA CAG CCC
Beta-Globin F CCA ATC TGC TCA CAC AGG 494
ATA GAG AGG GCA GG
R CCT TGA GGC TGT CCA AGT
GAT TCA GGC CAT CG
Two founders (5.4%), one male and one female, were positive for the transgene. Mice
that had not incorporated the transgene were culled by cervical dislocation.
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5.2.3 Production and maintenance of transgenic lines
Typically, transgenic founders are bred to mice of defined genetic background such as
C57BL/6. Due to a limitation of time for this project, the two transgenic founders were
bred to heterozygous wasted (wst/+) mice in order to produce a sufficient amount of
male and female heterozygous mice carrying the transgene (tg/+ wst/+) for further
breeding. The transgenic offspring were maintained as hemizygotes.
5.2.4 Production of homozygous wasted mice carrying the HSA-
EEF1A2 transgene
To generate homozygous wasted offspring carrying the HSA-EEF1A2 transgene (+/tg
wst/wst), heterozygous wasted mice carrying the E1SA-EEF1A2 transgene (tg/+ wst/+)
were bred with non-transgenic heterozygous wasted mice (+/+ wst/+), as shown in figure
5-7. The expected genotypes are shown in figure 5-8. The frequency ofwasted
homozygotes carrying the EISA-EEF1A2 transgene that were produced would be at 1 in
8. Of two transgenic founder mice, the female one did not yield any transgenic progeny
after the five litters were screened.
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transgenic founder wasted heterozygote
(1 in 4)
chromosome with integrated transgene
chromosome with wasted deletion
wild-type chromosome













chromosome with integrated transgene





Figure 5-8 Diagram showing possible outcome from mating a transgenic wasted
heterozygote with a non-transgenic wasted heterozygote.
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5.2.5 Identification of transgenic HSA-EEF1A2 wasted mice
The offspring from these matings were genotyped at the time of weaning using three sets
of primers which included the HSA-EEFlA2-junction primers, the wasted allele
(wstspan)-specific primers, and the wild-type allele (P2)-specific primers. The P2
primers were designed to detect a portion of the wasted deletion sequence. The wstspan
primers were employed to detect the wst deletion. The forward or 'split' primer of the
wstspan primers was designed with 18 nucleotides from just outside the 5' end of the wst
deletion, and 6 nucleotides from just outside the 3' end of the wst deletion as illustrated
by figure 5-9. Using the P2 and wstspan primers helped distinguish wasted homozygotes
from heterozygotes. Positive amplification of both P2 and wstspan PCR products
indicates DNA is isolated from the heterozygotes. The absence of P2 product and the
presence ofwstspan product indicate wasted homozygotes.
1 2
Figure 5-9 Diagram showing the strategy for designing the primers for genotyping
wasted mice.
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5.2.6 Protein expression and tissue specificity of the HSA-EEF1A2
transgenic wasted mice
Western blots were used to screen and confirm expression of the transgene in tissues of
transgenic HSA-EEF1A2 homozygous wasted mice using an antibody against the
eEFlA2 protein (Figure 5-10). The human eEFl A2 protein was found to be expressed in
skeletal muscle of transgenic wasted mice, as shown in figure 5-10a - 5-1 Of, although its
expression in cardiac muscle was also found in some transgenic wasted mice (Figure 5-
lOd and 5-10e). However, these findings was consistent with Dr. Hardeman's studies
(Brennan and Hardeman, 1993), which used the HSA promoter to drive muscle-specific
expression of a transgene and showed muscle-specific expression of the transgene
together with its expression in cardiac muscle in some transgenic mouse lines. Some
transgenic wasted mice produced in my study showed expression of eEFl A2 in stomach
and eyes in addition to its expression in heart, as shown in figure 5-1 Of. This expression
pattern could be a result of random integration of the transgene, in which franking
sequences might contain regulatory elements of nearby genes that acted on the promoter
of the transgene as an enhancer, which could lead to ectopic expression of the transgene.
However, as eEFlA2 was not found to be expressed in the nervous system but was
present in muscle, the pattern of expression in heart, stomach, or eyes was considered
not to affect the studies ofmuscle denervation.
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B Sc H L Li Sp St K M Th E Sk
c.
B Sc H L Li Sp St M K Th E Sk
B Sc H L Li Sp St K M Th E Sk
B Sc H L Li Sp St K M Th E Sk
B Sc H L Li Sp St K M Th E Sk
ggjf
B Sc H L Li Sp St K M Th E Sk
Figure 5-10 Expression of eEFl A2 in transgenic wasted and non-transgenic wild-type
tissues, (a) - (f) Tissues from transgenic wasted mice, (d) and (e) Tissues for female, (g)
Tissues from a non-trasngenic wild-type mouse, (h) Tissues from a non-transgenic
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wasted mouse, (i) Photograph representing loading control. eEFlA2 is not detected in
brain and spinal cord of transgenic mice. Tissues: B, brain; Sc, spinal cord; H, heart; L,
lung; Li, liver; Sp, spleen; St, stomach; K, kidney; M, skeletal muscle; Th, thymus; E,
eye; Sk, skin.
In transgenic heterozygous wasted mice (tg/+ wst/+), expression of eEFl A2 was
significantly higher than the expression in non-transgenic heterozygous wasted
littermates (+/+ wst/+), with P value equals 0.0085, as shown in figure 5-11.




































Figure 5-11 Comparison of eEFlA2 expression in muscle from non-transgenic
and transgenic heterozygous wasted littermates. (a) Western analysis for eEFlA2 in
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muscle samples, (b) Relative expression level for each muscle sample, (c) Average of
relative expression from 4 muscle samples for each genotype. Asterisk denotes P =
0.0085 (Unpaired /-tests).
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5.3 Analysis of transgenic HSA-EEF1A2 homozygous wasted
mice
5.3.1 Comprehensive phenotype assessment of sensorimotor
functions
Muscle and lower motor neurone function of the transgenic homozygous wasted mice
were assessed and compared with those of controls and non-transgenic wasted mice by
using modified SHIRPA (SmithKline Harwell/Imperial College/Royal
Hospital/Phenotype Assessment) primary screen of neurologic function (Rogers et ah,
1997; Hatcher et al., 2001). A wide array of tests enhances capability of defining
deficient and spared functions. The SHIRPA primary screen consists of quantitative and
semi-quantitative observations of reflexes and basic sensorimotor functions as well as
body weight and size. In my study, the tests for assessment ofmuscle and sensorimotor
functions were used, although some of the results could be used to interpret other aspects
of neurologic function such as spinocerebellar and sensory functions. However,
assessment of autonomic function and neuropsychiatric functions were not included in
this study. Transgenic homozygous 25-day-old wasted mice (n = 6) were assessed and
compared to age-matched non-transgenic wasted mice (n = 6) and wild-type controls (n
= 6). For a quantitative measure, group comparisons were assessed by the unpaired
student /-test.
As presented in table 5-6, HSA-EEF1A2 transgenic wasted mice were distinguishable
from non-transgenic wild-type controls on certain aspects of the primary screen. The
mean body weight of transgenic wasted mice was lower than that of controls (P <
0.0001), and their body length was shorter than that of controls (P < 0.0005; Table 5-6
and Figure 5-12). The HSA-EEF1A2 transgenic group showed significant abnormalities
in every array of the tests except the tail-lifting test, with P < 0.0001 for gait, and body
tremor, P < 0.001 for spontaneous activity and contact righting reflex, P < 0.005 for grip
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strength and wire manoeuvre, and P < 0.05 for righting reflex. These abnormalities
indicated an impairment of lower motor neurone and spinocerebellar functions,
including muscle.
Non-transgenic wasted mice differed from controls on the same aspects as those of
transgenic wasted mice, including body weight and length, with the same ranges of
statistic significances, except for grip strength and wire manoeuvre, in which those of
non-transgenic wasted mice showed a greater significance than those of transgenic
wasted mice. However, there was no statistic significance in any aspect of the tests
between transgenic and non-transgenic wasted mice (P > 0.1). These results meant that
with regard to sensorimotor function tests used in this study as well as body weight and
length, HSA-EEF1A2 transgenic wasted mice were indistinguishable from non-
transgenic spontaneous mutant wasted mice.
Figure 5-12 Length comparisons of a non-transgenic wild-type control (a), a HSA-
EEF1A2 transgenic wasted mouse (b), and a non-transgenic wasted mouse (c).
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Table 5-6 Mean + S.E.M. values from the modified SHIRPA primary screen of
HSA-EEF1A2 transgenic wasted mice, non-transgenic wasted mice and non-transgenic
controls














Trunk curl 1.0 + 0
Limb grasping 1.0 + 0
Visual placing 3.0 + 0
Horizontal grid
Grip strength 2.2 + 0.2
Body tone 1.0 + 0
Horizontal wire
Wire manoeuvre 0.2 + 0.2
Righting reflex 0.0 + 0
Tube
Contact righting reflex 1.0 + 0
Body measures
Weight (g) 12.1+0.2


























1.2 + 0.2 b
0.7 ± 0.2c
0.2 +0.2a
7.7 ± 0.5 a
6.0 + 0.1a
a P < 0.001 vs. controls (unpaired t-test).
b
P < 0.005 vs. controls (unpaired t-test).
c
P < 0.05 vs. controls (unpaired t-test).
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5.3.2 Progressive paralysis in HSA-EEF1A2 transgenic wasted mice
Motor function in the hind limbs of HSA-EEF1A2 transgenic wasted mice was scored
using the neurological rating scale as previously presented in chapter 3, table 3-1. The
scores were compared to those of non-transgenic wasted mice and wild-type controls.
The number of mice for each group was varied with age, as shown in table 5-7.
However, there were six animals in each group at the beginning of the evaluation. The
groups were compared with the unpaired /-test.
Two ofHSA-EEF1A2 transgenic wasted mice were allowed to live until they got the
neurological score of zero at the age of 30 days, and then were culled. As presented in
table 5-7 and figure 5-13, the transgenic group showed signs of paralysis beginning at
weaning (score 4 + 0), and progressed to severe paralysis with an absence ofmovement
(score 0.5 + 0.58, P < 0.009, n = 4) at the age of 29 days. Of these, two died, and the
other two were culled at the age of 30 days with the score of zero. The trend of
progression of paralysis observed in the transgenic group was similar to that of non-
transgenic wasted mice when compared to the controls. When compared the
neurological scores of the transgenic wasted mice to those of non-transgenic wasted
group, no statistically significant difference was observed at any age of the mice, as
shown in table 5-7. Although the transgenic group seemed to live 1-2 days longer than
the non-transgenic wasted mice, the number of animals was too small to make this
conclusion. Ataxic walking was observed to occur 1 day later in the HSA-EEF1A2
transgenic wasted mice, at 24 days old (score 2.83 + 0.41) than the non-transgenic
wasted group, at 23 day olds (score 2.83 + 0.41).
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Table 5-7 Neurological rating scores of hind limbs of HSA-EEF1A2 trasngenic
wasted mice, non-transgenic wasted mice, and wild-type controls.
D20 D21 D22 D23 D24 D25 D26 D27 D28 D29 D30~
Control 1 5 5 5 5 5 5 5 5 5 5 5
Control 2 5 5 5 5 5 5 5 5 5 5 5
Control 3 4 5 5 5 5 5 5 5 5 5 5
Control 4 5 5 5 5 5 5 5 5 5 5 5
Control 5 4 5 5 5 5 5 5 5 5 5 5
Control 6 5 5 5 5 5 5 5 5 5 5 5
Mean 4.67 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00
S.D. 0.52 0 0 0 0 0 0 0 0 0 0
Ntg-wst 1 5 4 3 3 3 2 2 1
0
1 HHH

























4 4 3 3 2 2 1 0 0
4 4 4 2 2 2 Wit!! >4 ■■
4.33 4.00 3.33 2.83 2.33 2.00 1.40 0.60 0.40 -





P value vs. 0.31 M < U.UIO
controls*
Tg-wst 1 5 4 3 3 3 2
Tg-wst 2 5 4 3 3 3 2
Tg-wst 3 4 4 3 3 3 2
Tg-wst 4 4 4 3 3 3 2
Tg-wst 5 4 4 4 3 2 2
Tg-wst 6 5 4 3 3 3 2
Mean 4.50 4.00 3.17 3.00 2.83 2.00
S.D. 0.55 0 0.41 0 0.41 0
P value vs. 0.64 < 0.005 fc-
controls*
P value vs. 0.64 0.90 0.59 0.90 0.11 0.90
ntg-wst*
2 1 1 1 0
2 2 1 1 0
2 1 1 0
2 1 1 0
1 1 0
1!' ' '
1.80 1.20 0.80 0.50 0
0.45 0.45 0.45 0.58 0
< - <0.009 ►
* Mann-Whitney test.
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Figure 5-13 Mean of the neurological scores in hind limbs ofHSA-EEF1A2
transgenic wasted mice compared to those of non-transgenic wasted mice and wild-type
controls.





5.3.3 A decline in body weight and muscle mass
Spontaneous mutant homozygous wasted mice have been shown to begin to lose weight
at about 21 days of age, with a significant decline to less than their normal littermates by
23 days (Tezuka et al., 1986). Recently, the decline in body weight of wasted mice has
been demonstrated to occur along with a disproportionate decline in muscle, in which
the mean muscle:body weight ratio in wasted mice was 1.49 compared with 4.44 in
heterozygous mice by day 27 (Newbery et al., 2005). In my study, I compared total body
weights of HSA-EEF1A2 transgenic homozygous wasted mice, which expressed
eEFlA2 specifically in skeletal muscle, with those of non-transgenic wasted mice and
normal littermates so as to investigate whether expression of eEFl A2 in muscle affected
body weight ofwasted mice.
HSA-EEF1A2 transgenic wasted mice showed a gradual incline in body weight to their
peaks of 8.57 + 0.98 grams at day 20, then began to progressively decline to less than
Chapter 5 - Construction and characterization ofmuscle-specific human EEF1A2 transgene 150
body weights of non-transgenic normal littermates with a statistically significant
difference at day 21 (8.00 + 0.08, P < 0.05), as shown in figure 5-14 and table 5-8. At
day 25, the average weight of transgenic wasted mice was 7.50 + 1.38 grams, whereas
that of non-transgenic normal littermates was 12.8 ± 0.92 grams (P < 0.0001). Non-
transgenic homozygous wasted mice showed a decline in their body weights compared
with those of controls similar to HSA-EEF1A2 transgenic wasted mice. Their weights
also reached a peak of 8.50 + 0.53 grams at day 20, then began to decline. However, the
statistical significance, compared to controls, was observed at 1 day (day 22) later than
that of transgenic wasted mice (P vs. controls < 0.05). There was no significantly
statistic difference observed in body weight measurements at any age of animals
between transgenic and non-transgenic wasted mice
14





Figure 5-14 Body weights of HSA-EEF1A2 transgenic wasted mice, non-transgenic
wasted mice, and controls
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Table 5-8 Body weights of HSA-EEF1A2 transgenic wasted mice, non-transgenic wasted mice, and non-transgenic controls
D14 D15 D16 D17 D18 D19 D20 D21 D22 D23 D24 D25
Body weight (g) +
S.D.
Controls 6.00 + 7.13 + 7.13 + 7.20 + 7.50 ± 8.20 ± 8.50 ± 9.10 + 9.9 + 10.5 ± 11.08 ± 12.8 +
0.47 0.35 0.64 0.93 0.53 0.63 0.71 0.74 0.74 0.97 1.86 0.92
Non-tg, wst/wst 5.88 ± 6.88 + 6.88 + 7.00 + 7.63 ± 7.75 + 8.50 + 8.14 + 8.00 ± 7.71 + 7.50 + 7.38 +
0.64 0.83 0.64 0.79 0.74 1.13 0.53 1.35 1.11 0.95 0.55 0.72
Tg, wst/wst 5.57 ± 6.43 + 7.00 ± 7.29 + 7.57 + 8.29 ± 8.57 + 8.00 + 7.86 + 7.67 ± 7.50 ± 7.50 +
0.53 0.79 0.82 1.11 1.13 1.38 0.98 0.08 0.90 1.21 1.05 1.38
P value *
Tg, wst/wst vs. 0.101 0.0413 0.7451 0.8545 0.8629 0.8644 0.8629 0.011 0.0001 0.0001 0.0008 <0.0001
controls
Tg, wst/wst vs. 0.3416 0.3079 0.7451 0.6272 0.9411 0.5364 0.8606 0.8142 0.4435 0.9381 1.0000 0.8580
non-tg, wst/wst
Non-tg, wst/wst 0.6395 0.4483 0.4483 0.5962 0.6819 0.4491 1.0000 0.0775 0.0260 <0.0001 0.0005 <0.0001
vs. controls
Unpaired /-test.
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Muscle:body wet weight ratio was further analyzed. Quadrieeps muscles from aged-
matched HSA-EEF1A2 transgenic wasted mice, non-transgenic wasted mice, and
normal littermates were weighed at 20 to 29 days of age. As shown in table 5-9 and
figure 5-15, both transgenic and non-transgenic wasted mice showed a disproportionate
decline in muscle mass as they deteriorated. At the age of 24-25 days onwards, their
muscle:body weight ratios were significantly lower than those of normal mice (P <
0.05). By day 29, the average muscle:body weight ratio in transgenic wasted mice was
1.73 + 0.45 compared with 3.70 + 0.14 in normal controls ( P < 0.02), whereas the ratio
in non-transgenic wasted mice was 1.57 + 0 (P vs. controls < 0.005). There was no
significantly statistic difference in musclerbody weight ratio between the transgenic
wasted mice and non-transgenic wasted group at any age of animals. The size of the
spleen of the transgenic wasted mice was also observed and was similar to that of non-
transgenic wasted mice, as shown in Appendix 2.
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Table 5-9 Mean ± S.D. and P values ofmusclerbody wet weight ratios ofHSA-
EEF1A2 transgenic wasted mice compared with non-transgenic wasted mice and
controls.
D20-D-21 D24-D25 D28-D29
Muscle:Body weight ratio (x 1(F) + S.D.
Controls 3.44 ±0.06 3.88 ±0.25 3.70 ±0.14
Non-tg, wst/wst 2.76 ±0.91 1.85 ±0.59 1.57 ±0
Tg, wst/wst 3.20 ±0.28 1.41 ±0.02 1.73 ±0.45
P value *
Tg, wst/wst vs. controls
Tg, wst/wst vs. non-tg, wst/wst











Figure 5-15 Musclerbody wet weight ratios ofHSA-EEF1A2 transgenic wasted mice
compared with non-transgenic wasted mice and controls.
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5.3.4 Muscle pathology in HSA-EEF1A2 transgenic wasted mice
5.3.4.1 Analysis of fibre size differences
Quadriceps muscles were taken from three 28-day-old HSA-EEF1A2 transgenic wasted
mice, non-transgenic wasted mice and non-transgenic wild-type controls. 200-700 fibres
in the transverse sections from each group were analysed. Data (means ± S.E.M) were
compared between groups by the unpaired /-test. Fibre analysis showed a significant
smaller fibre diameter in transgenic wasted mice compared with the controls (15.5 + 0.2
um in transgenic group, 20.8 + 0.3 um in control group, P < 0.0001), as shown in table
5-10 and figure 5-16. When compared the transgenic wasted mice with the non-
transgenic wasted group (15.5 + 0.2 um) there was no statistical significance between
the groups.
Table 5-10 Minimum and maximum diameters of muscle fibres
Muscle Fibre Analysis Tg, wst/wst Ntg, wst/wst Wild Type
Minimum diameter (um) 14.3 13.5 18.5
Maximum diameter (um) 16.1 16.5 22.4
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Figure 5-16 Analysis ofmuscle fibre size differences, (a) H&E-stained cross-sections,
(b and c) Comparisons between groups ofmice. Asterisk denotes P < 0.0001.
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5.3.4.2 Muscle in HSA-EEF1A2 transgenic wasted mice shows features
of neurogenic atrophy
Hematoxylin and eosin-stained cross-sections of quadriceps from three 28 day-old HSA-
EEFl A2 transgenic wasted mice were analysed. Multiple small groups of atrophic fibres
were demonstrated in addition to small angular fibres (Figure 5-17). These findings
suggested that the pathologic process was in the early stage of denervation, like those
previously demonstrated in muscle of spontaneous mutant wasted mice (see 3.2.2.2). A
range of severity in muscle pathology was found. Pyknotic nuclear clumps, an end
product of denervation atrophy, were also found in several areas of severely atrophic
fibres, which suggested that denervation existed without reinnervation. The findings of
these pathologic processes are the same as those found in spontaneous mutant wasted
mice (Figure 3-3), suggesting that neurologic atrophy in wasted mice might be a result
of the loss of eEFlA2 in nerve fibres that supply the muscle rather than of the loss of
eEFlA2 in muscle itself.
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Figure 5-17 Hematoxylin and eosin-stained cross-sections of muscles of 28-day-old
HSA-EEF1A2 transgenic wasted mice, showing grouped atrophic fibres with severe loss
of contractile apparatus and prominent pyknotic nuclei, (a) 20x magnification, (b) 60x
magnification.
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5.3.4.3 Evidence of regenerating muscie fibres is found in muscle of
HSA-EEF1A2 transgenic wasted mice
Centralized nuclei have previously been found in muscles from 25-day-old wasted mice,
as described in 3.2.2.3. Herein, they were also demonstrated in muscles from 25-day-old
HSA-EEF1A2 transgenic wasted mice (Figure 5-18), suggesting that the regenerating
process ofmuscle fibres is taking place during the ongoing process of muscle
denervation.
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Figure 5-18 Hematoxylin and eosin-stained cross sections of quadriceps of two 25-
day-old HAS-EEF1A2 transgenic wasted mice (a and b, 40x), showing centralized
nuclei typical of regenerating muscle fibres (arrows).
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5.3.5 Expression of nerve-regulated genes in muscle of HSA-
EEF1A2 transgenic wasted mice
As previously shown in 3.2.4, muscle of homozygous wasted mice showed upregulation
ofAchRal and myogenin, and downregulation of C1C-1, which is a typical pattern
found in atrophic muscle resulting from denervation. In order to confirm that muscle
atrophy in wasted mice is a consequence of denervation, I studied patterns of these
denervation-sensitive genes in muscle ofHSA-EEF1A2 transgenic wasted mice, in
which there is no eEFlA2 protein expressed in nerves but only in muscles, the
hypothesis being that the lack of eEFA2 in nervous system, but not in muscle, is a
leading cause ofmuscle atrophy in wasted mice.
5.3.5.1 HSA-EEF1A2 transgenic wasted mice showed an upregulation of
AchRal and myogenin, and downregulation of CIC-1
Hindlimb muscles, quadriceps, were taken from 29-day-old HSA-EEF1A2 transgenic
wasted mice, non-transgenic wasted, and wild-type littermates (n = 3 for each group).
Student's unpaired t-test was used to compare data (mean + S.E.M) between groups.
Figure 5-19 shows the levels of expression ofAchRal, myogenin, and CIC-1 genes,
which are normalized to those of P-actin. As expected, the transcripts ofAchRal in
muscle of transgenic mice were a significantly upregulated 8.59-fold above the levels in
wild-type mice (P < 0.0005). In a similar fashion, the expression ofmyogenin were
elevated 21.83-fold higher than in wild-type mice (0 < 0.005). Interestingly, the levels of
expression of AchRal and myogenin in FISA-EEF1A2 transgenic wasted mice (8.85 +
0.65 for AchRal; 21.83 + 2.46 for myogenin) were higher than those in non-transgenic
wasted group (5.88 ± 1.23 for AchRal; 1.33 + 0.36 for myogenin), when normalized to
the levels in wild-type controls. The difference is significant in the expression of
myogenin, where P is less than 0.005 (transgenic vs. non-transgenic).
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When normalized to the levels ofGAPDII expression, the levels of AchRal and
myogenin followed the same patterns as that of P-actin gene, as shown in figure 4-18.
When compared between the transgenic and non-transgenic groups with normalization
to the levels ofGAPDH expression in wild-type controls, the HSA-EEF1A2 transgenic
wasted mice showed a higher expression ofAchRal (22.33 + 1.88 in transgenic; 9.12 +
1.88 in non-transgenic; P < 0.01) and myogenin (25.57 + 5.83 in transgenic; 6.03 + 1.99
in non-transgenic; P < 0.05).
For the expression of C1C-1 gene, which is downregulated upon denervation, the levels
of its expression were lowered in muscle of the HSA-EEF1A2 transgenic wasted mice,
compared to those of wild-type controls. Normalized to the expression of P-actin, those
of C1C-1 in the transgenic wasted mice were 6.67-fold lower than in wild-type mice (P <
0.05), as shown in figure 4-17. Similar patterns were demonstrated when normalized to
the expression levels ofGAPDH (Figure 5-20). However, unlike the expression of
AchRal and myogenin, there was no significant difference of C1C-1 expression between
the transgenic and non-transgenic wasted mice (0.13 + 0.8 vs. 0.39 + 0.06 when
normalized to P-actin expression; 0.25 + 0.07 vs. 0.61 + 0.09 when normalized to
GAPDH expression).
Values (mean + S.E.M) of the levels of expression of AchRal, myogenin, and C1C-1 are
given in table 5-11.










































Figure 5-19 Expression levels normalized to those of P-aetin





















































Figure 5-20 Expression levels normalized to those ofGAPDH
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Table 5-11 Mean + S.E.M of the levels of expression ofAchRal, myogenin, and C1C-
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5.3.5.2 EEF1A2 promotes expression of AchRal and myogenin in
denervated muscle
As the expression ofAchRal and myogenin in the HSA-EEF1A2 transgenic wasted
mice were significantly higher than those in non-transgenic wasted group, it would be
interested to figure out that whether these high levels of expression were a direct effect
of a high level of eEFl A2 protein in the HSA-EEF1A2 transgenic wasted mice with no
regard to denervation. To address this question, the levels of expression of AchRal and
myogenin were compared between transgenic non-wasted (tg/+ wst/+) and transgenic
wasted (tg/+ wst/wst), including non-transgenic wild-type mice as controls. Quadriceps
from six 25-day-old mice for each groups were taken for real-time RT-PCR.
The expression ofAchRal mRNA in muscle of HSA-EEF1A2 transgenic wasted mice
(11.82 + 1.63) was significantly higher than in muscle of transgenic non-wasted (1.92 +
0.48) and controls groups (2.27 + 0.70), with P = 0.005 (Figure 5-21). For myogenin
mRNA expression, the transgenic wasted mice also showed significantly higher
expression (10.59 + 1.58) than the transgenic non-wasted (1.00 + 0.24) and controls
(1.90 ±0.52), with P < 0.0005, as shown in figure 5-22. No differences in the expression
ofAchRal and myogenin mRNAs between transgenic non-wasted mice and wild-type
controls were found. For C1C-1 mRNA expression, as expected, there was no difference
in the expression between the transgenic non-wasted mice and controls, but its
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expression was lowered in the transgenic wasted group (Figure 5-23). Similar patterns
were demonstrated when normalized to the levels ofGAPDH mRNA expression, as
shown in figure 5-24.
Chapter 5 - Construction and characterization ofmuscle-specific human EEFIA2 transgene 166
□ controls 1-6
ll tg, non-wasted 1-6






Figure 5-21 Expression of AchRal mRNA in quadriceps of 25-day-old mice (n = 6
for each group), normalized to those of (3-actin. Asterisk denotes P = 0.005.
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Figure 5-22 Expression of myogenin mRNA in quadriceps of 25-day-old mice (n = 6
for each group), normalized to those of P-actin. Asterisk denotes P < 0.0005.
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Figure 5-23 Expression of CIC-1 mRNA in quadriceps of 25-day-old mice (n - 6 for
each group), normalized to those of P-actin. Asterisk denotes P < 0.0001.
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Figure 5-24 Expression of AchRal, myogenin, and C1C-1 mRNAs in quadriceps of
25-day-old mice (n = 6 for each group), normalized to those of GAPDH. Asterisks
denote P < 0.0001 for AchRl, P = 0.0001 for myogenin, and P < 0.005 for C1C-1.
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In a similar fashion, 29-day-old transgenic wasted mice showed a high level ofAchRal
and myogenin expression, whereas there was no difference in the expression between
the transgenic non-wasted and controls (n = 3 for each group), as presented in figure 5-
25 and 5-26. These findings, including from 5.3.5.1, indicate that muscle denervation
leads to an increased expression ofAchRal and myogenin in wasted mice, whether they
are HSA-EFF1A2 transgenic or spontaneous mutant, but their levels of expression are
remarkedly increased if the animals also express a high level of the eEFlA2 protein in
muscle.
Values (mean + S.E.M) of the levels of expression of AchRal, myogenin, and C1C-1 are
given in table 5-12.












































Figure 5-25 Expression of AchRal, myogenin, and CIC-1 genes in quadriceps of 29-
day-old mice (n = 3 for each group), normalized to those of |3-actin. Asterisks denote P <
0.05 for AchRal, P < 0.005 for myogenin, and P < 0.05 for CIC-1.






















Figure 5-26 Expression of AchRal, myogenin, and CIC-1 genes in quadriceps of 29-
day-old mice (n = 3 for each group), normalized to those of GAPDH. Asterisks denote P
< 0.01 for AchRal, P < 0.01 for myogenin, and P < 0.05 for CIC-1.
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Table 5-12 Mean + S.E.M of the levels of expression ofAchRal, myogenin, and C1C-
1 in muscle of 29-day-old transgenic wasted, transgenic non-wasted, and wild-type
controls.
Mice Normalized to (3-actin Normalized to GAPDH
(n = 3) AchRal Myogenin C1C-1 AchRal Myogenin C1C-1
Controls 1.00 + 1.00 + 0.33 1.00 + 1.00 + 1.00 + 0.37 1.00 +
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5.4 Discussion
Data of the transgenic study presented here is unfortunately somewhat preliminary due
to time constraints in experiments relating to the generation of transgenic progeny. In
some instances the number of transgenic lines generated for the HSA-EEF1A2 construct
and the number of progeny analysed may be not sufficient enough to make firm
conclusions. However, data presented here gives useful and interesting knowledge or
information regarding the role of eEFl A2 in motor neurons and muscles of wasted mice.
5.4.1 Production of transgenic progeny
Of two transgenic founder mice, one male and one female, the female one did not yield
any transgenic progeny after the five litters were screened. Analysis of some of the
offspring indicated that there possibly were more than one separate transgene integration
event, and transgenes were transmitted independently, as eEFl A2 protein was also
detected in eyes and stomach. However, this pattern of expression did not affect my
study on muscle denervation because eEFl A2 protein was not expressed in all HAS-
EEF1A2 transgenic homozygous wasted mice used in the study.
5.4.2 Characterization of HSA-EEF1A2 transgenic wasted mice
5.4.2.1 Primary screen
The screening battery was designed by modification of the SHIRPA primary screen.
Only the tests for assessment of muscle and sensorimotor functions were used. Despite
its simplicity, correct interpretation of the measurements depends on what is considered
normal for the controls being examined. Systematic SHIRPA primary screens have not
been carried out on heterozygous and homozygous wasted mice. In the present study,
non-transgenic wild-type animals were used as normal controls and non-transgenic
homozygous wasted mice were used as wasted controls. HSA-EEF1A2 transgenic
wasted mice were distinguishable from non-transgenic normal controls on several
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sensorimotor measures of the primary screen, in addition to physical differences.
However, the transgenic group was unable to distinguish from the non-transgenic wasted
mice. Balance and coordination, which are a category in the SHIRPA secondary screen,
have been examined in spontaneously mutant-wasted mice, using a rotorod (Newbery et
al., 2005). Taken together with my present study, it might be possible to conclude that
muscle, lower motor neurone, and spinocerebellar functions are the main systems
involved in motor and behavioural abnormalities in wasted mice. As some tests can be
used for evaluation of other nervous systems, such as righting reflex, it would be
interested to examine wasted mice in other aspects of the SHIRPA primary screen.
Correlations should also be undertaken, when more mice are produced enough, in the
experimental group between body weight and length, on one hand, and other variables,
on the other, by using the Pearson product-moment correlation test.
5.4.2.2 Evidence of denervation atrophy
Spontaneous mutant-wasted mice lack the eEFl A2 protein in neurones, heart, and
muscle, and exhibit muscle atrophy on ageing. The results from Chapter 3 indicate that
denervation is a cause of atrophy. Here, I generated and examined HSA-EEF1A2
transgenic homozygous wasted mice, and the results showed that muscle pathology and
regulation of denervation-sensitive genes are the same as those found in spontaneous
wasted mice. These findings suggest that the loss of eEFl A2 in motor neurone, but not
in muscle, is a leading cause ofmuscle wasting. Compensation of eEFl A2 for the
complete loss ofeEFlAl in muscle by 21 days of wasted mice could not rescue these
pathologic processes. Muscle of the HSA-EEF1A2 transgenic wasted mice occasionally
contained centralized nuclei typical of regenerating muscle fibres. The extent of
centralized nuclei cannot be studied easily under light microscope ofH&E sections.
Fibres with centralized nuclei have been shown to induce expression of the myosin
heavy chain (MyHC) neonatal isoform, a hallmark of regenerating myofibres, in insulin¬
like growth factor-1 transgenic model (Musaro et al., 2001). To further analysis of
muscle regeneration in transgenic or non-transgenic wasted mice,
Chapter 5 - Construction and characterization ofmuscle-specific human EEFIA2 transgene 176
immunohistochemistry using MyHC or proliferation cell nuclear antigen (PCNA)
antibodies is needed.
The high level of expression ofAchRal and myogenin in muscle ofHSA-EEF1A2
transgenic wasted mice compared with non-transgenic wasted group is an interesting
finding, although the results in Figure 5-19 and 5-20 do not show an increase in
myogenin expression in the non-transgenic wasted group, like those found in wasted
mice in Chapter 3 (Figure 3-10 and 3-11). This could be explained by an internal error of
the experiment such as pipetting error because the levels ofAchRal and myogenin have
been shown to express in the similar patterns, and myogenin itself is a transcription
activator for AchRal. The high level of expression of AchRal and myogenin in muscle
of HSA-EEF1A2 transgenic wasted mice could be an effect of the increased level of
expression ofEEF1A2 as their levels of expression in transgenic non-wasted mice
(Figure 5-21 to 5-26) are not increased. The response of skeletal muscle to denervation
is complex. At the molecular level, the reaction of skeletal muscle to denervation
embodies many cellular processes. On the one hand, individual muscle fibres undergo
significant atrophy along, and there is considerable disassembly of the contractile
apparatus, along with significant myonuclear loss. On the other hand, there is a
considerable increase in the satellite cell population within days of denervation, as well
as formation of new muscle fibres in long-term denervated muscle (Borisov et al., 2001;
Dedkov et al., 2001; Snow 1983; Viguie et al., 1997). Denervation also leads to
apparently paradoxical patterns of genes expression, in which genes or proteins that
normally function only during the prenatal period are expressed (Adam et al., 1995;
Voytik et al., 1993). A high level of expression of eEFlA2 in transgenic wasted mice
may play a role in the upstream regulation of other genes or proteins, at least for
AchRal and myogenin.
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Chapter 6 General Discussion
There are many mouse models ofMND, each with their own advantages and
disadvantages. Wasted mice represent one of the few model systems for which the basic
molecular defect has been identified. There are three related aspects to this project, all
aimed at addressing the relative roles of eEFl A2 in muscle and neurons. Firstly, to
describe the characterization of neuromuscular abnormalities of spontaneous mutant
wasted mice, and evaluate whether muscle atrophy in wasted mice is a consequence of
denervation or intrinsic muscle diseases. Secondly, to study distribution and
colocalisation between eEFl A2 and SMN in mammalian cells. The last aspect, which is
the major and crucial experiment, is to generate transgenic homozygous wasted mice
that specifically express human eEFl A2 in muscle, in order to evaluate the phenotype
that results from loss of eEFlA2 in neurons but not muscle.
6.1 Neuromuscular abnormalities in wasted mice
Wasted mice exhibit severe muscle wasting and degeneration ofmotor neurons,
beginning at 21 days after birth and die by the age of 28 days. The principal finding of
this study is that muscle of wasted mice shows evidence of neurogenic atrophy
(denervation), characterized by the presence ofmultiple small groups of small angular
fibres and pyknotic nuclear clumps. Muscle pathology shows a range of severity. The
finding of atrophic groups of angulated fibres suggests that the process is in the early
stage of chronic denervation. The finding of pyknotic nuclear clumps, which is an end
product of denervation atrophy, indicates that denervation exists without reinnervation.
Numerous small regions of grouped angulai^atrophic muscle fibres have also been
demonstrated in patients with ALS (Fischer et al., 2004), and mouse models ofALS
(Gurney et al., 1994; Ripps et al., 1995; Wong et al., 1995;Bruijin et al., 1997). By
contrast, although small groups of atrophic fibres can be found in muscle of patients
with SMA (Adams and Victor, 1993) and a transgenic mouse model of SMA (Frugier et
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al., 2000), the small muscle fibres are often rounded, and large hypertrophied muscle
fibres are usually found. In addition, pyknotic nuclear clumps are not present in SMA.
At the level of neuromuscular junctions, I report here the lack of terminal axons
observed in synaptic areas ofmuscle from wasted mice, which is consistent with the
muscle denervation process. Examination ofwasted NMJ also shows striking
abnormalities of terminal axons filled with NF, with reduction of branched structures of
the subneural apparatus. Moreover, no axonal sprouting is detectable. These results
indicate an abnormal organization of synaptic terminals associated with a defect of
axonal regeneration. These abnormalities are similar to those found in Smn mutant mice,
but contrast with SODG93A transgenic mice (Cifuentes-Diaz et al., 2002), indicating that
NMJ changes in wasted and Smn mutant mice may be caused by a common axonal
degenerative process. Previous studies have demonstrated accumulation ofNF in
perikaryons of SODCj93A (Gurney et al., 1994), Smn (Cifuentes-Diaz et al., 2002), and
wasted mice (Lutsep and Rodriguez, 1989; Newbery et al., 2005). These data indicate
that NF accumulation observed in these mutants results from distrinct pathways.
Whether the accumulation ofNF is a primary effect of the loss of eEFl A2 or SMN
function, or a secondary event via an unidentified pathway remains to be investigated.
NF are normally not present in synaptic terminals, and it is thought that NF are degraded
by a calcium-activated protease to prevent the accumulation ofNF in terminal axons
(Schlaepfer, 1974; Schlaepfer and Micko, 1978). As cytoskeletal components play a
major role in axonal growth and plasticity (Tanaka and Sabry, 1995), abnormal
accumulation ofNF in terminal axons of wasted and Smn mutant mice may contribute to
the defect in terminal axonal growth and plasticity, as suggested by the paucity of
terminal arborization, the reduction of branched structures of the subneural apparatus,
and the defect in axonal sprouting. The resulting aberrant cytoskeletal organization at the
NMJ of wasted mice may contribute to the loss ofmotor neurone function. The finding
of accumulation ofNF in terminal axons, presented in this thesis, and in neuronal cell
bodies in spinal cord of wasted (Lutsep and Rodriguez, 1989; Newbery et al., 2005) and
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Sinn mutant mice (Cifuentes-Diaz et al., 2002) with normal or mild reduction in motor
neurone cell bodies suggest that degeneration ofmotor neurons may result from a dying-
back axonopathy starting from terminal axons.
Several mouse models ofMND such as SODG93A (Fischer et al., 2004), pmn (progressive
motor neuropathy) and mnd (motoneuron degeneration) have been characterized as
"dying-back" neuropathies (Fischer et al., 2000). Flowever, neuronal and axonal
degeneration are not necessarily linked, and in some situations, may occur by separate
and independent mechanisms (Coleman and Perry 2002; Finn et al., 2000; Deckwerth
and Johnson 1994). Wasted mice should represent a valuable model for elucidating the
pathway linking these phenomena.
6.2 Regenerating muscle fibres in muscle of wasted mice
Examination ofH&E-stained muscle sections of wasted mice also gives an interesting
finding. Muscle of wasted mice occasionally contains centralized myonuclei, which are
absent from wild-type muscle. Centralized nuclei are typical of regenerating muscle
fibres, which might have been thought not to happen in muscle ofwasted mice that
express neither isoform of eEFl A. In an absence of immunochemical data, one needs to
look at the tissue composition and known changes in denervated muscle to try to infer
reasons for possible mechanisms. Skeletal muscle contains a complex array of cell types.
Among its principal components are multi-nucleated muscle fibers and muscle satellite
cells, which are cells located in close association with muscle fibers and containing
precursors capable of giving rise to new muscle fibers. Concurrently, new myotubes
have been shown to begin to form in association with both intact atrophying and
degenerating muscle fibres (Dedkov et al., 2001). The newly forming myotubes have the
characteristics of embryonic muscle fibres, which during normal development contain
high levels of eEFlAl. The activity ofeEFlAl protein in muscle of symptomatic
wasted mice may contribute to protein synthesis in regenerating muscle fibres. This
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hypothesis is partly supported by the expression of eEFl A1 at low levels in 28-day-old
wasted mice (Khalyfa et al., 2001) It is also possible that upregulation of myogenin that
is expressed in both immature and denervated muscle fibres, which I have demonstrated
in this thesis, plays a role in regeneration of muscle fibres in wasted mice.
Myogenesis requires energy production for the execution of a number of regulatory and
biogenesis events. I have found an increase in SDH staining in muscle ofwasted mice,
giving another supporting clue for regenerating muscle fibres. It has been shown that
skeletal muscle regeneration is accomplished by a marked stimulation ofmitochondrial
biogenesis concomitant with the onset ofmuscle cell differentiation (Duguez et al.,
2002). However, as SDH stain is the most sensitive and specific stain for mitochondrial
proliferation, increased SDH staining may indicate mitochondrial dysfunction.
Mitochondrial dysfunction has been reported to occur in skeletal muscle ofALS patients
(Dupuis et al., 2003) and SODG93A transgenic mice (Leclerc et al., 2001), in addition to
central nervous system. It is thus necessary to determine mitochondrial abnormalities,
both morphologically and functionally, in muscle ofwasted mice prior to make a
confirmed conclusion regarding its role in regenerating muscle fibres.
6.3 Expression of nerve-regulated genes in muscles of wasted
mice
To support the findings in muscle and NMJ of wasted mice that suggest muscle atrophy
is neurogenic, I have investigated expression of nerve-regulated genes in muscle of
wasted mice, and demonstrated that the patterns of gene expression are characteristic for
the type of denervation. These results are similar to the studies in some mouse models
for human spinal muscular atrophies, including the mutant "wobbler" (wr), "muscle
deficient" (mdf), and pmn (Sedehizade et al., 1997). The positive correlation between the
expression of nicotinic AchRal and that of myogenin reflects a mechanistic relation.
Studies suggest that the dependence of the expression ofAchRal on the activity pattern
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ofmuscle is mediated by the myogenic transcription factors MyoD and/or myogenin. A
tight correlation between the time course of the expression of the AchRal and that of
MyoD and myogenin after muscle denervation and during muscle maturation has been
found in that the changes ofMyoD/myogenin expression preceded that of AchRal
(Eftimate et al., 1991; Piette et al., 1990). The amount of AchR on the muscle cell
surface changes during myogenesis and upon muscle innervation and denervation.
During embryogenesis, AchRs appear throughout the muscle cell surface. In mature,
innervated muscle, AchR is found in very dense clusters localized to the NMJ.
Denervation of muscle results in a renewed synthesis of AchRs, which again appear
throughout the surface of the muscle fibre (Evans et al., 1987).
The expression of C1C-1 is also developmentally regulated. There is very little C1C-1
mRNA in myotubes, C1C-1 mRNA levels are steeply upregulated during the first few
weeks after birth (Steinmeyer et al., 1991, Wischmeyer et al., 1993). The chloride
channel C1C-1 controls the excitability of adult muscle but its own expression is
dependent on actual muscle activity. This regulation is probably mediated, at least in
part, by myogenic factors (Klocke et al., 1994). C1C-1 mRNA is reduced upon
denervation (Lorkovic and Tomanek 1977; Klocke et al., 1994).
It has been shown that myogenin and MyoD bind to and activate the enhancer region of
the AchRa gene (Piette et al., 1990). The E (CANNTG) boxes, the cis elements that
bind myogenic factors, are also found in the 5' regulatory region of the mouse Clc-1
gene. E boxes, consensus binding sites for muscle-specific transcription factors of the
MyoD/myogenin family, are found in many muscle specific genes.
I show here that a chronic denervation in wasted mice leads to changes in denervation-
sensitive gene expression. The drastic upregulation of AchRal and myogenin could be
used as a sensitive indicator of the pathological state of muscle. As mRNA levels of
MyoD, myogenin, and AchRa are higher both in immature and in denervated muscle
fibres than in innervated adult muscle fibres, they indicate either regeneration or
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physiological denervation. The same holds for the down-regulation of C1C-1 mRNAs.
These findings also support the evidence of regenerating muscle fibres in ongoing
atrophying muscle ofwasted mice, as described above.
6.4 A potential role of Akt in muscle of wasted mice
The molecular mechanisms ofmuscle atrophy in human are poorly understood. A recent
study showed that at the protein level ALS patients had a 68% lower content of the
active phosphorylated Akt protein, and SOD(,93A transgenic mice also had a reduction in
the active Akt protein content (Leger et al., 2006). These findings contrast with the data
I have found in muscle of wasted mice. Muscle ofwasted mice shows a significant
increase in Akt and phosphorylated Akt proteins as demonstrated by western blot
analysis. There are several signaling proteins that can act as upstream regulators of
translational mechanisms that have been associated with the decreased protein synthesis
rate caused by muscle atrophy. The protein kinase Akt has been shown to have growth-
promoting effects in muscle, and it is a known upstream activator of protein synthesis
(Rommel et al., 2001; Takahashi et al., 2002). Proteins downstream of Akt that are
involved in regulating protein synthesis are mTOR and p70S6 kinase (Nader et al.,
2002). One report has shown that overexpression ofAkt attenuates denervation-induced
atrophy in rodents by 70% (Bodine et al., 2001). Muscle unloading is also associated
with a decrease in both mTOR (Reynolds et al., 2002) and p70S6 kinase
phosphorylation (Bodine et al., 2001; Hornberger et al., 2001), which is consistent with
the decreased translation rate. Upon stimulation by hormones or growth factors, Akt
phosphorylates target molecules that have been implicated in glucose metabolism,
proliferation, and cell survival (Lawlor and Alessi 2001; Whiteman et al., 2002). A
recent study has shown that eEFl A is a potential binding partner in a protein complex
with Akt2 (Lau et al., 2006). Three isoforms ofAkt have been characterized in
mammals, with Akt2 being expressed particularly in insulin responsive tissues,
including fat, muscle, and liver (Altomare et al., 1995). The interaction of Akt2 and
Chapter 6 - General discussion 183
eEFIA may have implications in cytoskeletal regulation. A role eEFlA in regulation of
cytoskeletal dynamics, directing protein synthesis to sites of cell activity, has been
postulated (Liu et al., 2002). Association ofAkt with eEFIA may be important in
directing it to particular regions of the cell. Elevations in Akt in muscle of wasted mice,
which lack both eEFlAl and eEFlA2, may reflect compensatory changes occurring in
muscle in response to denervation, potentially in an attempt to maintain muscle mass
and protein synthesis or alternately, promote cell survival. Figure 6-1 shows an Akt
signalling network during hypertrophy and atrophy.
Catabolic Signals Anabolic Signals
ATROPHY HYPERTROPHY
Figure 6-1 Akt signalling network during hypertrophy and atrophy. Akt lies at the
centre of a network in which its activation regulates the protein synthetic machinery and
its inactivation allows the expression of possibly atrophy-associated genes (—►
activation,—I inhibition). Reproduced from Nader (2005).
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To address whether an increase in Akt and its phosphorylation proteins in skeletal
muscle of wasted mice are operating to target imperative biological processes, further
studies on relevant downstream targets will aid in an understanding of the role ofAkt in
progressively denervated muscle. These can be done by studying changes in PI3-K,
mTOR, p70S6 kinase, or BAD. Additional support for the role ofAkt and its
downstream targets has been carried out in Sprague-Dawley rats and C57BL/6 mice,
showing that genetic activation of the Akt/mTOR pathway is sufficient to cause
hypertrophy and prevent atrophy in vivo, whereas genetic blockade of this pathway
blocks hypertrophy in vivo (Bodine et al., 2001). Recently, eEFlA2 has been shown to
activate Akt in a P13-K-dependent fashion (Amiri et al., 2006).
6.5 Distribution of eEF1A2 and its colocalisation with SMN in
HeLa cells
The eEFl A protein is mainly present in the cytoplasm of cells. Nuclear localization of
eEFl A has been identified in some studies (Colling et al., 1994; Janssen et al., 1994;
Barberse et al., 1995; Billaut-Mulot et al., 1996; Sandres et al., 1996). However, two
recent reports have been unable to show nuclear localization of eEFl A (Calado et al.,
2002; Bohnsack et al., 2002). The reasons for these opposite findings might be
differences in cell culture conditions. In this thesis, I have demonstrated that upon serum
or EGF stimulation, a small proportion of eEFl A2 molecules redistribute from
cytoplasm to the nucleus of previously serum-starved HeFa cells. Intranuclear eEFl A2
may be involved in nuclear translation. This finding supports the earlier study (Iborra et
al., 2001) that has demonstrated 10-15% of cellular protein synthesis occur in the
nucleus.
There is some indirect evidence implying that eEFlA may be part of the so-called SMN
complex (Gangwani et al., 1998; Gangwani et al., 2001; Charroux et al., 2000).
Similarity in NMJ abnormalities between wasted and Smn mutant mice has been shown
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in this thesis, suggesting that there might be a pathogenic process in common. One
hallmark of SMA is the failure of SMN to localize within the nuclear bodies (Gangwani
et al., 2001). By using a transfection study and quantitative immunocolocalisation, the
result in this thesis suggests that a proportion of cytoplasmic eEFlA2 colocalises with
SMN. This finding supports the result of immunoprecipitation with anti-SMN antibodies
that often pull down a 50-kD band similar to that of eEFl A (Charroux et al., 2000).
The ICA-ICQ costaining analysis is a key element of this study. It was used for the first
time to study colocalization of syntaxin 1, Ga0, and N-type calcium channel complex at
a presynaptic nerve terminal (Li et al., 2004). This technique is distinguished from the
usual dye-overlap method by its focus on the variations in protein concentrations across
the cell and not simply their locations. Perhaps the worst limitation of the dye-overlap
method is that when one protein target is distributed across most, or all, of the cell, a
second protein will be identified as colocalised even when its distribution is totally
random with respect to the first. The ICA method avoids this mistake because if a
randomly distributed protein overlaps with a broadly staining one, it will not be reported
as associated because it does not vary in synchrony. The ICQ in this method serves as a
statistically testable, single-value assessment of the relationship between the stained
protein pairs. The ICA-ICQ analysis represents a powerful complement to standard
immunoprecipitation (IP) tests for analysis of protein complexes (Li et al., 2004). The
strength of the IP approach lies in identifying proteins bound in high-affinity complexes.
However, it has disadvantages in missing any low-affinity associations because of the
necessary washing steps, and in the requirement for solubilization of the tissue, which
effectively eliminates virtually all clues not only to the location of the complex within
the cell, but even from which cell or tissue type the complex originates. ICA-ICQ
analysis, on the other hand, has advantages in identifying potential low-affinity protein
complexes and in retaining information on the cellular and subcellular location. Its
limitation is an inability to resolve colocalisation of two proteins that are components of
a small organelle, which might be a cause of the poor staining intensity relation that is
found when analyzing colocalisation of myc-tagged eEFl A2 and SMN in the nucleus.
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6.6 Wasted mice expressing human eEF1A2 in skeletal
muscle
Here, I report the creation of a transgenic mouse model, by the expression of human
eEFlA2 under transcriptional control of the human a-skeletal actin promoter, that has
the potential to be used as a model for studying pathogenesis ofmotor neurone
degeneration, or even motor neuropathy, all of which resulting in denervation of muscle.
The HSA promoter was chosen since it is transcribed specifically in skeletal muscle
(Muscat and Kedes, 1987). The promoter is well characterized and the 2.2-kb fragment
used contains all necessary elements for selective expression in skeletal muscle
(Brennan and Hardeman, 1993). During development, a-cardiac actin is the predominant
isoform of sarcomeric a-actin (Grunning et al., 1987), and it is only post-partum that
there is a switch to a-skeletal actin (Brennan and Hardeman, 1993). Thus, by using the
HSA promoter, any possibility that embryonic expression of eEFl A2 might interfere
with development was minimized.
Investigations of the HSA-EEF1A2 transgenic homozygous wasted mice support the
hypothesis that loss of eEFl A2 in neurons, but not in muscle, ofwasted mice leads to
development of muscle atrophy. Although the primary screen I used to assess mouse
phenotype is not the full screening battery, but only covers the sensorimotor category, it
gives enough information to determine abnormalities and distinguish the transgenic mice
from non-transgenic wild-type controls. The results can also be used as a useful body of
data by which one can reproducibly assess the effect of a genetic manipulation or strain
variation. Evaluation at the younger age will give some more useful information that
might be used to follow-up the mice and distinguish between groups. In this thesis,
transgenic mice, non-transgenic wasted controls, and non-transgenic wild-type controls
were assessed at 25 days, and the results shows that the transgenic wasted mice are
indistinguishable from the non-transgenic wasted group. An additional method for
assessment ofmotor function was used. This method has been used to assess motor
function in the hind limbs of SOD]G93A Vegfa transgenic mice (Lambrechts et al., 2003).
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The neurological scores show no significant differences between the transgenic and non-
transgenic wasted mice, suggesting that the presence of eEFl A2 in muscle ofwasted
mice does not modify the deteriorated motor function. Because of the limited availability
ofwasted mice carrying the transgene, I could not analyze whether there is difference in
survival rate between the transgenic and spontaneous wasted mice.
The presence of the transgene results in high expression of human eEFlA2 protein in
skeletal muscle of transgenic wasted mice. Although the efficacy ofHSA promoter to
drive gene expression was confirmed (Brenna and Hardeman, 1993), this does not
guarantee that the expressed protein is functional. One possibility that the HSA-EEF1A2
transgenic wasted mice have no phenotypic differences, both physically and
histologically, is that the expressed eEFl A2 protein in muscle is non-functional. It is
difficult to verify whether the expressed eEFl A2 protein is functional since the methods
have not yet been well developed. The easiest, but indirect and time-consuming, method
is to perform primary muscle cell culture and study the protective role of eEFl A2
against caspase-3-mediated apoptosis (Ruest et al., 2002). eEFl A2 was shown to protect
cultured differentiated myotubes from apoptosis by delaying their death, which suggests
a prosurvival function for eEFl A2 in skeletal muscle. Its protective function is the first
noncanonical function associated with the protein. However, this method has not yet
been carried out in vivo. It will also be interesting to study in vivo the expression and
effect of eEFl A2 in skeletal muscle during aging and determine whether the loss of
eEFlA2 may expedite the age-dependent myofibre decline in skeletal muscle. However,
the findings of high levels of the expression and no mutation found from the sequencing
results suggest that the expressed eEFl A2 protein should be functional.
As in spontaneous wasted mice, muscle pathology of transgenic wasted mice shows
abnormalities compatible with denervation, which include grouped small angular muscle
fibres in the background of generalized small fibres. However, it cannot be clearly stated
whether these findings are more like those found in ALS or SMA, as grouped muscle
fibre atrophy and small angular atrophic fibres can be found in both diseases. The
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grouped atrophic pattern found in wasted mice is rather scattered and not as marked as
that found in ALS and SMA. Hypertrophic muscle fibres, which can be found in SMA,
are not observed in wasted mice. Internal nuclei found in wasted mice are found in some
cases of SMA, however, in SMA this finding is more prominent. Increased internal
nuclei is also a typical finding in muscle diseases, however, most of the fibres are large.
It should be noted that in normal human skeletal muscle, as many as 3% of the
myofibres can have internal nuclei (Carpenter and Karpati., 2001; Eagel and Franzini-
Armstrong, 1994).
Transgenic wasted mice also show a physical feature, like that found in spontaneous
wasted animals, to which the term "tremor" is assigned. In neurological terminology,
tremor is a rhythmic oscillatory, non-purposeful movement of a body part produced by
regular or sequential contractions of opposing muscles. Its pathogenesis is believed to
result from dysfunction of basal ganglia. However, pathological abnormalities in basal
ganglia of wasted mice have not been identified. Intention tremor observed at the neck
of wasted mice may result from dysfunction of the cerebellar pathway. Body tremor in
wasted mice, however, could be referred to the term "fasciculation", or physiologically,
"fibrillation". Fibrillation activity, the spontaneous incoordinate activity ofmuscle, is
often found in denervated muscle. This can be easily confirmed by electromyography
(EMG). In human, it is one of the most classic and easily detectable signs of muscle
denervation (Midrio 2006). Fasciculation or fibrillation is a characteristic clinical feature
ofALS. Its presence indicates active denervation. Recently, based on the results
obtained with in vitro myogenesis, it was proposed that fibrillation is related to the
autocrine activation of AchRs in muscle membrane (Bandi et al., 2005).
Upregulation of AchRal and myogenin, and downregulation of C1C-1 mRNAs are also
demonstrated in HSA-EEF1A2 transgenic wasted mice, like those found in non-
transgenic wasted mice. These patterns of gene expression are compatible with
denervation. It is widely accepted that nicotinic AchRs play an important role during
myogenesis. Increased expression ofAchRal not only supports the presence ofmuscle
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denervation in wasted miee, it probably also supports the findings of centralized nuclei
and increased SDH staining, suggesting that muscle regeneration takes place in ongoing
denervated muscle in wasted mice.
The major aim of this thesis is to study the role of eEFl A2 in pathogenesis ofmotor
neurone disease in wasted mice. I have reported here that the loss of eEFl A2 in
neurones, but not in muscle, leads to denervation ofmuscle in wasted mice, suggesting a
specific role in neurons. Although eEFlAl and eEFlA2 proteins share similar features
such as molecular weight of about 50 kD, transcript length 1.8-1.9 kb, and 92.4% amino
acid sequence similarity (Knudsen et al., 1993), the function of eEFl A2 is still elusive,
and why two isoforms exist has never been understood. In light of the results obtained
with this thesis, eEFlA2 might have some unidentified, but specific roles in regulation
of survival ofmotor neurone. It has been shown in skeletal muscle that eEFlA2 has a
prosurvival function against caspase-3-mediated apoptosis (Ruest el al., 2002). Caspase-
1 and caspase-3 have been shown to be activated in motor neurone death in SOD1
mutant mice (Pasinelli et al., 2000). It is possible that eEFl A2 also plays a protective
role in neurone via the caspase pathway.
6.7 Future work
6.7.1 Characterization of wasted mice
I have reported here some characterization of wasted mice, mainly on muscle pathology,
neuromuscular abnormalities, and patterns of gene expression in muscle. The findings
point to the cause ofmuscle atrophy as denervation, or more specifically, degeneration
ofmotor axons. From a clinical point of view, it would be more useful ifmore studies
could be conducted to narrow down whether wasted mice could be a model for which
forms of human motor neurone degeneration, and even to confirm the results presented
in this thesis. ATPase staining can be used to investigate fibre type grouping. Finding of
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fibre type grouping indicates chronic denervation with reinnervation or collateral
sprouting. It is also helpful in identifying primary myopathy that may exist in muscle of
wasted mice as eEFl A2 is known to be specifically expressed in muscle. Increased SDH
staining as found in wasted mice may indicate mitochondrial diseases, in addition to
regenerating muscle fibres. Other staining used for studying mitochondrial disorders
such as cytochrome oxidase and NADH-TR staining would be useful since altered
mitochondrial function has recently been found in skeletal muscle in ALS patients
(Echaniz-Laguna et al., 2006).
I have demonstrated in HeLa cell transfection assays that eEFl A2 partially colocalizes
with SMN in the cytoplasm. Skeletal muscle has been reported as another tissue targeted
by the Smn defect, leading to destabilization the sarcolemma as determined by marked
reduction of dystrophin expression and upregulation of utrophin (Cifuentes-Diaz et al.,
2001). Both proteins represent key components of skeletal muscle fibres linking the F-
actin cytoskeleton to the extracellular matrix. Therefore, an Smn defect directed to either
neurons or skeletal muscle cell leads to destabilization of cytoskeletal components or
interacting proteins in targeted tissues. eEFl Al, but not eEFlA2, is known to interact
with actin and microtubules, which are components of the cytoskeleton (Liu et al., 2002;
Shiina et al., 1994; Yang et al., 1990). It is possible that in skeletal muscle cells,
eEFl A2 and SMN may interact via an unidentified pathway. It will be interesting to
investigate expression of dystrophin and utrophin, using immunostaining and western
blot analysis, in muscle of wasted mice and normal controls. The results will give
additional information on the role of eEFlA2.
I have shown here that muscle ofwasted mice show an increase in Akt and
phosphorylated Akt proteins. eEFlA contains a minimal Akt2 phosphorylation motif
RXRXXT (residues 67-72) and is therefore a potential Akt2 substrate. Loss of eEFlA2
in wasted mice thus may induce upregulation of Akt. It is possible that eEFl A interacts
with Akt2 through a complex with P-tubulin (Lau et al., 2006). However, whether Akt2
interacts directly with eEFl A or P-tubulin remains a question to be addressed.
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6.7.2 eEF1A2 arid its roles in motor neurons and muscle
Cell death pathways differ in several mouse models with motor neurone degeneration.
The analysis of gene expression alterations in motor neurons provides one means of
studying their specific vulnerability. With the development in technology for isolating
individual cells using laser capture microdissection, it has been possible to analyze
molecular changes in one particular cell type such as muscle cell or neuronal cell.
Furthermore, gene expression profiling ofmRNA from these cells has become possible
by the use ofmicroarray and quantitative real-time RT-PCR. The combined use of these
technologies in investigating muscle cell or neuronal cells of spontaneous wasted mice,
HSA-EEF1A2 transgenic wasted mice, and control animals could be a further tool to
investigate specific cell death in particular cell types, that link to a role of eEFl A2.
A prosurvival function for eEFl A2 has been demonstrated in skeletal muscle (Ruest et
al., 2002). A switch between two peptide eEFlA isoforms has been shown in cultured
differentiated myotubes (Ruest et al., 2002), as well as in tissue during development
(Khalyfa et al., 2001). This switch from eEFl A1 to eEFl A2 may confer to the long
lived, terminally differentiated myotubes a translation elongation factor, which also
prevents accidental cell death from occurring. It will be interesting to see whether this
protective function of eEFl A2 behaves in neurons in the manner that is similar to its
behaviour in skeletal muscle.
To study the relative roles of eEFl A2 in muscle and neurons, I have already generated
transgenic mice specifically expressing eEFlA2 in muscle. Although I have found that
the presence of eEFlA2 in muscle, but not in neurons, does not modify phenotypes of
wasted mice, the roles of eEFl A2 in muscle have not yet been studied. In order to
evaluate the phenotype that results from loss of eEFlA2 in muscle, but not in neurons,
generating transgenic wasted mice which specifically express eEFl A2 in neurons will be
another useful mouse model. The transgenic mice can be produced by using neuron-
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Sequence of the HSA-EEF1A2 fragment of the pUC19-HSA-EEFlA2 plasmid (HSA
sequence is indicated in blue, and its first exon is in bold; Sequences of Exon 2 to Exon
8 of human EEF1A2 are indicated in bold; Underlines denote Hindlll and Kpnl sites










































































































































































































































































































Photographs comparing sizes of bodies, hindlimbs, and spleens of non-transgenic wild-
type, transgenic wasted, and non-transgenic wasted mice.
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